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CHAPTER 1 
GENERAL INTRODUCTION 
9 
1.1 INTRODUCTION 
In the mid-eighties it became apparent that a human retrovirus of the lentivirus subfamily 
(4), later designated human immunodeficiency virus type I (HIV-l), was the etiological 
agent of the acquired immune deficiency syndrome (AIDS) (124). This disease was 
characterised by unusual opportunistic infections, neurologic abnormalities, gastrointestinal 
disorders and malignancies due to an insidious decay of the immune system (79), TIle 
urgent need to gain insight in certain aspects of the pathobiology of this infection demanded 
relevant animal models. As a consequence of this need the search for similar lentivimses 
present in other animal species intensified. Several lentivimses have been identified to 
induce AIDS-like disease in a vruiety of animals (75), however, only simian 
immunodeficiency virus (SIV) and feline inununodeficiency virus (FIV), wWcb cause 
AIDS-like symptoms in macaques and cats, respectively, have been commonly used as 
animal models (76). 
In this chapter an overview of the molecular biology of SIV and the utilisation of the 
SIV -macaque model for AIDS research is given. In prulicular, the use of molecular clones 
of SIV to elucidate the pathogenesis of AIDS is described. 
1.2 ORIGINS OF SIMIAN AND HUMAN IMMUNODEFICIENCY VIRUSES 
In 1969, at the California Regional Primate Research Centre a large number of rhesus 
monkeys were diagnosed with a high incidence of lymphoma. Animals having this type of 
lymphoma had unusual opp0l1unistic infections such as Mycobacterium avium. Studies 
suggested a viral etiology of this disease, especially when lymphocyte-associated 
herpesviruses, adenovimses and retrovimses could be detected in cultured tumour tissue 
(42). In the early 1980's comparable cases began occurring at the New England and Tulane 
regional primate centres as well (78). However, it was not until 1985 that lymphoma 
transmission studies, morphological comparisons and growth characteristics suggested that 
the observed disease was associated with the presence of a lentivirus: STLV-III, later 
designated SN, the simian counterpat1 of HTLV-III (HIV-I) (6). Although type D 
retrovinlscs (known as simian retroviruses, SRV) were also found to be associated with 
simian AIDS (SAIDS) in several species of macaques (Macaca lilli/alta, M. cyclopis, M. 
Jlemestrilla, M.fasciclllaris, M.juscata andM.nigra), it was excluded as the etiologic agent 
for the observed disease in these rhesus macaques, since 1) experimental infection with a 
cell-free type D retrovirus stock failed to induce disease in healthy animals, 2) it was 
impossible to isolate type D retrovimses from the majority of these monkeys upon 
cocultivation and, 3) T-cell lines producing SIV did not yield a type D retrovirus when 
cocultured on cell lines (42, 45, 77). Studies revealed that SlY ~ (22), and closely related 
isolates from various other Asian macaque species, were all derived from SIVsm• a naturally 
occurring infection of sooty mangabeys (42, 93) (Figure I). 
!O 
Figure 1. Distribution of African primate species naturally infected with Ientiviruses that are resistant to 
disease (with the exception of humans (8, C, D, and E». The geographic separation of Asian rhesus 
macaques which are susceptible to AIDS is shown in A. The approximate distribution of humans infected 
with HIV-J versus HIV-2 early in the epidemic is depicted in B. 
SIV~m' like lentiviruses isolated from other naturally infected African nonhuman primates, 
does not cause AIDS in its natural host (50, 99). Lentivims infections have not only been 
found in sooty mangabcys (Cercocebus torquahls clfYs) (56), but also occur in African green 
monkeys (Cercopithecus aethiaps) (2,99), mandrills (Mandrillus sphinx) (133), L'Roest's 
monkeys (Cercopithecus lhoesti) (54), sun-tailed monkeys (Cercopithecus solatus) (8), 
Sykes' monkeys (Cercopitheclls mitis albogularis) (55), and chimpanzees (Pall 
troglodytes). (58, 106). Based on sequence analysis these African nonhuman primate 
lentiviruses can be classified into 5 main lineages represented by; 1) SIVagm from different 
subspecies of African green monkeys, 2) SIV mmI from Mandrills, 3) SIV"k from Sykes' 
monkeys, 4) SIV~m from sooty mangabeys, SIV mac' and HIV-2 of humans, and 5), SIVcpz 
from the chimpanzees and HIV -1 from humans (Figure 2). African nonhuman primates 
II 
were found to harbour SIV asymptomatically while inoculation of SlV5m into rhesus 
macaques (Asian in origin) induced a disease remarkably similar to AIDS in humans (77). 
Retrospective evidence suggested that SIV mac was introduced to the New England rhesus 
colony through a COh0l1 of ten female rhesus macaques obtained from the Califomia colony 
in 1970 (42). The high degree of genetic homology between SlY isolated from captive 
rhesus macaques (SIV,,!,}..,) and the virus found in naturally infected sooty rnangabeys (SIVsm) 
suggested that SlY ~ originated from SIV,m by cross-species transmission (40, 42, 56, 93). 
Similar evidence suggests that HIV -I may have been introduced into the human population 
from a specific subspecies of chimpanzees (Pall troglodytes troglodytes) (39) (Figure I). 
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FiguI'e 2. The genetic relatedness of the five currently identified lineages of primate Icntiviruses (141). 
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1.3 GENETIC ORGANISATION 
The linear SlY provirus in host cells is 9.2-kb in length and contains stmctural genes 
(gag and env), non-structural genes (pol, fat, rev) and accessory genes (vif, vpx and/or vp,. 
and nej), and is flanked by two long temlinal repeats (LTR) (Figure 3). The gag open 
reading frame encodes the core proteins p7, p9 (NC), P 17 (MA) and p24 (CA), whereas pol 
codes for the viral enzymes reverse transcriptao;c (RT), RNAse H. protease (PR) and 
integrase (IN). The envelope gene encodes the envelope glycoprotein (precursor) that is 
proteolytically cleaved into gp130 (SU) and gp41 (TM). The viral precursor RNA code for 
Gag. Pol and Env proteins as well as for the accessory Vif, Vpr, Vpx and Nef proteins 
which are not required for viral growth ill vitro but are essential for viral replication and 
pathogenesis in vivo (132), 
HIV-1 
vif ~rev 
LTR gag D D ......... tat~D LTR 
DLI ----c==p:ol==:JvprGOI+-vpu 0 0 
C:::==~ID 
env nef 
HIV-2! SIVsm 
......... rev ......... 
LTR gag vilvprG 0 nef 
D[=~~=~p~o~1 =:::5DDO-fat-DD 
I' 0 
vpx env LTR 
Figure 3. Comparison of the genetic organisation of proviruses of the HIV~lISIVq>z lineage versus the 
SNm•d",-/HIV-2 lineage. The organisation of the structural and regulatory genes is highly similar with the 
exception ofvpll and vpx, respectively. 
The LTR flank either side of the SIV proviral genome and contain a TATA box for 
initiation of viral transcription, which is carried out by the cellular RNA polymerase II. 
Other regulatory elements include high affInity binding motifs for the nuclear factor-kappa B 
(NF-K~) and the cellular transcription factor SPI (64). Molecular clones of SIV mutated in 
these pruticular regions still showed efficient viral replication in primary lymphoid cell 
cultures and in rhesus macaques (60, 145). This is in contrast with the hypothesis that NF-
Kfl and SP 1 are required for persistent infection and for the induction of AIDS in rhesus 
macaques. It also suggests that the SlY L1R promoter contains multiple functionally 
redundant elements capable of supporting sufficient transcription to allow productive viral 
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replication (109). The LTR also contains signals for integration, transcription-regulation and 
poly-adenylation of mRNA. Transcriptional activation of LTR-driven gene expression as 
well as elongation of newly initiated transcripts requires the transactivator protein (Tat), 
encoded by a highly conserved regulatory gene. Tat interacts both with cellular factors (46) 
and binds to the Tat activation response element (TAR) sequence that is located in the U5 
region of the LTR. The regulator of viral expression (Rev) is encoded by the regulatory 
gene rev, consisting of two exom. The 19 kDa Rev protein exerts its function by interacting 
with the Rev-responsive element (RRE), located within the ellv rnRNA. This element is 
about 200 base pairs in size and forms a secondary structure necessary for its recognition by 
Rev (11). It has been shown by mutational analysis that a putative activation domain could 
be assigned to the carboxy-terminus (second exon) of the Rev protein (103). The function 
of Rev has been associated with the switch from the synthesis of (multiple) spliced 
messengers coding for the regulatory proteins to the unspliced and single-spliced 
messengers, (coding for the Gag, Pol and Env proteins), taking place in the early and late 
phase in viral replication, respectively. As a consequence Rev down-regulates its own 
expression and that of Tat and Nef as weB (34). Studies in which Rev regulation could be 
replaced by the introduction of the cis-acting transp0l1 element (CTE) of the type D simian 
retroviruses I (SRV-l) suggested that Rev functions by promoting transp0l1 of single 
spliced and unspliced viral messengers out of the nucleus. 
Vpr and Vpx are two small auxiliary proteins of about 15 kDa that are incorporated into 
virus particles (126). Vpr together with the MA protein facilitate transport of the viral pre-
integration complexes from the cytoplasm into the nucleus of infected cells (21, 65, 82, 
144). The vpx gene also encodes a small protein, which is hypothesised to act in nuclear 
imp0l1 of viral DNA. Vpr has also been associated with cell cycle arrest and is dispensable 
for the infection of macrophages, while Vpx has no effect on the cell cycle but is required 
for virus replication in macrophages (35, 108). Vpx and Vpr are highly related and able to 
substitute for each other, as was shown by studies in which SIV clones mutated in either 
vpr or vpx genes were able to induce disease in rhesus macaques while the same clone 
mutated in both genes did not. Both vpr and vpx genes are only present in members of the 
HIV-2 and the SIV'n1 family while the HIV-l, SIVcpL ' SIVagm, SIV mnd and SIVS)i.: primate 
lentivirus lineages have only the vpr gene as depicted in figure 3. 
The nej open reading frame extends from the 3'end of env into the 3' LTR. Structural 
studies of the nej gene product showed that it is a 280 residue multifunctional regulatory 
protein with a molecular mass of 34 kDa. Research on the function of Nef showed its ability 
to down-regulate the expression of cell surface CD4 receptor molecules (10, 41) and MHC 
class I surface antigens (125). Studies in SIV infected macaques also showed that SIV Nef 
is essential for maintaining high virus loads and is required for viral pathogenesis (67). 
Furthermore, the Nef proteins of HIV-I and SlY have been suggested to playa fundamental 
role in altering T-cell signalling pathways (I, 7, 128), to enhance viral infectivity, and to 
increase the state of viral replication in lymphocytes (20, 74, 88, 130). These functions of 
Nef may be attributed to the interaction of a SH2 binding domain (YxxUYxxR) present in 
Nef with Src tyrosine cellular kinases (104, 120). It was demonstrated that by generating an 
t4 
SH2 motif in the Ncf amino terminus of the wild type SIV m~d.19 molecular clone that this 
new mutant was able to replicate in resting rhesus peripheral blood mononuclear cell 
(PBMC) cultures, due to an altered state of lymphocyte activation (28). 
1.4 THE VIRUS LIFE CYCLE 
After entry of the cytoplasm of the infected cell the viral capsid is disrupted and a 
ribonucleoprotein (RNP) complex is released consisting of viral RNA, NC, MA, RT and IN 
(14). During reversed transcription the two RNA molecules in the virion are cOl1velied to a 
linear double-stranded DNA (92, 136, 137). This complicated process requires priming by 
binding of tRNA to the primer binding site (PBS) of the viral RNA (13, 30), RNA-
dependent DNA synthesis, degradation of the RNA in the DNA-RNA hybrid intermediate 
by viral Rnase H (89, 106), two template transfers and elongation of plus strand DNA (9). 
It is mediated by reverse Iranscriptase and results in the formation of a linear double-
stranded DNA molecule with one complete LTR at each end. Since the reverse transcriptase 
enzymes of retroviruses lack proofreading activity, the mutation rate is extremely high. This 
results in the rapid accumulation of vast numbers of highly-related but different vil1ls 
genotypes, called a quasi species (57, 110, 115, 143). The fonnation of a pre-integration 
complex (double stranded DNA complexed with MA and Vpr) promotes the transport of 
viral DNA to the nucleus were it randomly integrates in the host genome. Proper integration 
requires par1icular sequences at the end of both LTR and is catalysed by viral integrase (IN) 
(15,32, 112, 122, 140). 
1.5 GENE EXPRESSION 
The 5' LTR promoter, in combination with cellular factors, present in the integrated 
double-stranded DNA (provirus) generates the first viral transcript. This transcript serves 
both as the genomic RNA that is encapsidated in the virion, and as mRNA encoding viral 
proteins. Early after infection multiple-spliced messengers are synthesised coding for viral 
regulatory proteins (Tat, Rev and Nef). Later in infection synthesis of unspliced and single 
spliced messengers predominate encoding the Gag-Pol proteins and the Env, Vif, Vpu, Vpr 
and Vpx proteins, respectively. This shift which occurs rapidly after infection (within 
hours) is mediated by the Rev / RRE interaction which specifically changes the transpOli of 
the different transcripts to the cytoplasm, away from the host cell splicing machinery in the 
nucleus. 
1.6 VIRUS ASSEMBLY AND RELEASE 
During transport to the cen membrane the envelope polyprotein becomes glycosylated 
and is cleaved into separate TM and SU proteins (31). Upon budding of the virus particles 
SU proteins are exposed on the surface of the virions. These glycoproteins react with the 
Gag and Gag-Pol precursor proteins. The intemal proteins (MA, CA, NC, and p6) and the 
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enzymatic proteins (PR, RT, and IN) are derived from Gag protein and the Gag-Pol fusion 
protein, respectively. The nature of their transp0l1 to the cytoplasmatic face of the membrane 
is not known. However, balanced ratios of Gag and Gag-Pol proteins are incorporated and 
drive the fOlmation and release of virions from the infected host cell. Two copies of the viral 
RNA genome are encapsidated, presumably through specific interactions with the Gag 
protein, together with tRNA and Vif, Vpr and Nef. The final process, the proteolytic 
cleavage of Gag and Gag-Pol proteins, is essential for producing infectious virions and 
occurs just before or immediately after virus release (140). 
1.7 NON· HUMAN PRIMATE LENTIVIRUSES 
Studies conducted on biological material from HIV -1 infected humans and AIDS patients 
have contributed enormously to the current knowledge of the biochemistry and molecular 
biology of the vims and about the pathology of the disease it induces. However, since it is 
difficult to identify humans early, at the time of primary HIV infection, animal models have 
been invaluable in providing insights into these eady events (16, 96). Primate models have 
enabled the detailed studies of the target cells for viral infection within the first days of 
infection and have assisted in correlating this infomlation with the biological phenotype of 
the infecting vims (131). Animal models have also been invaluable for elucidating the role 
of particular viral variants in pathogenesis (69), and have proved essential in experimental 
vaccine development and evaluation (97, 127, 142). As a member of the retrovims 
subfamily Lentiviridae, HIV -I is morphologically and genetically related to other, non-
human primate lentivimses. Indeed, the morphological similarity of HIV-I to Equine 
Infectious Anaemia Virus (EIA V) led to its identification as a lentivims. Since then 
lentiviruses have been discovered in cattle (47, 95, 119), cats (105) and several African 
primate species (Figure l), Lentiviruses naturally infect a number of African non-human 
primates such as chimpanzees (SIY,p,) (106), African green monkeys (SIV,,,,,,) (23), sooty 
mangabeys (SIY.m) (56), Mandrills (SIVrnrnI) (133), L'Roest's monkeys (SlY",) (54), and 
Sykes monkeys (SIVS}'k) (33). These vimses cause a persistent but asymptomatic infection 
when transmitted naturally mnongst their natural hosts (50, 98, 138, 139). The pathogenic 
potential of these infections was not realised until molecular evidence revealed that Asian 
rhesus monkeys (Figure 1A), which had developed and died from an AIDS·like disease had 
been accidentally infected with material derived from a sooty mangabey (59, 78). Thus 
SlY mac' the vinls isolated from rhesus macaques was really SIV~m which had undergone 
cross-species transmission to a species previously na'tVe to lentivimses. A number of years 
later several lines of research based on compelling molecular similarities came to the same 
conclusion regarding HIV-2 infection in man (18,40). The remarkable molecular sirnilmity 
between the sequences of HIY-2 in humans and SIVsm of sooty mangabeys makes them 
almost indistinguishable (56). Although direct proof is still lacking, the circumstantial 
evidence is compelling .. More recently, similar sequence evidence has strongly suggested 
that SIV cpz infection from a subspecies of chimpanzees (Pan troglodytes troglodytes) is the 
source ofHIV·1 infection in the human population (Figure 2) (39). 
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1.8 EXPERIMENTAL NON-HUMAN PRIMATE MODELS FOR AIDS 
RESEARCH 
When the magnitude of the evolving IllV-l epidemic in the human population was 
realised, it became clear that animal models would be needed to develop vaccines, therapies 
and to better understand the pathogenesis of AIDS. HIV-I proved to be very species 
specific and only great apes (chhnpanzees and gibbon apes) conld be successfully infected. 
Chimpanzees were, and still are, the model of choice for HIV -1 infection, vaccination and 
immune prophylactic studies (52). This is largely because they are biologically and, most 
importantly, genetically more similar to humans than any other primate species. The 
majority of chimpanzees are, however, resistant to AIDS (50, 51) making them of interest 
for comparative pathohiology and illununisation strategies (94), but limiting their utility 
when the development of AIDS or its treatment requires an animal model. 
For the study of AIDS pathogenesis, therapy and the study of vaccines to prevent disease 
development the rhesus macaque model has been most widely used. In addition to rhesus 
macaques, cynomolgus and pig-tailed macaques are also susceptible to AIDS when given 
SIVsm and are also used, but to a lesser extent. Tilis is largely due to the fact that for rhesus 
monkeys the immunological reagents are best developed, and the inununogenetics are more 
extensively studied. The models using SIV sn/SIV mae or related strains are, however, only 
surrogate models for HIV -I induced AIDS. 
1.9 THE CHIMERIC SIMIAN-HUMAN IMMUNODEFICIENCY VIRUS 
(SHIV) MODEL 
To develop an altemative model for the use of chimpanzees, chimeric viruses based on 
molecular clones of SIVSn\in\;): were constructed. Either HIV -1 RT -encoding sequences (for 
antiviral drug studies) (134) or the HIV-I ellv gene (for HIV-I based envelope vaccine 
studies) (49, 80, 81, 113, 114) were cloned into the SIV =,239 infectious molecular clone. 
The first generation of ellv-SHIV chimeras was not pathogenic (Le. could infect but did not 
cause AIDS in rhesus monkeys), whereas the RT-SHIV proved to be moderately pathogenic 
(134). III vivo passage of SHIV chimeras has resulted in certain mutations occUlTing in the 
SHIV genome which are assumed to have contributed to their ability to cause an AIDS-like 
disease in rhesus macaques (17, 61, 62, 113). The pattems of CD410ss with these ill vivo 
passaged SHIV are, however, atypical. For example, infection with the env-SHIV89•6P 
variant results in an acute and profound loss of CD4+ T-cells. In contrast, the chimeric RT-
SHIV causes disease only after a long period of infection and with only slight decline jn 
CD4+ T-cells. 
The SHIV model is very useful for addressing specific questions of HIV-l pathogenesis. 
For example, HIV -1 utilises two major co-receptors, CXCR4 and CCR5 in addition to a 
large number of potential minor co-receptors (12, 27, 116). To address the significance of 
HIV -1 co-receptor use in AIDS pathogenesis, SHIV chimeras were constructed from HIV-l 
molecular clones with distinct CCR5 or CXCR4 usage, designated R5 and X4 viruses, 
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respectively. These specific SHIV chimeras were used to infect rhesus macaques, which 
were then observed to develop quite distinct pathological lesions (48). 
1.10 THE USE OF MOLECULAR CLONES TO STUDY GENETIC 
DIVERSITY WITHIN SIV ISOLATES 
The early cases of reported disease in Asian macaques were caused by cross-species 
transmission from sooty mangabeys. The resulting viral isolates were designated based on 
the species they were isolated from, for instance from rhesus macaques (SIV rna)' stump 
tailed macaques (SIY"m) and pigtailed macaques (SIV _). Several SlY isolates, varying in 
pathogenic potential, have been characterised over the years (26, 42, 44, 73, 83, III) and 
have been used in preclinical evaluation of antiviral agents, vaccines and in 
immunotherapeutic studies (43, 44, 142). In addition, they were useful in mother-to-infant 
viral transmission studies (87, 118, 129, 135), in defining viral and host detenninants 
involved in various stages of disease, and in correlating certain emerging virus variants with 
disease progression (68, 69). 
Lentivimses are highly variable RNA viruses. The high error rate of the viral reverse 
transcriptase results in the rapid evolution of genetic variants following initial infection of 
the host. These variants, called a quasispecies, continue to accumulate mutations ill vivo 
resulting in the maintenance of a genetically diverse population throughout the infection. In 
addition, template switching during reverse transcription can result in recombination 
contributing to the high levels ofHIY/SIY genetic variability. The heterogeneity in SIYIHIV 
inocula represents a drawback in studies that require a well-defined virus genotype. The use 
of molecular clones of SIV or HIV has been important as statting material in such studies 
because of their high genetic unifOlmity. HlV develops the highest heterogeneity in the early 
asymptomatic stages of disease and the lowest levels at later stages (ARC/AIDS) of disease 
(24). Vims variants, which emerge late in infection, display characteristics being 
significantly different from variants evolving shortly after infection. The early variants are in 
general macrophage-tropic, the later variants are T-ccll-tropic and induce formation of 
syncytia. These late variants are cOImnonly believed to contribute significantly to the clinical 
outcome of infection (69). As a consequence, the characteristics of a molecular clone 
derived from an infected animal greatly depends on the patticular variant that was selected 
for the cloning procedure and this may be influenced by both the stage of disease and the 
cell type from which the vims was isolated. Over the years several molecular clones for SIV 
have been generated (26, 36, 53, 66, 70, 100, 107). The vimlence of those molecular 
clones in macaques ranges !i'om highly pathogenic (26) to non-pathogenic (107). Thus, the 
clinical disease they cause following infection is highly variable which makes some clones 
more suitable for certain experiments than others. 
Molecular clones have been used to detennine genetic detenninants responsible for 
certain pathogenic propel1ies of the virus. Studies have revealed that the detenninants for 
viral vimlence (Le. macrophage tropism) are multiple and are dispersed throughout the 
genome (91, 101). Other studies have identified the env gene as the major determinant 
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responsible for differences in biological properties such as ceHular tropism and 
cytopathogenicity (3, 63, 90), More recently, the importance of the lIej gene on cellular 
activation ill vitro and disease progression ill vivo was confirmed using molecular clones 
(28,71,72, 121), 
1.11 OVERVIEW OF sn's"'''Ac-STRAINS AND RELATED MOLECULAR 
CLONES 
Several molecular clones of SNsrnlrna..: have been generated over the years. The first virus 
isolates and molecular clones were generated at the New England Regional Primate 
Research Centre with the injection of rhesus monkey 251-79 with tissue of animal 78-72 
(Figure 4), The SIV isolate from this particular rhesus monkey (251) served as the source of 
several molecular clones. Since then the original virus isolates and clones have been 
unwittingly designated SIV m.x and repeatedly passaged ill vitro resulting in altered 
properties. For that reason comparisons between viral isolates or molecular clones can only 
be evaluated in their historical context. TIle origins and relationships of conullonly used 
isolates and their derivatives are depicted in figure 4 and described below. 
SIV mao316EM 
IAh78.72H 
2 
SlVmao251 
SlVmaoBk28 
1 SIVmaoBk44 Rh251-79 1 
SIVmao102 5 
LIA_h6.~_'82~~[I~R~h2~38~--~4~~I~;;~==J 
SIVmao1A11 
6 
SIV mao32H (pJ5) 
'-Rh32H 
7 8 
SIV mao32H (11/88)~ 
9 
SIV mac32H (pB 1) 
SIV mao32H (PCB) 
Figure 4. Overview of current SlY rUe molecular clones. Rh indicates animals infected with the SIV moe 
strain. The molecular clones are all listed in the boxes on the right hand side of the chart. 1 == filtered 
lymphoma homogenate, 2 == PBMC pool from three different macaques, 3 == plasma. 4 == Hut78 cell culture 
supernatant, 5 == low passage SIVmae251 inoculum prepared on C8166 cells, 6 == H9 cell culture 
supernatant, 7 ==Rh PBMC/huCBL cocuiturc, 8 == C8166 coculture, 9 == JM cell culture .• == inoculation of 
seven rhesus macaques .• ;:;:: inoculation of six rhesus macaques (including Rh 61-82). 
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SIV mac251 moleculal' clones: The virus isolate derived from the rhesus monkey 251 
was designated SIV mac2SJ> This was the source for several different molecular clones of 
SIV mac' A first group of clones (SIV mac25J1 SIV m~cBK28' SIV Ull(:I02 and SIV maclAll) was derived 
after SlY mac251 was propagated on H9-cells, a human T-cell line. The second group of clones 
(SlY mac2J9 and SlY madl6EM) was derived after SIV mac25J had been passaged in animals 239 and 
316-85, respectively. A third group of clones (SIV =<32H (pJ5), SIV =<3lH (pBI) and SIV3lH 
(pC8» was generated from the 251 isolate after inoculations into rhesus monkey 32H 
following in vitro culture (117). 
SIVsmPBJl4 molecular clones: The virus isolate SIV~ffi.9, which had been used to 
inoculate the pigtailed macaque (PBJ), had been passaged once on human PBMC following 
isolation from a seropositive sooty mangabey, After infection of animal PBJ with this 
isolate, vims was isolated by cocuiture with human PBMC. Similar virus preparations were 
made of spleen and lymph node tissues obtained after monkey PBJ died 8 days after 
infection, The biological clone SIVSmPBjl4 had acquired increased vimlence, which 
approached 100% mortality in M, llemestriua following intravenous inoculation (38). 
Mortality rates of 33%, 75% and 33% were observed for M. IIIl1lalla, C. atys and 
M.nemestrilla, respectively (38). Animals inoculated with SIVSmPBjl4 developed profuse 
hemonhagic diarrhea within five days and died within two weeks post-infection (37). Three 
molecular clones (SIVsmPBj.1.9' SIV~mPBj-4.9 and SIVsmPBJU4) were derived from SIYSmPBj4.l4 and 
induce similar disease symptoms (102), In rhesus macaques, however, these clones do not 
cause an acute, but rather a more chronic disease progression (37). 
SIV maclAl1: Virus derived from cells transfected with tlus clone are cytopathic for rhesus 
PBMC, replicates in cultures of rhesus macrophages, and infects rhesus macaques when 
inoculated intravenously. Six macaques inoculated with SlY maclAIl all became infected and 
produced antibodies to viral envelop glycoproteins that neutralise virus, This molecular 
clone is markedly attenuated (84, 85). No clinical evidence of disease was observed 
throughout a 7 months expetimental period, Other reports described even longer disease-
free periods (86). 
SIVsmPGms.3: Blood transfusion from a SIY/STLV positive sooty mangabey to rhesus and 
pigtailed macaques resulted in induction of a neurologic disease and AIDS, Lesions in 
infected animals include extensive SIV -RNA positive giant cells in brain parenchyma and 
meninges, Based on morphology infected cells proved to be from the macrophage lineage, 
SIVsmPGm5.3 shows high levels of replication in pigtailed and rhesus macaque PBMC and 
macrophage cultures (100). 
SIVsmH59J.3: The biological isolate SIVsmE543 was obtained late in disease from an 
immuno-deficient rhesus macaque which suffered from SlY-induced encephalitis, Then, 
molecular clone SIVSmE5-lJ .J replicates well in macaque PBMC and monocyte-derived 
macrophages and resists neutralisation by heterologous sera which broadly neutralise 
genetically diverse SIV variants ill vitro (53). 
SIV mne027: Uncloned virus isolate SlY Il1Jle was used to infect pigtailed macaques and the 
molecular clone SIV mne027 was derived from mesenteric lymph node tissue, This molecular 
clone is minimally cytopathic and not syncytium-inducing, replicates well in non-stimulated 
PBMC and is highly cytopathic for CD4' T-cell subpopulations in stimulated PBMC (70). 
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1.12 PATTERNS OF PROGRESSION TQ AIDS IN SUSCEPTIBLE 
OUTBRED POPULATIONS 
IfillV-l infection is left untreated the mean survival time is approximately 10 to 12 years 
post-infection. Because of host differences and genetic polymorphisms of key regulatory 
genes such as WfC, some individuals will progress slower or faster than the majority of the 
population (Figure 5). Similarly. in younger individuals such as juveniles or neonates or 
very old individuals such as geriatrics, the disease can progress more rapidly, in prot due to 
an immature or weakened irmnune system. Wllile the mean time to death due to AIDS was 
approximately 10 to 12 years in humans. In Indian rhesus macaques the mean survival time 
of an animal infected with a strain of medium virulence (SIV mx251) is approximately 1.5 to 2 
years (Figure 5), 
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Rapid progression 
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Figure S. A scheme depicting the different rates of progression to disease in an outbred population with 
survival being dependent on the interaction of both viral and host factors, 
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Similar to humans, in an outbl-ed population of macaques there is a host dependent 
variation in the time to development to AIDS which, together with the vil1llence of the 
inoculum virus, detennines if an animal will be a rapid, intermediate or slow progressor 
(Figure 5). In rhesus macaques, a highly vil1llent strain of SIVsmlma" will likely cause a high 
and sustained viral load (Figure 6A). This in general is accompanied by a more rapid decline 
in CD4+ T cell levels than in animals infected with a less virulent strain of SlY (Figure 6B). 
Viral strains which have an intennediate virulence potential have a lower steady state level of 
plasma viral RNA than those of higher vil1llence (Figure 6A). 
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Figure 6. Two schemes depicting A, the virus loads in plasma (concentration of viral RNA per ml 
plasma) and the influence of virus load on the rate of disease progression, which is inversely correlated with 
"B", the rate of CD4+ T-cell decline. 
Similar to HIV-I, in rhesus monkeys the principal cell targets for SIV,mhnoo are the CD4+ 
T cells and cells of the monocyte/macrophage lineage. Infection of both cell types by HIV-I 
is thought to be important for the pathogenesis of AIDS. Cell tropism of HIV-I has been 
correlated with the type of biological variants of HIV -1 and the co-receptors these vinlses 
use to enter cells. mv -I utilises two major co-receptors and this co-receptor use also 
correlates with the two different biological vm'iants of HlV-I observed in patients (12). In 
the early stages of infection of man viral variants tend to be non-syncytium inducing (NSI). 
These vimses are macrophage-tropic (m~) and use the CCRS co-receptor (12). In later 
stages towards the development of AIDS, syncytium inducing (S!) variants of HIV-l 
emerge and become dominant (123). SI variants are primarily T-cell-tropic and use the 
CXCR4 (3) co-receptor, or they may be dual-tropic for both macrophages and T-cells 
(R5X4). The conversion from NSl to SI variants in infected patients indicates development 
of AIDS and thus a poor prognosis (123). 
SIV'mI~ also infects both T-cells and macrophages (2S). Indeed multinucleated giant 
cells are a frequent observation in SIV infected monkeys which develop AIDS (S). SIV,mhnoo 
isolates are also capable of infecting CD4t T cells, even resting T -cells in some cases (28). 
This seems to be caused by utilising a co-receptor, other than CXCR4. In fact to date no 
SIV5m!rIlJ.C group vhuses have been shown to be CXCR4 utilising, but all strains are using 
CCRS co-receptor (19, 29). 
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In conclusion, there are a vast number of important similarities between the SIV -macaque 
model of AIDS and HIV ~ 1 infection of humans, though in some instances, interesting 
differences exist. The similarities are, however, overwhelming, especially with regard to the 
cOlTelation of vims load patterns (Figure 6A) with disease progression, and to the individual 
variation in susceptibility for the development of AIDS in outbred monkey populations 
(Figures 5 and 6). 
1.13 SCOPE OF THIS THESIS 
This thesis addresses the issue of increased viral vimlence as a possible cause of rapid 
progression to AIDS. The working hypothesis was that additional virulence factors could be 
acquired by viral variants which would accelerate the progression to AIDS faster than occurs 
in the majority of individuals infected with HIV ~ 1. 
A study was performed in the rhesus model of AIDS which supported this hypothesis. 
Efforts were then directed at acquiring proof by developing a new strategy to derive truly 
representative molecular clones of SlY from an animal which had very rapidly progressed to 
AIDS (less than one month). One molecular clone was then studied at the molecular level, as 
well as ill vitro and ill vivo to determine its unique biological characteristics. 
Studies were initiated to examine possible virulence factors encoded by the lief gene by 
utilising a unique Ilefmutant identified during the molecular cloning of this virus. Finally, a 
strategy was developed to deliver this molecular clone as DNA directly to cells ill vivo in 
lymph nodes. 
By using this technique in the accumulation of underived mutations, due to in vitro 
propagation of the virus, can be circumvented. This will enable us to better correlate 
genotypic changes within altered phenotype, and may lead to the identification and 
characterisation of molecular determinants responsible for the accelerated progression to 
AIDS. 
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2.1 ABSTRACT 
To detcmune if passage of late stage variants of SIV would lead to a more virulent 
infection and rapid progression to AIDS, we designed a study in Macaca mu/afta. In a 
ullifOlm group of ten age-matched animals from the same genetic breeding stock infected 
with SIV B67O' it took seven months before one of the ten animals developed AIDS. Passage 
of VilUS taken inunediately prior to death from this animal resulted in death due to AIDS 
developing within four months in the recipient. Again subsequent passage of virus taken latc 
in disease resulted in an accelerated disease course with AIDS developing in 2.5 and 1.8 
months, respectively. The fourth passage of virus taken latc in disease from the most rapid 
progressor (1.8 months) resulted in AIDS developing in this recipient within I month of 
infection. During each consecutive passage ill vivo, the loss of memOlY T-cells became 
more acute. Evidence that the vims became more virulent with selective passage of late stage 
variants was the markedly increased level of both plasma antigen and viral RNA. The 
pathology of acute AIDS in these cases closely resembled that seen after a chronic disease 
course. 
2.2 INTRODUCTION 
The rate of progression to AIDS is highly variable, influenced by both viral and host 
factors. The median time to AIDS if left untreated has been estimated to be between II and 
14 years dependent on the cohOlt studied (41). At each end of the survival spectrum in a 
population infected with HIV - I, individuals can be identified which either develop the 
disea<;e more rapidly (rapid progressors, disease within three years of infection) or become 
10ng-tetID survivors or long-term non-progressors (40). In addition to host factors (i.e. co-
receptor mutations) (2, 7, 22, 30, 48, 57), viral factors have been identified (Le. deletions 
in nej) wWch contribute to a less pathogenic disease course (25, 45). However, despite the 
well documented host factors \vhich may contribute to a more rapid disease course, the viral 
virulence factors responsible for rapid progression to AIDS have not been identified. In 
contrast to viral vimlence factors associated with rapid progression, several viral virulence 
factors associated with chronic progression to AIDS in the SIV macaque model are being 
localised to particular regions of the genome (II, 23, 34). To develop a model to evaluate 
the possible role of viral vimlence on rapid progression to AIDS, we turned to the use of 
non-human primates. Rhesus monkeys (Macaca l1l11latta) when infected with certain strains 
of SN, develop a disease which in almost all respects mimics AIDS in humans (17). 
The simian immunodeficiency viruses (SIV) are a group of human immunodeficiency 
virus (HIV) related, but distinct lentivimses (33) isolated from several different African 
primates including Chimpanzees (SIV",) (43), sooty mangabeys (SIV,m) (12, 42), 
Mandrills (SIV=d) (54) and African Green monkeys (SIV.,m) (I, 21). The infection of 
Asian macaques with different SIV strains derived from sooty mangabeys results in the 
development of an AIDS-like disease remarkably similar to AIDS in humans infected with 
HIV-I (47). The SIV macaque model has proven important for investigating the 
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pathogenesis of lentivims induced immunodeficiency (4, 8, 20), tranSll11SSlOn (37, 53), 
viral-host interactions (31, 46) as well as the evaluation of antiviral therapy (10, 56) and 
candidate vaccines (17). 
A number of different SIV strains which cause AIDS in Asian macaques have been 
described (47), which have different disease causing potential (39), Certain commonly 
studied SIV strains stich as SIV 1ILJ.,25J cause AIDS over a variable period of time in outbred 
macaques with 50% mortality ranging from 1-2 years (5, 6, 32, 39), Yet other isolates 
which have been passaged more extensively in human T-cell lines become highly attenuated 
(5,29) and some molecular clones, for instance, are non-pathogenic (38). This attenuation 
is frequently attributed to passage of SIV on human T-cell lines which may result in 
tmncations in the SIV transmembrane open reading frame (19) and in a growth advantage of 
certain ill vitro adapted variants over others (15, 26, 36). 
In contrast to the more chronic AIDS causing SIV isolates, a pruticular isolate designated 
SIV~mmPBJ has been described which causes rapid death of pigtail macaques. SIYSrrunPBjl4 was 
derived from SIVsm (13). The histopathology of the acute disease syndrome, however, does 
not resemble AIDS. SIV,mrnPBJ infection results in an acute hemorrhagic diruThea culminating 
in metabolic acidosis and death in experimentally infected pigtailed macaques within 10 to 
14 days (9, 14,58), Since this syndrome is distinct from the AIDS-like illness observed in 
rhesus macaques and since infection of pigtailed macaques does not result in long-telm 
progressive disease, this SIV,mmPBjJ4 isolate is considered an atypical lentivirus (14). 
Interestingly, if the acute hemorrhagic diarrhea is treated successfully, animals may recover 
and then only after a protracted period develop a chronic disease course resembling a more 
classic AIDS-like disease only after more than a year following infection (44). 
The aim of this study was to determine if primate lentiviruses become more virulent with 
ill vivo evolution, as was supported by the recent observations of Kimata et a1. (18, 24). We 
proposed that by selective end-stage disease passage of SIVa true AIDS-like disease may 
develop acutely in rhesus macaques. Using the strategy of serial in vivo passage we 
attempted to increase the virulence of the SlY strain used and to determine how rapidly 
AIDS could develop in a unifonn group of juvenile macaques. The result was a SIV strain 
designated SlY 8980 which was capable of inducing a highly accelerated AIDS-like syndrome 
with extremely high viral loads and rapid loss of CD4 T-cells within weeks of infectioll. The 
histopathological lesions observed in all acute cases were indistinguishable from those 
found following a chronic disease course resulting in AIDS. 
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2.3 MATERIALS AND METHODS 
2.3.1 Animals and viruses 
The study population consisted of a uniform group of sixteen captive bred, retrovirus 
free and male juvenile macaques (Macaea IIlli/atta) which were approximately 18 months of 
age at time of infection. The animals were from a common outbred stock of Indian origin 
and bred in captivity at the Biomedical Primate Research Centre (BPRC). All were raised 
matemally until six months of age, then weaned and group housed in preparation for the 
study. In the first ill vivo passage (P 1) ten age-matched male juvenile Macaca mulatta were 
infected with 5 x 102 monkey infectious doses (MID50) of the SIVsm derived strain, SlV B670 
(3,42) From the first animal which developed AIDS (seven months post-infection) 2 x 106 
peripheral blood mononuclear cells (PBMC) were used to passage the infection 
consecutively to the following group of animals in each subsequent passage. Animals were 
monitored hematologically to measure T helper/memory cell loss, as well as to detemline 
levels of plasma viraemia ftir evidence of development of AIDS. Based on clinical and 
hematological evidence of AIDS animals were euthanised followed by comprehensive 
autopsy with complete histopathological and bacteriological assessment. 
2.3.2 Biochcmical- and hematological analysis 
Routine clinical biochemistry and hematological analysis were performed at routine 
intervals to support the clinical diagnosis of AIDS. FACs analysis was performed using Leu 
3a (anti-CD4), Leu 2a (anti-CD8) and 4B4 (anti-CD29) to monitor changes in T-
helper/memory subsets. Staining of mononuclear cells for lymphocyte subsets was 
perfonned by double labelling using FACs analysis Leu 3a and 4B4 as previously 
described. Plasma antigen levels were determined by SIV p27 antigen capture assay 
(Coulter Corp. Hialeah, Fl.) according to manufacturers recommendations. 
2.3.3 Vi!'al RNA levels in plasma 
In order to detenuine SIV RNA levels in plasma of infected macaques a highly sensitive 
and reproducible quantitative competitive (QC) RT-PCR assay has been developed (49). 
Briefly, 200 J.!1 of plasma was added to 600 J.l1 of guanidine-isothiocyanate-based lysis 
solution containing 300 copies of internal standard RNA. The RNA was precipitated by 
propanol-2 and was reversed transcribed and amplified with rTth DNA polymerase. TIle 
amplification products were hybridised in six five-fold dilutions to a capture probe that was 
streptavidin-horseradish-peroxidase-rnediated colorimetric reaction. The amplified intemal 
standard was hybridiscd to a realTanged 26-bp capture probe in separate microwells. The 
number of RNA copies in the plasma sample was calculated from the optical density of the 
sample wells compared to that of the corresponding lntemal standard. Data was plotted for 
each individual animal involved in the sequential ill vivo passage in RNA eq/ml (Figure 3). 
Furthermore, to compare survival with virus load, the concentration of plasma viral RNA at 
the threshold achieved at the set point (defined for tllis model by ten Haaft ct ai, 1998)) (49), 
was plotted against the number of weeks each animal survived post-infection (Figure 4). 
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2.3.4 Preparation of SIVs980 virus stocks 
PBMC from rhesus monkey 8980 (P4) were isolated from EDTA-treated blood by 
banding over Lymphocyte Separation Medium and washed twice with RPMl supplemented 
with 10% Fes. Cells were cultured in an autologous system using only the animal's own 
PBMC (16) to avoid culture bias or attenuation as has been reported when SIV is 
propagated on human T-cell lines. After 14 days of culhlre, cells were transferred to fresh 
feeder plates and grown for another 14 days. The supernatant from each well was collected 
and measured for the presence of SIV Gag antigen, using a p27 antigen capture assay 
(Coulter). Supernatants from wells containing the highest amounts of p27 were pooled, 
clarified to remove cellular debris, mtrated over a 0.22 urn sterile mter (Millipore) and 
aliquoted. Vims was administered intravenously to 8 rhesus macaques as perfonned 
previollsly. Animals were followed for disease progression for comparison of survival with 
animals (P l) infected with the pre-passage isolate, SIV B670' 
2.3.5 Statistical analysis 
The survival of animals infected with the two viral strains (SlV B670 and SIV 8980) were 
compared by plotting Kaplan-Meier curves. The difference in the survival times between 
these two viral isolates in separate groups of monkeys was compared to demonstrate the 
increase in vimlence following serial ill vivo passage. The significance of this observation 
was tested using logrank analysis. 
2.4 RESULTS 
Each consecutive passage in age Ihatched juvenile rhesus monkeys resulted in a reduction 
of the asymptomatic period and a dramatic acceleration in the progression to AIDS until the 
most rapid progression time to AIDS of I month was reached by the fourth passage. In the 
first passage (PI) in ten monkeys, the time to death due to AIDS ranged from seven months 
(PIa and Plb) to more than three years (Plj) (Table I), The first animals to develop AIDS 
in P I were asymptomatic for approximately five and a half months. Disease development in 
the first animals to succumb to AIDS was characterised by loss of T-helper/memory 
(CD4fCD29) cells and persistent plasma antigenemia. Table 1 lists the AIDS defining 
pathological diagnosis of all animals included in the study based on complete 
histopathological and microbiological workUp. Although the length of the asymptomatic 
period decreased, the clinical and pathological manifestations of the disease did not change. 
Surprisingly, the same spectrum of pathological lesions that developed after chronic SIV 
infection was also found after more rapid disease course (Table 1). By the third and fourth 
passages (P2 and P3 respectively), only a brief asymptomatic period could only be observed 
for a period of days. In the ten monkeys infected in passage I, plasma antigen levels were 
predominantly below the detection level of the antigen capture assay « 10 ng) (Table I), T-
helper cell numbers, and most prominently T-helper/memory cells declined slowly but 
persistently after four to five months of infection in animal Pia, the first animal in passage I 
to develop AIDS (not shown), 
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Table 1. Progression time to death due to AIDS, plasma antigenemia and principal 
findings at autopsy in sequential passage of SIV in macaques 
Plasma antigenemia 
Monkey Time to death SIVp27 Duration Principle histopathological findings 
(months) (ng/mW 
Passage 1. Infected with SIVBn~ stock 
Pia 7 <10 Persistent pneumocystis, candidiasis, CMV. lymphoid atrophy 
Plb 7 <10 NP interstitial pneumonia, CMV, cryptosporidium, candidiasis 
PI, 9.5 <10 NP meningitis, candidiasis, pulmonary abscesses 
Pld t3.5 <10 NP interstitial pneumonia, cryptosporidium, candidiasis 
PI, 16 <10 NP interstitial pneumonia, meningitis, glomerulosclerosis 
Plf 20.8 <10 NP persistent encephalitis, interstitial pneunomia. CMV, 
candidiasis 
Pig 23 <10 ~'P peritonitis, cholangitis. interstitial pneumonia 
Plh 32.7 <10 ~'P disseminated CMV, interstitial pneumonia, gl. sclerosis 
PH 32.8 <10 NP interstitial pneumonia, candidiasis, giardiasis 
Plj alive <10 ~'P 
Passage 2. Infected from Pl. 
1'2 4.1 15.5 NP persistent interstitial pneumonia, Clv[V, glomerulonephritis, 
cfyptosporidium 
Passage 3. Infected from P2 
P3, 1.8 35.5 Persistent encephalitis/meningitis, cryptosporidium, interstitial 
pneumonia 
P3b 2.5 39.9 Persistent e nte ritis/wasting, ence phalitis/me n i ngi tis 
Passage 4. Infected from P3a 
P4 1.0 104.8 Persistent interstitial pneumonia, CMV, diarrhea I wasting, encephalitis 
I meningitis 
Passage S. Infected from P4 
P5a 2.0 45.3 Persistent interstitial Pneumonia, CMV, encephalitis I meningitis 
P5b 2.0 12.7 Persistent interstitial Pneumonia, C~fV I generalised lymphoid atrophy 
"'Maximum concentration of plasma antigen measured during the course of the disease. 
NP, Not persistent; CMV, cytomegalovirus. 
TIle second passage (P2), consisted of a single animal inoculated with cryopreserved 
PBMC taken from the first animal to develop AIDS in PI at six and a half months post 
infection. This animal, P2, was only asymptomatic for three months during which 
CD4'/CD29' T-cells declined (Figure 1) and plasma antigen levels slowly increased and 
persisted until AIDS developed at 17 weeks (4.1 months) (Figure 2). PBMC taken from P2 
from the last time point before death were administered to two animals, P3a and P3b. These 
animals developed levels of plasma antigen which were persistent and rose to higher 
concentrations (Figure 2) than the previous animals PI or P2 from which they had acquired 
the virus (35.5 and 39.9 ng p27 for P3a and P3b) respectively (Table I). During Ole 
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asymptomatic period in these animals, which ranged from four to six weeks, T-
helper/memory cell numbers declined rapidly. AIDS developed in animals P3a and P3b, by 
1.8 and 2.5 months respectively. 
In the fourth passage PBMC were administered to animal P4 from animal P3a which had 
developed AIDS the fastest in passage 3. Within two weeks plasma antigen levels rose to 
levels greater than 100 ng/ml (Figure 2) with an abmpt decline of CD4'/CD29' T-eells 
(Figure I). This rulimal P4 died with AIDS within one month of infection with 
histopathological lesions characteristic of AIDS (Table I). PBMC from P4 taken from the 
last time point before death were administered to animals P5a and P5b. Progression to AIDS 
more rapid than I month post-infection was not observed. It appeared that a maximum 
virulence had been achieved by the fourth passage since the approximate time to AIDS in the 
fifth passage was similar to that observed in the third passage. Both animals P5a and P5b 
progressed to rather uniformly to AIDS within two months with a characteristic rapid loss of 
T -helper/memmy cells (Figure I) as well as a very high and persistent plasma antigenaemia 
(Figure 2). To lUle out that other pathogens, opportunistic infections or cofactors were not 
transmitted during the ill vivo passage all animals were carefully studied for seroconversion 
of herpesvilUses post SIV infection. There was no evidence of transmission of 
herpesviruses with the SlY inoculum. Furthermore, all animals remained free of S1L V and 
type D retroviral infections during the course of these studies. By all criteria the accelerated 
disease course was due solely to an increase in virulence of SIV following ill vivo passage. 
One of the most important predictors of the rate of progression to AIDS in humans is 
level of viral RNA in plasma (35). In the rhesus SIV and SHIY models we have also 
demonstrated that there is a critical threshold of viral RNA in plasma which is required for a 
pathogenic disease course. Furthermore a correlation with the magnitude of plasma viral 
RNA maintained and viral vimlence was observed (49). Retrospectively we examined all 
available plasma samples from this passage study ruld compared them with the rate of 
disease progression and the level of passage (Figure 3). A relationship was observed 
between the maximum or sustainable level of plasma viral RNA and the rate of progression 
to AIDS (Figure 4) although statistically this would require more animals to strengthen this 
analysis. The animal which developed AIDS most rapidly had the highest overall level of 
plasma viral RNA (Figure 3) whereas those which survived longer had lower RNA loads 
(Figure 4). Not unexpectedly there was a relationship between plasma RNA loads and 
plasma Ag levels (Table I, Figure 2 and Figure 3). An inverse relationship was found with 
the final level of plasma RNA and the CD4'CD29' T-cell levels per rulimal. In general, the 
higher the sustainable plasma RNA loads obtained, the more rapid T-helper/memory T-cells 
declined (Figures I and 3). Taken together these data suggest that the virulence of the SlY 
strain increased substantially with each passage. Further proof of the increased virulence 
acquired by sequential end-stage disease passage was obtained by infecting eight more 
animals with SIV from the fourth passage animal (P4). Comparison of the survival of 
macaques infected with the original pre-passage SIV B670 strain with animals infected with 
the post-passage vims strain (SIY"so) isolated from the P4 acute AIDS ease (animal 8980) 
(Figure 5), revealed distinctly different Kaplan-Meier curves with a significrultly (p=0.0036) 
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poorer survival in the group of animals infected with the passaged SIV 8930 strain. 
Remarkably, the vimlcnce of the passage SIV89so strain was even more pathogenic in mature 
rhesus monkeys than in the juvenile animals infected with the pre-passage SIV B670 stock 
(Figure 5). If it had been possible to infect more juvenile macaques with the passaged 
SIVs9sO stock derived form the P4 animal, then a more acute disease course similar to the P5 
animals would have been expected. 
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Figure 1 
Changes in the CD4+/CD29+ T-cell population 
during progression to AIDS in animals infected 
with each subsequent passage of virus. 
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Figure 2 
Plasma antigen concentrations (fig/ml) during 
progression to AIDS in animals infected 
following subsequent in vivo passage of SIV. 
2.S DISCUSSION 
This study demonstrated that serial ill vivo passage of SIV from end stage disease 
resulted In an accelerated disease course of AIDS in rhesus monkeys. The ten animals 
infected with SIV B670 in the first passage developed tcmtinal AIDS in a period of time 
ranging from seven months to more than three years. In contrast, during the passage of this 
vims a marked reduction in the time to develop AIDS was observed which ranged from 4.1 
to 1 month post infection. Our experiments also demonstrated that the accelerated 
development of AIDS following SIVsm passage in Asian monkeys was associated with the 
development of very high concentrations of plasma antigen and RNA in the host. These data 
strongly support the hypothesis that AIDS causing lentivimses become more virulent upon 
in vivo evolution and acquire the capacity to accelerate the progression to AIDS (18, 24), 
SIV infection is a naturally occun'ing asymptomatic lentivhus infection restricted to several 
Africml primate species including sooty mangabeys (SIVsm) (12, 42), African green 
monkeys (SIVagm) (1,21) and Chimpanzees (SIVcpz) (43). SIV infection does not occur 
naturally in Asian primate species such as macaques, yet when experimentally infected with 
SIV strains derived from sooty mangabeys they develop AIDS with remarkable similarity to 
the disease in man (19, 47). TIlls model has enabled the study of possible causes of rapid 
progression to AIDS in a uniformly susceptible host population. Certain host factors such as 
infection in the neonatal or geriatric period, immunosuppressive treatment for autoimmune 
disease or transplantation or patients with other concurrent chronic diseases are potential risk 
factors for rapid progression to AIDS. In an absence of host risk factors some infected 
individuals still become rapid progrcssors to AIDS. We propose that such individuals who 
do not have such host risk factors but become rapid progressors are infected with 
particularly vimlent strains. Several reports suggest that more vimlent HIV -1 variants 
emerge late in the course of the disease as AIDS develops (27, 28). The vast majority of 
HIV -I transmissions occur unknowingly from apparently healthy individuals relatively early 
in infection before symptoms of AIDS develop. Occasionally however, transmission of 
more vimlent variants may occur from individuals with more advanced HIV infection and 
infection with such variants may give rise to a rapid progression in the absence of host 
susceptibility factors (50-52). Although it can be expected that transmission from advanced 
AIDS patients is currently unlikely now that the disease is adequately diagnosed and that 
treatment and counselling take place in developed countries, it may still occur in some 
instances. Indeed, certain individuals such as IV drug users and sexworkers may continue 
to share needles or sell unprotected sex despite having developed AIDS. Infections acquired 
from individuals with advanced disease may result in a more virulent infection and rapid 
disease course. To model this scenario we selectively transfelTed blood animals with a from 
late stage infection to healthy naive animals of the same age, sex, and breeding stock. 
Although not inbred they were from the same origin and bred in the same facility under the 
same conditions. By I) selecting the fIrst animal in a group to develop AIDS and, 2) 
selecting late stage samples (2 weeks prior to AIDS) for passage we eventually acquired a 
vims (SIV 8980) which caused a very rapid progression to AIDS. 
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Figure 3. 
Plasma viral RNA concentrations (RNA Eqlml) 
during progression to AIDS in animals infected 
following subsequent in vivo passage of with SIV. 
Although the number of rhesus monkeys 
used were relatively limited, after several in 
vivo passages of SlV a remarkably 
accelerated progression time to AIDS was 
noted which was not observed in the initial 
group of ten animals. These results 
suggested that our experimental late stage 
transmission from the most rapid 
progressors selected for particularly vimlent 
viral variants. Finally, the importance of 
controlling for host variables became 
apparent when we examined the virulence 
of the derived SIV strain in older animals 
(data not shown). When the same vims 
inoculum was administered to animals of a 
different age group or geographic origin, 
the pattern of disease observed was 
somewhat different from this group, 
emphasising the importance of controlling 
for host variables in studies on disease 
progression. With passage there was a 
marked increase in maximum plasma 
antigen levels observed (from <10 ngfml 
p24 to > 100 ng/ml). These results were 
similarly reflected when plasma RNA levels 
were examined. In passage 3 vims loads 
rapidly reached levels of JxID' RNA EqlmI 
and tended to persist at these relatively high 
levels until death ensued shortly after. In 
passage 4 a markedly high peak reaching 
ahnost Ix 10' RNA Eq/ml was accompanied 
by death of the animal (Figure 3). A plot of 
the time to AIDS against the last plasma vims load measured before death was also 
indicative of the relationship between a very rapid disease course and high vims loads 
(Figure 4). Further evidence of selection of more vimlent variants was obtained at the 
molecular level. On studying the variation of envelope during each successive passage there 
was a narrowing of the quasispecies over time with the emergence of a dominant genotype. 
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In the first two passages there was a decrease in the ratio of synonymous to non-
synonymous mutations suggestive that immune responses played a role in selective pressure 
(55). However, as the virulence of the inoculum increased and the progression time to AIDS 
decreased to less than two months, then a dominant variant emerged in which only 
synonymous mutations were observed (55). This is likely due to the marked degree of viral 
replication as evidenced by the very high levels of viral RNA reached in the most rapid 
progressors (Figure 4). These animals progressed to AIDS before an effective immune 
response could be mounted (Table 1). 
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Figure 4. Correlation of survival in months with virus load (RNA Eq/ml) in animals. Virus load was 
based on the value observed at the "set point" as previously documented in this model as being between 6 
and 8 weeks. If animals died before 2 months, then the last plasma load value before death was used. 
The pathology observed in these cases was relatively indistinguishable from AIDS 
observed after a chronic disease course. Imp0l1antly, the pathology observed in these cases 
was distinctly different from the rapid disease syndrome observed with SIY,b) (9) in pigtail 
macaques (14, 58), The acute disease syndrome observed in SIVpbj infected animals are 
characterised by hemorrhagic enteritis with death in approximately 10 to 14 days post-
infection. If these animals are treated symptomatically they can survive the acute enteritis, to 
later develop a chronic disease course resulting in AIDS one to two years later (44). 11mt 
end-stage AIDS can develop as rapidly as one month post-infection after infection with tillS 
post-passage strain of SIV, which distinguishes it from SIV PBJ' is in itself of pathologic 
importance. The study of the pathogenic events that precipitate such an acute disease course 
may provide more fundamental understanding into the mechanisms of the disease itself. To 
further understand the pathogenesis of the acute AIDS disease course, a molecular clone has 
been derived from the most rapid progressing animal. Further studies are in progress with 
this molecular clone to define the viral virulence factors associated with rapid progression to 
AIDS. 
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3.1.1 ABSTRACT 
Of the viral factors that are proposed to influence the rate of progression to AIDS, the 
role of infectious dose remains unresolved. Intraveneous infection of out bred Macaca 
mllialta with varying doses of SIV 8980 revealed an endpoint from which an Infectious Dose 
50 (IDso) of 5xlO·6 was defincd. In the six infected animals, the time to develop AIDS was 
variable with a spectmIU of rapid, intermediate and slow progressors. High and sustained 
plasma viremia with marked loss of CD4+ T -cells was a distinguishing feature between rapid 
versus i"ntelmediate and slmv progressors. Animals that received the highest doses did not 
develop the highest sustained viral loads, nor did they progress more rapidly to disease. 
Similarly animals infected \"lith lower doses did not uniformly develop lower viral loads or 
progress more slowly to AIDS. Furthermore, compiled data from more than 21 animals 
infected with different doses of the same virus administered by the same route failed to 
reveal any correlation of infectious dose with survival. Indeed, host factors of these outbred 
animals, rather than dose of the initial inoculum were likely an impOltant factor influencing 
on the rate of disease progression in each individual animal. Comparison of animals infected 
with SlY B670' from which SlY 8980 was derived, revealed marked differences in disease 
progression. Clearly, although dose did not influence viral loads nor disease progression, 
the vi11l1ence of the initial inoculum was a major determinant of the rate of progression to 
AIDS. 
3.1.2 INTRODUCTION 
The observation that SIVsm infection of Asian macaques resulted in the development of 
AIDS similar to that seen in HIV -I infected humans has resulted in the development of an 
impOltmltprimate model for the understanding of AIDS pathogenesis (4,20,31,48). TIle 
evolution ofHIV-l infection and the development of AIDS varies considerably, with some 
individuals progressing to AIDS within three years of infection while others remain 
clinically asymptomatic without evidence of CD4+ T-cell decline for more than 18 years (7, 
26,32,39,43). Studies of rapid progressors and long-tenn nOIl-progressors have revealed 
that host immunogenetic (8, 24) and immunologic responses (7, 9, 10, 3D, 33, 38), as well 
as ceJiain virological factors 03, 15, 25, 36) 02, 35, 42) Illay delay the onset of SlY or 
HlY -induced disease (l7, 18, 44, 49), 
Viral factors such as infectious dose, route of infection, repeated exposure and viral 
virulence have been proposed to influence the rate of progression to AIDS (1, II, 27, 34, 
35, 40. 43. 47). To date only the issue of viral virulence has been addressed in depth, but 
only with regard to attenuation of viral vimlence. The Nef protein of SIV and HIV is one of 
the best defined viral factors and is widely considered to be a critical factor for the 
pathogenesis of AIDS in both humans (HIV -1/HIV-2) and rhesus macaques (SIV,,,,,,,,,,) (27, 
29, 48). The molecular detenninants of vimlence appear to be encoded by several viral 
genes in different regions of the genome and in general appear to evolve in an interrelated 
fashion (14, 34). In a series of SIV studies using single Ncf and multiple deletion mutants, 
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Baba et al. showed that AIDS could develop in neonatal mlimals when given high doses of 
the virus (2). Subsequently, the viral threshold hypothesis was proposed to explain in part 
the pathogenic potential of attenuated vilUses if high enough levels of viremia were achieved 
(45). More recently, a pathogenic threshold of plasma viral load has been defined which not 
only distinguishes between pathogenic and non-pathogenic infections, but also predicts the 
rate of disease progression (46). Based on these as well as observations from other 
infectious disease models, we set out to detennine the influence of the dose of the inoculum 
on the initial viral load, the threshold achieved, and thus the influence on disease 
progression. To address this question, different dilutions of the SIV 8930 isolate were 
administered intravenously to ten mature rhesus monkeys. Animals were foHowed for 
evidence of infection, plasma viral load, CD4+ T-cell decline and the rate of progression to 
AfDS. These results were compm'ed to data compiled from other animals infected previously 
with different doses of the same virus stock. 
3,1.3 MATERIALS AND METHODS 
3.1.3.1 Animals, clinical and pathological observations 
Two separate studies were performed with mature, outbred rhesus monkeys (Macaca 
IIIl1latta) free of SIV, STLV, and type D retroviruses. In the first study 10 animals, two 
animals per group, received an intravenous administration of serial ten-fold dilutions of 2 IllI 
of SIV8980 ranging from IxlO" to IxlO" of the original vhus stock (21). Following 
inoculation, animals were monitored daily for clinical evidence of disease. At two-week 
intervals for the first two months and at monthly intervals thereafter, animals were lightly 
anaesthetised for physical examination and blood sampling. Haematological analysis 
included measurements of CD4+ and CD4+/CD29+ T-cell subsets, in addition to complete 
blood cell counts including differential leukocyte analysis. Semm and plasma samples as 
well as peripheral blood mononuclear cells (PBMC) were stored for retrospective virological 
analysis. Upon clinical and haematological evidence of AIDS animals were euthanised to 
avoid unnecessary suffering. A full autopsy was performed at the time of euthanasia. 
Necropsy and histopathological findings were compiled to confirm the diagnosis of AIDS in 
all cases. 
The second study consisted of retrospective data of rhesus monkeys which had been 
infected with the same stock virus by the sanle route of administration but by using different 
doses. The clinical and pathological follow-up of each animal had been performed using the 
same standardised criteria. 
3,1.3.2 Vims slock and virological analysis 
All animals were infected with the same SIVS980 stock (TCIDso lxIO·4.8) for comparative 
purposes. The stock was derived from animal 8980 (P4) following four in vivo passages of 
SIV B670 in juvenile rhesus monkeys bom and purpose bred from the BPRC's breeding 
colony of Indian rhesus monkeys (21). The SIVs980 stock was propagated on autologous 
PBMC. Within 10 days of autologous 8980 PBMC cultivation the supernatant was 
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harvested, clarified to remove cellular debris, aliquoted and preserved at -135°c' 
Virological analysis of inoculated animals included plasma lmtigen (p27 pg/ml), ELISA for 
anti-SlY antibodies, vims isolation, DNA-PCR on PBMC and qmUltitative RT-PCR on 
plasma, Plasma antigen and anti-SlY ELISA (SlY antigen kindly provided by MRC I 
programme EVA reagent repository, Potters Bar, UK) were measured as described 
previously (5). The DNA-PCR assay was performed on genomic DNA isolated from 
PBMe from inoculated animals. Genomic DNA was isolated from separated and washed 
PBMC by protein K I Triton X-IOO-based lysis followed by ethanol precipitation. Nested 
PCR was performed on each sample using SlY-gag primers as follows: SlY-gag 5' (outer) 
TTGAAGCATGTAGTATGGGCAGC (1139-1161 nt), SlY-gag 3' (outer) TGCCACCTA-
CTTGCTGCACTGGG (1453-1475 nt), SlY-gag 5' (inner) TGGATTAGCAGAAAGCCT-
GTTGG (1180-1202 nt) and SlY-gag 3' (inner) CCTCCTCTCGACACTAGGTGGTGC 
(1424-1446 nt). Outer reaction PCR mixes contained l~g genomic DNA, 20 mM Tris-HCI 
(pH 8.3), 50 mM KCI. 0,01 % gelatine, 2.5 mM MgCI" 200 uM each dNTP, 250 nM each 
primer and 2U of Taq DNA polymerase (AmpliTaq, PE Biosystems, The Netherlands) in a 
total volume of 50 ~l. Cycling conditions for outer primers consisted of an initial 
denaturation step (95"C, 3 min), followed by five cycles (95"C, 30 sec; 50"C, 30 sec; 70"C, 
30 sec), thirty cycles (95"C, 30 sec; 55"C, 30 sec, n"C, 30 sec), and finally by one cycle 
(72°C, 7 min.; 4°C, 7 min.; 20°C, 1 sec). From the outer reaction mix, 5~1 of product was 
transferred to an inner reaction mix containing 20 mM Tris,HCI (pH 8.3), 50 mM KCI. 
0,0 I % gelatine, 2.5 mM MgCI" 200 ~M each dNTP, 250 nM each primer and 2U of Taq 
DNA polymerase in a total volume of 50 ,.Il. Cycling conditions for inner primers were 
identical to the first PCR except that 20 cycles (95"C, 30 sec; 55"C, 30 sec; n"C, 30 sec) 
were carried out. PCR products were analysed by agarose gel electrophoresis. 
3.1.3.3 Quantitation of plasma vii'al load 
A quantitative competitive RNA-PCR was used to estimate the virus load in plasma (46). In 
brief, RNA was extracted from 200 111 of serum or EDTA plasma using guanidine 
isothiocyanate mediated lysis, followed by propanol-2 precipitation of the RNA. A known 
amount of synthetic intemal standard RNA was added prior to the RNA purification and 
was co-purified to monitor the efficiency of the purification. The RNA was reverse 
transcribed and amplifie.d in a single reaction protocol using rTth DNA polymerase (PE 
Biosystems, the Netherlands) and biotinylated primers. The internal standard RNA was co-
amplified to monitor the amplification efficiency. The amplified fragments were detected by 
a capture probe that was covalently bound to Nucleolink microwells (NUNC AlS, 
Denmark). The amplification products were detected by a streptavidin-horderadish 
peroxidase-mediated colorimetric reaction. The amplified internal standard was hybridized to 
a different capture probe in separate microwells. The number of RNA copies in the sample 
was calculated from the optical density of the sample wells compared to that of the 
corresponding internal standard well. 
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3.1.4 RESULTS 
Each pair of animals receiving each virus dilution became infected (table 1) until the 
doses of IxlO·s and IxlO·6 , where only one of each animal became infected. This indicated 
that the infectious dose 50 (ID50) was between these two dilutions at approximately 
3.2xIO·6. Thus, a clear dose-effect and infection was achieved. To detcnnine if animals 
which received higher doses also developed higher virus loads in plasma, either at the peak 
or set point of infection, we quantified the plasma vitus RNA concentration on sequential 
samples from each of these infected monkeys. The kinetics of the plasma virus RNA load of 
each of the infected animals is pIotted in figure 1. 
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lE+05 
----
CK (to··J) 
~ 8877 (10·5) 
IE"" 
-
lZI (10·6) 
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iE+02 
0 2 4 6 S 10 12 14 16 IS 20 22 24 
weeks post.inrectlon 
Figure 1. Plasma viral RNA le\'els in rhesus monkey after intravcnous inoculation with different doses of 
SIVS9iO (table I). Plasma virus RNA concentrations are presented as RNA equivalcnts per ml of plasma 
(RNA Eq/ml of plasma). 
At two weeks post-infection there was no difference in the pre-seroconversion peak of 
plasma viral load between animals receiving different doses of virus (figure 1). The 50-
called steady state or set point has been correlated with the rate of progression to disease in 
HlY-1 infected patients (37) and SlY or SillY infected rhesus monkeys (46). Comparison 
of the viral load levels established following the initial peak, when the apparent set points of 
plasma viral loads were reached also 'did not reveal any correlation with dose. For instance, 
animal IZI which received the lowest dose of virus had the highest viral load far above Ule 
pathogenic threshold as defined by ten Haaft et al. (46). Similarly animal 3175 which 
received the highest dose of virus had one of the lowest set point values (figure 1). There 
was also no correlation between dose, the viral peak, or the set point of the plasma viral 
load. Furthennore, the CD4+ T-cell subsets in the infected animals did not decline inversely 
with the dose of virus (figure 2). 
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To ensure that a possible con'elation was not overlooked because of the relatively small 
number of animals studied in this titration study, we retrospectively compiled data from 39 
mature rhesus macaques exposed to intravenous doses of SIVs980 ranging from 5xlO-
3 to 
100 ID,o' Of these 39 animals 21 became infected and the survival time until onset of AIDS, 
as was confinned by necropsy was documented (table 2). The dose and the survival period 
post-infection clearly did not correlate in rhesus monkeys which became infected with this 
pathogenic strain of SlY. 
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Figure 2. Percentage of CD4+ T·cells in circulation in mature rhesus macaques following intravenous 
inoculation of SIVS9>rl at different dilutions; A) lxlO-3, B) lxlO--4, C) lxlO'5, D) IxlO·6 and E) lxlO-1 • 
Animals 894 t (C), 1 YX (D) and 8737 and 2704 (E) remained free of infection and maintained CD4+ T-cell 
numbers within the nannal range. 
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Table 1 Virological readouts from Macaca 11Iulatta inoculated wi~h ten-fold dilutions of 
SlY 8980 
Animal Dilution of Plasma Ag (pg/ml}t Virus isolation'l Anti-SIV Ab~ Proviral* 
0.0 0.5 1.0 0.5 1.0 0.5 1.0 PCR 
2999 10"3 + n.d. + n.d. n.d, o.d. + 
3175 10.3 + + n.d. + + + 
4103 1O~ + + + + + + 
CK 1O~ + + + + + + 
8877 10.5 + + + + + + + 
8941 10.5 
IZI 1O~ + + + + + 
IYX 1O~ 
8737 10-7 
2704 JO·7 
*: diluted virus stock, #: plasma antigen at 0.0/0.5/1.0 months, !]I: virus isolation from PBMe at 0.5/1.0 
months, §: anti-SIV eoy at 0.5/1.0 months, :j:: pol peR from PBMC 
3.1.5 DISCUSSION 
A number of host, as well as vims factors, interact to influence the rate of progression to 
AIDS. The effect of the virus dose on the rate of progression to AIDS has been suggested 
but not proven. TIle effect of viral dose on disease development in animal models has been 
reported for cytomegalovirus (23), adenovirus (19) rabies virus (41), hepatitis B virus (22) 
and herpes simplex virus type 2 (16). To study the effect of HIV-l dose on disease in 
humans has proven difficult, even in documented cases of contaminated blood transfusions 
in cohorts of haemophiliacs. To address the hypothesis that higher doses of HIV -I may 
accelerate progression to AIDS we tumed to the SIV,m model of AIDS in rhesus macaques. 
This model mimics the pathogenesis ofHIV-I-induced AIDS in almost all respects (48). 
Two studies were undertaken using this model. Firstly in a prospective study ten mature 
rhesus monkeys were inoculated with serial ten-fold dilutions of the pathogenic SIV 8980 
isolate. TIlere was a clear correlation with the dose that the animal received and infection 
(table 1). However, there was no correlation between the infectious dose and peak virus 
loads or the set point (steady state) virus loads in plasma (figure 1). Furthermore, there was 
no inverse correlation between the decline of CD4' T-cells (figure 2) and the SIV dose Ule 
animal received. Lastly, a retrospective analysis of survival data (table 2) of 39 animals 
exposed to different doses of SlY 8980 administered intravenously, failed to reveal any 
correlation between the infectious dose administered and the time to development of AIDS. 
A number of host factors which may influence the rate of progression to AIDS have been 
documented, including age, concurrent disease, and host immunogenetics. We have 
previously found a correlation between survival and the MHC type of the SIV-infected 
animals (3, 6). Similarly, several viral vimlence factors have been reported to influence the 
rate of disease progression in man as well as in monkeys. 
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Table 2 Compiled results of survival of rhesus macaques inoculated with different doses 
of SIV89,o 
SIV DOSE Survival DNA Results Clinical outcome Macaque 
MID Months peR Ab Ag VI 
100 18.10 + 
I 
+ + 
I 
AIDS 900lb 
100 16.30 + + + AIDS 8984b 
100 15.00 + + + AIDS 8928b 
100 10.50 + + + + I AIDS 8771 100 7.00 + + + + AIDS 8606 100 5.30 + , + + + AIDS IX! 
100 9.00 + + + + I AIDS IVS , 
50 0.50 + I + AIDS 2999 50 + + + + Asymptomatic 3175 
5 14.50 + 
I 
+ 
I 
+ + 
I 
AIDS 4103 
5 not infected HQ 
5 7.20 + + + + AIDS eK 
5 4.80 + + + + AIDS 3991 
1.6 j not infected 4091 
1.6 not infected 9001a 
1.6 not infected 8986a 
1.6 not infected 89840 
1.6 not infected 8977a 
1.6 7.40 + + + + AIDS 8967 
1.6 not infected 89280 
1.6 + + + + not infected 8754 
1.6 30.75 + + + + AIDS 8604 
1.6 3.50 + + + AIDS lRO 
1.6 9.00 + + + + I AIDS L65 1.6 6.90 + + + AIDS es 
0.5 
I 
I I 
not infected 8941 
0.5 5.50 + + + + AIDS 8877 
0.5 not infected 3215 
0.5 9.60 + + + + AIDS 3049 
0.5 I I not infected eY 0.5 not infected eF , I , 
0.16 not infected 3532 
0.16 not infected 3598 
0.05 3.50 + 
I 
+ + 
I 
AIDS lZI 
0.05 not infected lYX 
0.05 not infected HT18 
0.05 not infected 3974 j 
0.005 not infected 8737 
0.005 not infected 2704 
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Celtain SIV mac nefmutations may either cause an attenuated disease course and prolonged 
survival or cause acute haemorrhagic enteritis. But a viral virulence factor that is capable of 
actually accelerating the disease progression to AIDS has not yet been identified. In a 
previous study (21) the ill vivo passage of SIV B670 led to an acute progression to AIDS 
following four ill vivo passages in monkeys. Comparison of the Kaplan-Meier plots of the 
survival of animals infected with pre-passage stock versus the post-passage stock clearly 
revealed that the virus had acquired a significant increase in vimlence capable of causing an 
accelerated disease course (21). Our data indicate that infectious dose is important for 
establishing SIV infection but does not influence the rate of progression to disease. Once 
infection has occurred, it is most likely that the replication rate and the virulence properties 
of the dominant viral variant in the viral inoculum detelminant the post-seroconversion level 
of viral load established (28, 46). Together, viral vimlence factors and host responses 
appear to dictate the rate of progression to AIDS once infection has been established. 
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3.2.1 ABSTRACT 
The efficacy of vaccine protection afforded by Jive attenuated vaccines was tested by 
heterologous SIV 8980 challenge following successful protection against homologous 
SIV I\l.lCJ1H challenge. Animals immunized with the attenuated SIV rnacBK28 molecular clone were 
asymptomatic and vinls isolation negative by quantitative virus isolation prior to challenge. 
Two groups of four animals previously immunised five years and four months 
(respectively) were challenged with 100 MID" of SIV"so as was a third group of four naive 
controls. All control animals that were challenged developed high levels of plasma 
antigenemia within two weeks of challenge and developed rapid T him cell loss whereas 
vaccinated animals did not. Quantitative virus isolation from peripheral blood mononuclear 
cells revealed that one out of four animals in each group became vims isolation positive but 
that the virus load in the two vaccinated animals was markedly lower than in non-vaccinated 
controls. Shldies are undenvay to determine the duration and immunological correlates of 
protection from AIDS. 
3.2.2 INTRODUCTION 
The SIV-macaque model is currently the only suitable primate lentivirus model in which 
vaccine protection from infection as well as disease (AIDS) can be studied. The significance 
of the early successes achieved using whole inactivated vims vaccines was diminished by 
the demonstration that human cell components incorporated into both the inununogen and 
challenge vims preparations (I. 5, 8. 9) appeared to be responsible for the protective 
inununity (2, 11). In fact, no animals have been protected from infection with cell-free, 
rhesus-grown challenge vims by immunization with whole inactivated vims. Protection 
against challenge with infected monkey peripheral blood mononuclear cells (PBMC) has 
been achieved using such imrnunogens (7), whereas atttenuated live virus vaccines appear to 
protect against cell-free virus grown in monkey cel1s (4). In both instances vaccine 
protection was achieved against an intravenous challenge with vims derived from 
homologous SIV rmc25J strains. 
This study was performed to determine whether vaccine protection from heterologous 
rhesus macaque-propagated SIV challenge could be achieved with an attenuated live 
vaccine, and if so, to determine if the duration of the immunization period was a factor in 
establishing broader protection against heterologous challenge. 
3.2.3 MATERIALS AND METHODS 
3.2.3.1 Immunisation 
Mature outbred rhesus monkeys bred in captivity at the TNO Primate Center (Rijswijk, 
The Netherlands) were infected with 2.5 rnl of tissue culture supernatant of Hut-78 cells 
transfected with the BK28 molecular clone of SlY =,m (10). The TCID" (50% tissue 
culture infectious dose) of the attenuated BK28 stock was approximately 6.3 x 103 per ml 
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when titrated on C8166 cells. Seven animals that had remained asymptomatic since May 
1988 were divided into two groups for the first (n = 3) homologous and second (n = 4) 
heterologous chaUenge experiments, respectively. Animals were monitored routinely for T-
cell subset analysis, Westem blot, and plasma antigen levels as previously described (7). In 
March 1993 a second group of four animals was infected with the same dose of the 
attenuated BK28 stock to provide additional immunised ~nimals for the second experiment. 
Almost two years post-immunization (February 1990) a homologous SIV mac251 challenge 
was perfolTI1ed on three of the 1988 inununized mlimals and two naive controls, hereafter 
designated as experiment 1. The challenge was perfOlmed with 50 MID" (50% monkey 
infectious dose) of the November 1988 pool of the 32H reisolate of SIV_251 grown on 
C8166 cells as previously described (3). Post-challenge follow-up included bleeding every 
two weeks for the first two months, with bleeding at two to four month intervals thereafter. 
3.2.3.2 Heterologous challenge 
Four animals immunized in 1988 and four animals immunized in March 1993 were 
challenged along with four naive controls with a highly virulent serial in vivo-passaged 
SIV 8980 strain derived in our laboratory and preserved as a virus stock. An additional four 
naive unchallenged control animals were added to complete this group of 16 animals, 
hereafter known as experiment 2. The SIV 8980 stock was prepared from autologous PBMC 
from macaque 8980, which died due to AIDS 28 days after htfection with SIV,mlI610 
passaged four times in vivo in juvenile macaques. This stock chacateristically causes a high 
level plasma viremia and rapid loss of T helper/memory (T him) cells in juvenile rhesus 
monkeys. The 8980 stock was prepared using PBMC taken from macaque 8980 two weeks 
prior to death and cultured without cocultivation in a T-cell culture system (see Quantitative 
Virus Isolation, below). \Vithin ten days culture supernatant was harvested, clarified to 
remove cellular debris, aloquoted and preserved at -135°C, III vivo titration was perfonned 
to establish the MID50' The three groups of animals in experiment 2 were challenged with 
100 MIDso of this stock by intravenous administration of 2 ml of 8980. Post-challenge 
follow-up was performed once every two weeks for the first two months, and once every 
two to four months thereafter. At each time point differential blood cell counts and subset 
analysis was performed for absolute CD8, CD4 T-cells and Thhnsubset analysis. 
3.2.3.3 Serological assays 
Virus neutralization (VN) titers were detcmuned in V-shaped microtiter plates by 
incubating in quadruplicate 10 ~I of heat-inactivated plasma at different dilutions with 20 
infectious particles of SIV ma,,251-32H in 10 J.d. After shaking and incubating at 37°C 2,000 
C8166 cells in 200 ~l were added to each well and the plates incubated for 7 days at 37°C, 
4% CO" 95% humidity. Subsequently, cells from each well were transferred to poly-L-
lysine-coated flat-bottomed microtiter plates, fixed in methanol, and immullohistochemically 
stained with SlY ~ specific antisemm and goat anti-human IgG-peroxidase conjugate. Wells 
containing no stained cells were scored as negative and the number of negative wells used to 
calculate the neutralisation dose 50% end point (NDso) by the method of Spearmann-Karber. 
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Antigen capture assay for SlY p27 was perfomled on serum, andlor plasma using a 
commercial antigen capture kit (Conlter, Hialeah, FL). Samples were serially diluted to 
detennine levels (pg/ml) of SIVp27 in plasma as previonsly described (7). 
3.2.3.4 Quantitative virus isolation 
Prior to heterologous challenge the two groups of animals vaccinated with attenuated 
BK28 in 1988 and 1993 were virus isolation negative, using a novel autologous PBMe 
virus isolation assay. This assay is performed using a T-cell culture system in which 1.0 x 
104 autologous rhesus PBMC are plated per well in steIile 96-well V-shaped tissue culture 
plates over itTadiated feeder cells. This number of PBmes per well was previously shown 
to provide suitable sensitivity, as well as a good working range for quantitation. Cells were 
cultured in an autologous system using only the animal's own PBMC to avoid culture bias 
resulting from the fact hat many human cell lines are not pennissive for all SlY isolates. A 
feeder system consisting of ilTadiated human PBMe, two human B cell lines, 
leukoagglutinin, and indomethacin was used to optimize the growth of a mature T-cell 
population for virus propagation. After 15 days of culture cells were transfen'ed to fresh 
feeder plates and grown for another 15 days. The supernatant from each individual well was 
collected and measured for the presence of SIV gag antigen, using a p27 antigen capture 
assay (Coulter). The number of infected cells per 106 PBMC was measured by enumerating 
the number of positive wells per plate after a minimum of 15 days of culture and calculated 
based on Poisson distribution. \Ve have evaluated and validated this quantitative virus 
isolation method in the chimpanzee model with quantitative virus RNA and DNA peR 
techniques (6). 
3.2.4 RESULTS 
3,2.4.1 Homologous challenge 
Three immunized and two naive animals challenged with 50 MIDso of the 32H reisolate 
of SIV m~25[ were followed post-challenge for evidence of infection and disease progression. 
Both naive controls became infected, as evidenced by plasma antigen levels, which peaked 
at weeks two and three in each of the controls, respectively. Neutralization titers in naive 
animals were below background on the day of challenge and rose in one of the animals 
(IXC), which survived the longest after challenge. In both naive controls circulating Th cell 
levels droped sharply within the first ten weeks after challenge. The animal (8683) that 
developed the highest concentration of SlY p27 in plasma post-challenge and that failed to 
mount a neutralizing antibody response within three months after challenge (Table I, 
experiment 1) died within five months due to lymphoma attributable to SIV infection. The 
other control animal developed a slow progressive decline of Tb cell numbers and was 
humanely euthanised at 11 months post-challenge, showing low-level plasma antigenemia 
and wasting at this time. Histopathology revealed multiple oPP0l1mllstic infections 
consistent with AIDS. 
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In contrast immunized animals in expetiment 1 (see Table 1) had neutralizing titers 
between 900 to greater than 3,000 on the day of challenge that persisted at the same levels 
until three months post-challenge. They failed 10 develop plasma antigenemia, maintained Th 
cell numbers greater than 500 x 10J/ml and have remained assymptomatic for more than 
three years post-challenge. 
Table 1. Neutralisation titers of challenged rhesus monkeys 
Immunized 1988 
Experiment 1: Challenged with 
Animal DC PC 
K98 905 4,305 
A30 1,290 4,305 
IVM 3,620 6,089 
Experiment 2: Challenged with 
IYO 6,084 14,482 
IYR 2.153 4,305 
2BR 1,522 1,076 
IVY 1,810 453 
Immunized 1993 
IRZ 1,280 2,153 
ISV 3,044 6,089 
IXY 80 3,044 
IYC 640 269 
a Virus neutralising liters measured on the day of challenge 
b Virus neulralising titers measured 12 weeks poslchallenge 
3.2.4.2 Heterologous challenge 
NaIve challenged 
homologous SIV mac3211 
Animal DC 
IXC 20 
8683 20 
heterologous SIV T8980 
IVS 
IX! 
8606 
8771 
8637 
8680 
8710 
8711 
14 
14 
14 
14 
14 
14 
20 
17 
PC 
2,560 
14 
34 
17 
17 
95 
17 
14 
14 
17 
TIle second experimental group, which received the heterologo!ls SIV smB676 macaque 
derived, PBMe grown, cell free challenge, consisted of four macaques inununized with 
BK28 in May 1988 and four hrnnunized only four months previously. In addition, four 
animals served as naive controls for challenge and an additional four naive animals were 
unchallenged controls. On the day of challenge all immunized had relatively high 
neulralizing antibody titers as shown in Table I (experiment 2), ranging from 1522 to 6084 
in the 1988 immunized animals, and from as low as 80 to 3044 in the animals immunized 
four months ptior to challenge. Naive animals had background levels on the day of 
challenge, but these increased to 34 and 95 in two of the four animals. In the animals 
immunized 5 years earlier neutralizing titers doubled in two of four animals, stayed 
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approximately the same in one, and dropped the fourth animal (fable 1, experiment 2). In 
contrast, the neutralizing titers in animals immunized four months earlier increased in three 
of four animals and persisted at the same high levels as at the day of challenge. 
Differences were also seen in the SIV envelope antibody titers between the two 
immunized groups prior to challenge. The animals inmmnized five years earlier had the 
highest SIV envelope antibody titers prechallenge, whereas the animals immunized four 
months earlier still had rising titers and had not reached maximum levels. Twelve weeks 
postchallenge three of four animals in each inununised group developed an increase in VN 
titer. All na'ive controls challenged rapidly developed anti-SIV envelope titers post-
challenge. 
As in the earlier homologous challenge experiment, inullunized animals failed to develop 
evidence of plasma antigenemia, in contrast to naive, challenged controls. Similarly, 
challenges controls developed rapid Thlm cell losses immediately post-challenge. whereas 
immunized animals retained relatively normal levels of Th/m cells post-challenge, suggesting 
that these immunized animals may be protected from disease progression even if sterilizing 
immunity was not achieved. 
3.2.4.3 Quantitative virus isolation 
The results of the PBMC virus isolation assay revealed significant differences in virus 
load in those animals receiving the heterologous SIV challenge. Naive control animals (SIV 
negative by all assays prior to challenge) developed high numbers of SIV-producing PBMC 
at levels greater than 80 x 106/ml measured at one and three months post-challenge. Virus-
infected PBMC were found in only one of four animals in each of the two vaccine groups 
(Figure 1). At four weeks post-challenge none of the animals immunized in 1988 were virus 
isolation positive, whems at twelve weeks post-challenge one animal became virus isolation 
positive, but was estimated to have only one infected cell in 106 PBMC at this time point. 
Similarly, only one of the animals immunized four months prior to challenge became 
infected. This animal was fIrst found to be virus isolation positive with 1 infected cell per 
lO' PBMC at one month post-challenge; this increased to 22 infected cells per lO' PBMC by 
three months post-challenge. These results suggest a reduced virus load in cases where 
sterilizing immunity was not achieved. 
3.2.5 DISCUSSION 
Previous studies have repOlied protection from homologous cell-free and cell-associated 
macaque cell-derived SIV challenge (4, 7). Heterologous protection from rhesus macaque-
derived challenge has not been previously reported until tius study. Because data from an 
earlier study (4) using attenuated live virus vaccines suggested that the duration of the 
immunization in the period prior to challenge was impOliant for protection, we designed an 
experiment to determine if a longer immunization period (five years) would provide broader 
protection against a heterologous macaque-propagated cell-free challenge than a shorter 
immunization period (four months). 
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Figure 1. Quantitative virus isolation of animals challenged with SIV8980. Data are shown as the number 
of infected cellsf106 PBMC. *, NaYvc controls were negative by all criteria prechallcnge. 
OUf results suggest that four months of immunization was as effective as a 5-year 
immunization period in which three of four animals from both groups were vims isolation 
negative. Animals immunized for only 4 months had, despite lower anti-SIV envelope 
antibody titers in general, homologous neutralizing titers similar to those of animals 
immunized 5 years prior to challenge. Importantly. the virus load in both groups of 
immunized animals challenged with heterologous vims was dramatically lower than in naive 
controls. Furthermore, the vims load in the infected animal immunized for five years was 
delayed and lower than in the infected animal immunized for 4 months prior to heterologous 
challenge. Hence, these results would suggest that with this system the duration of the 
immunization period did not appear to broaden immunity. or to increase the number of 
animals that were protected from infection with this heterologous challenge. However, a 
slight benefit in reduced virus load was observed. 
We have previously rep0l1ed that vaccination reduced virus load in homologous cell-free 
challenged chimpanzees that became infected, and that animals that had higher neutralization 
titers at the time of challenge had lower virus loads (6). Interestingly, in lhis SIV study lhere 
was no apparent cOlTelation between neutralizing antibody titers and virus load, suggesting 
that other mechanisms may be mediating protection in animals receiving attenuated vaccines. 
The mechanisms involved in this type of vaccine protection are not yet clear and require 
fut1her study to detemune if they are clearly immunological or related to the phenomenon of 
vims interference. They must also be considered in the light of other so-called "super-
infection" experiments. Vaccinated animals that became infected had much lower virus loads 
than na'ive controls, suggesting clearance of virus infected cells postinfection. Clearly, the 
attenuated live vaccines appear to be the most efficacious, giving the most consistent and 
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broadest protection based on results from the SIV model. However, important safety issues 
such as recombination of the challenge strain with the attenuated vaccine strain ill vivo 
remain to be addressed. 
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4.1.1 ABSTRACT 
To produce large eDNA strands from biological samples containing limited numbers of 
template molecules, it may be essential to minimise both non-specific primer attaclunents in 
first strand synthesis and secondary structure in RNA molecules. Failure to do so could 
result in the accumulation of shol1ened eDNA strands and therefore may reduce the yield of 
large cDNA molecules, sometimes below detection level. We show that 5.0-kb cDNA 
fragments can be generated from simian inununodeficiency vims RNA in a specific reverse 
transcription (RT)-PCR reaction by increasing the stringency of the primer-annealing 
conditions followed by the elimination of excess free primer. Since this method utilises a 
relatively long primer in the first strand eDNA synthesis, it is possible to heat-denature the 
non-specific RNA/primer complexes and RNA secondary stmcture without dissociating the 
primer from the specific template. In contrast to classic RT assays, in which an excess of 
primer is annealed to denatured RNA just prior to and during reverse transcription at relative 
low temperatures (37-42'C), this method eliminates false priming. To optimise the yield and 
fidelity of full-length cDNA molecules, two peR amplifications are first performed using 
both Taq and PIli polymerase, followed by PIli alone in the second amplification. 
4.1.2 INTRODUCTION 
Biologically relevant molecular clones of primate lentivimses are important for the study, 
development and evaluation of therapeutic and vaccine strategies for the prevention of 
AIDS. Experimental infection of various species of macaques with Simian 
immunodeficiency virus (Sly) induces AIDS closely resembling human immunodeficiency 
virus (HIY) infection in man (13, 21, 28) and is used extensively to evaluate vaccine 
strategies for HN (5, 8, 14, 19,33). To date, only molecular clones derived from cultured 
virus have been available. In an effort to fully utilise this animal model, it is important to 
have a technique for acquiring relevant, representative molecularly cloned viroses directly 
from biological materials. 
The use of conventional strategies, such as cloning from lambda phage libraries, has 
proven to be very difficult for the molecular cloning of SIV and other lentiviruses directly 
from in vivo samples, because of relatively low frequencies of infected cells (10, 22). 
Attempts to increase the number of infected cells by in vitro propagation caused selection for 
a limited subset of viral variants during growth in culture (18, 40). More recently, 
polymerase chain reaction (peR) amplification has been used to generate molecular clones 
of SlY (14) and HIY (27). 
The reasons for deriving molecular clones directly from virus present in biological fluids 
such as serum are twofold. First, the predominant virus population in semm or plasma at 
anyone point in time is most likely to represent an abundantly replicating viral population. 
Since their predominance is likely the result of escape from immune surveillance, they are of 
particular biological importance. Second, proviral DNA, is expected to be enriched in 
defective proviruse, (13, 25, 41). 
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Although reverse transcription (RT)-PCR allows us, in principle, to clone RNA viruses 
directly from biological fluids, it is difficult to produce large (first and second strand) cDNA 
molecules by reverse transcription and by PCR, respectively. RT-PCR cloning can be 
optimised by the isolation of high-quality (polyadenylated) RNA, efficient reverse 
transcription to generate a cDNA template for the PCR step and an efficient method to clone 
the PCR product into a suitable vector. Various methods have been described for the 
isolation of high-quality RNA for use as PCR template (4, 6, 32), as well as for the 
improvement in the synthesis of first- and second-strand eDNA. Ligation of blunt-ended 
peR products in pre-digested plasmids in the presence of a suitable endonuclease can 
increase the cloning efficiency considerably. This cloning procedure seems preferable to the 
ones that use restriction recognition sites in the primers, since the latter techniques have 
proven to be inefficient (16) andlor to generate complicated cloning artefacts (20). 
Unfortunately, short products tend to accumulate during the RT reaction as a result of non-
specific priming. Here we report on a method to minimise these undesired products by 
using a modified primer extension and a long RT primer in combination with stringent 
annealing conditions. Moreover, a supplement of spermidine to the first-strand reaction (26) 
and the use of a Taq and Pfu polymerase mixture in the second-strand synthesis assist in 
elongation and efficiency of PCR (I, 7). 
By applying this modified assay to monkey serum, we were able to amplify and clone 
the 5-kb 3' and 5' halves of the SIY"80 genome. We anticipate that thls method will be of 
interest for the cloning of large cDNAs from low-abundance RNA molecules and 
particularly for the generation of molecular clones of RNA viruses directly from clinical 
samples. 
4.1.3 MATERIALS AND METHODS 
4.1.3.1 RNA isolation and fil'st-strand cDNA synthesis 
The SIV89SQ isolate was derived from SIVddlaB670 (2) after a series of subsequent in vivo 
passages in rhesus macaques. Serum was taken from an SlV 8980 infected monkey, that had 
P27 (nucleocapsid protein) antigenemia (24.5 ng/mg), as measured by a commercially 
available SlY antigen capture assay (Coulter, Hialeah, FL, USA). For a variety of diverse 
biological assays, viral RNA from serum is frequently more suitable than that obtained from 
plasma, because the anticoagulant disturbs the particular assay or because after thawing a 
fibrin-clot is formed. Hence, for retrospective analysis from frozen samples, serum may be 
more readily available. 
RNA from 100 MI serum was isolated as previously described (4). RNA pellets were 
dissolved in 20 MI of 40mM piperazine-NoN' obis (2-ethane-sulfonic acid) (PIPES) (pH6.5), 
ImM EDTA, 0.4 M NaCI and 2.5pM (synthesis) primer No. 10120: 
GAGTGGCTCCACGCTTGCTTGCTTAAAGACCTCTTCAATAAAGCTGCCAATTAGA 
AGTAAGC (nucleotide [ntl 10058-10120 of the SIV"""", genome) (17) and incubated for 
10 min at 85'C in the presence of 60% (wtlvol) formamide. Specific annealing of the prhner 
to the template was carried out by slowly cooling the incubation mixture to 42°C and 
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keeping it at this temperature for 16 h. To eliminate the formarnide and to change from 
annealing buffer to synthesis buffer, the RNA/primer complexes were precipitated with 0.1 
volume (3M) of sodium acetate and 2.5 volumes of ethanol, followed by a single 70% 
ethanol wash. 
The complexes were dissolved in 13 ~l of KCI (90mM) and subsequently heated to 70°C 
for 10 min and snap·cooled on ice, immediately followed by the addition of 7~1 of the 
synthesis mixture: IOnu\1 MgCI" ImM dNTP (each), ImM dithiothreitol (DTT), 10 U 
Rnasin (Promega, Madison, WI, USA), 0.5mM spermidine (Sigma, Chemical, St. Louis, 
MO, USA) and 200 U Moloney murine leukemia vims (M-.ML V) reverse transcriptase 
(SuperScript II RT; Life Technologies, Breda, The Netherlands). First-strand synthesis was 
performed during a 60-min incubation at 45°C. Finally, the enzyme was heat-inactivated at 
90°C for 10 minutes. Control experiments were perfonned without reverse transcriptase. 
4,1.3.2 peR amplification of eDNA templates 
To evaluate the effect of modified reaction conditions on the length of the synthesised 
eDNA, test RT-PCR amplifications were perfonned on RNA aliquots obtained from 
infected monkey serum. In all RT-PCRs, the eDNA synthesis started at the 3' end of primer 
10120 (located in the R region of the 3' long terminal repeat [LTR]). The length of the 
cDNA was determined by a subsequent PCR amplification. PCR primer pairs consisted of 
the same 3' primer (No. 10077) combined with different 5' primers (9026; 8023; 7254; 
6551; 6059; or 5081) that were located more upstream each time than the previous one, 
producing fragments of increasing lengths with increased cDNA synthesis. Primers were 
designed from conserved regions between different SIV strains (Los Almnos database). The 
names of the primers correspond with the nucleotide positions of the SIV~mmh4 genome (17) 
(Figure 1). All primers were obtained from Phannacia Biotech, Roosendaal, The 
Netherlands, and all chemicals were obtained from Sigma Chemical. PCR fragments were 
generated by using a Ta'llPfu DNA polymerase mixture on eDNA templates, followed by a 
second PCR with Pfu polymerase (Stratagene, La Jolla, USA) on a small fraction (5-10 [11) 
of the first amplification. All PCR amplification reactions (100 ~I) were perfonned in a 
Perkin-Elmer DNA Thermal Cycler 480 (Norwalk, CT, USA). A mixture of AmpliTaq (PE 
Biosystems, Nieuwerkerk aid IIssel, The Netherlands) and Pfit DNA polymerase was used 
as recommended by Perkin-Elmer with two exceptions. TIle primer and MgCl2 
concentrations were adjusted to 15 pM and 2 mM, respectively, and one unit of both 
polymerases was used. The program used in these amplifications consisted of 10 cycles of 
denaturation at 94°C for 1 min; mmealing at 59°C for 50 s; extension at 72°C for various 
times depending on the desired fragment length (usually l-kb/minute elongation). 
Final extension at the end of the program for 10 min. Pfll DNA polymerase amplification 
was as recommended by Stratagene Europe, The Netherlands, except that 15 pM of 
phosphorothioated (11) primers and 3 units of Pfit DNA polymerase were used. In tlus 
case, the primers were extended with the following progrmn: 5 min. at 94°C, then 35 cycles 
of denaturation at 94°C for 1 min; annealing at 58°C for 1 min, followed by extensions as 
described earlier. A hot start protocol (17) using Ampli-Wax PCR Gems (PE Biosystems, 
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Nieuwerkerk aid Ussel, The Netherlands) was used in all PCRs as described by Perkin-
Elmer (3). The PCR products produced in the second reaction were analysed by 
electrophoresis on 1 % agarose gels (30). 
4.1.3.3 Cloning and analysis of S.O-kb PCR fragments 
peR fragments were recovered from agarose gels by a freeze-squeeze method (38. 39) 
and cloned into a (Srf) (35) pre-digested bluescript vector using the PCR-Script SK( +) 
cloning kit (Stratagene Europe, The Netherlands), Cloning conditions were based on the 
reconunendations of the supplier, except that the vector was gel-purified and co-precipitated 
with the fragment, facilitated by tRNA. Ligation was catTied out in the presence of Srf 
endonuclease (Stratagene Europe, The Netherlands) (4 U) at 20°C for 14 h in a total volume 
of 10 Ill. MAX. Efficiency STBL2 competent cells (Life Technology) were transformed 
according to the instruction manual supplied with the bacteria. Recombinant plasmids were 
isolated with a standard nllnipreparation method (12). Internal PCR fragments (Figure IC) 
were derived from recombinant plasmids and subjected to endonuclease restriction analysis 
using: Be/I, Pst, Balli ill, HilldlIl, EcoRY, Sst-I and EcoRI (Boehringer Mannheim, 
Almere, The Netherlands). The same fragments were used as oligolabelled probes (10' 
cpml~g) in dot blot hybridisations with membrane-bound SIY"so RNA (Figure ID). Nylon 
filters (Zeta-Probe; Bio-Rad, Yeenendaal, The Netherlands) were hybridised in 6x standard 
salinc citrate (SSC)! 5x Denhardt's at 65°C and washed in O.lx SSCIl% sodium dodecyl 
sulphate (SDS) at 45°C (30). 
4.1.4 RESULTS AND DISCUSSION 
To clone long SIV RNA sequences directly from semm, a primer extension method was 
optimised to generate eDNA molecules under various reaction conditions. To determine the 
progression in first-strand cDNA synthesis, we designed PCR primers for the 3' half (5-kb) 
of the SIV genome. The sequences of the primers along with their positions are shown in 
figure IA. The products runplified with these primers are indicated in figure lB. For the 
present study, we used purified SIV RNA from serum of an experimentally infected rhesus 
monkey. RNA was reversed-transcribed into eDNA using both the optimised protocol and 
the standard one provided by the supplier. Briefly, RNA together with the synthesis prImer 
(No.10120), was heat-denatured at 80°C and snap-cooled on ice. Reverse transcriptase was 
added and eDNA was synthesised at 42°C for 60 min. The enzyme was inactivated at 90°C. 
The reaction was then subjected to PCR. The RT -PCR results obtained with this standard 
protocol are presented in figure 2A. The standard protocol was perfOlmed four times and 
enabled us to efficiently generate double stranded cDNA fragments up to 3-kb. However 4-
kb and 3.5-kb products could be detected only faintly (one and two times, respectively). In 
all cases these products were present in lower amounts than the smaller non-specific 
products and tended to accumulate, likely at the expense of the larger amplimers. Cloning of 
3.5- and 4-kb fragments failed in all cases using the standard technique. 
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A Pf.mer Orientat;on 
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Cl'.GAGT=CCACGC=~= 
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GAGGA."'LAGC-C-GAThTG.tt,CCAGC 
GCTGGhGTChTATCCCC7A~CCTC 
ill !!'!"l 
~v I~ Primer pairs 
I'J (s·as) 
~ 9026·10077 
8023·10077 
7254 -10077 
6551 -10077 
6059 -10077 
5081 ·10077 
9026 ·10077 
8023·9051 
7254· 8048 
6551· 7278 
5081·6575 
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Figure 1. E.imdA: Names and sequences of the PCR primers used for 3' half genome amplifications. The 
eDNA synthesis primer (No. 10120) is printed in bold. Sense (s) and antisense (a) orientations of the primers 
are indicated in the table. The nucleotide positions (nt) positions cOITC-spond with the SN,mmM genome (14). 
Panel B: PCR amplification of increasing larger fragment. PCR amplification of increasing larger fragment 
was used to detennine the specificity and length of e-DNA strand synthesis. The horizontal lines represent 
PCR products generated from (single strand) c-DNA templates of different size. The black bar in the viral 
Long Tenninal Repeat ( LTR ) (R region) represents the position of the cDNA synthesis primer (No. 
10120). TIle horizontal arrow indicate-s the direction of the eDNA synthesis. Panel C: Cloned (5-kb) 
fragments were subjected to restriction site analysis. Internal fragments, represented by the horizontal bars, 
were generated by PCR amplification from recombinant plasmid DNA containing the full-length amplimer 
and examined for the presence of specific endonuclease restriction sites (vertical lines). 'The position of 
restriction sites is positioned schematically in relation to the SIV$II'.J:!lh--l genome. Conserved sites between 
SN .,--orr~~ and SIVplIll~ arc shown in bold. Sites unique to SlY =h~ arc in nonnal print. Panel D: Dot blot. 
Dilutions of viral RNA, isolated from (50jll) Rhesus serum were bound to nitro-cellulose filters and filter 
strips separately hybridised with probe A-E. Probes A-E were PCR amplimers from a recombinant plasmid 
containing the full-length PCR product. Uninfected serum probed with probes A-E was negative (data not 
shown). Positive controls (+): Recombinant Bluescript SK(+) containing probes A-E (10 ng). Negative 
controls (-): Blucscript SK(+) (40ng). 
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Apparently, under these conditions, when primer mmealing takes place at temperatures weB 
below the melting temperature (Tm) of the primer, short(er) cDNA molecules are generated 
because of mispriming, resulting in short products after RT-PCR with primer No. 5106. In 
our attempt to define optimiscd conditions for production of full-length cDNA, we modified 
the annealing conditions for both the RT synthesis of first-strand cDNA and the subsequent 
PCR conditions. 
By using annealing temperatures as high as, or close as possible to, the T m of the cDNA 
synthesis primer, we favoured specific primer hybridisation and reduced mispriming (15). 
Since fOlmamide reduces the melting temperature of DNNDNA and DNAIRNA duplexes in 
a linear fashion by 0.72°C for each percent forrnamide, it became possible to stringently 
anneal long primers (T m> 42°C) at a decreased temperature of 42°C. The fonnamide 
concentration of 60% gave the highest yield of full-length product during RT-PCR when 
lIsing synthesis primer No. 10120. In principle, cDNA synthesis should thus strut from 
only one hybridised primer per template and proceed to the 5' terminus of the RNA 
template. To remove'the formamide from the annealing buffer, RNA/primer complexes were 
precipitated and washed. After cDNA synthesis and PCR, only the DNA product of the 
expected molecular weight was generated. Syntheses of smaller amplimers due to non-
specific primer hybridisation were not observed. However, cDNAs less than fun-length 
may still be generated because of secondary structure in the RNA that tends to cause the 
reverse transcriptase to pause or stop (23). Since we used long primers (62-mer; 45% CG) 
with high T m in the first-strand cDNA, it permitted heat-denaturation of some secondary 
structures to 70°C before synthesis, without dissociating RNA/primer complexes. In our 
experiments, we tested avian myeloblastosis vims (AMY) and M-ML V (SuperScript II RT) 
reverse transcriptases. The latter enzyme yielded the largest products in the best clonable 
amounts in the modified RT-PCR. Secondary stlUctures may also cause RNAse H to cleave 
the RNA near the 3' -OH end of the growing cDNA chain. This results in premature 
tennination of cDNA synthesis. Since SuperScript II RT, Jacking RNAse H activity, has a 
higher progression rate than the wild type enzyme (AMV), we assume that this accounts for 
the better results of this enzyme in our test. Alternatively Tllermus thenllopJiilus (Ttll) DNA 
polymerase, in the presence of Mn2+, possesses an intrinsic reverse transcriptase activity. 
Because of its high temperature optimum, tltis enzyme should perform well in regions 
containing secondary structures. However, since TIll polymerase has been shown to be less 
sensitive relative to M-MLV reverse transcriptase (9), we did not consider this enzyme 
useful for our purpose. The addition of spemlidine in the reverse transcriptase buffer 
showed a slight increase in the amount of S-kb product and a decrease in background 
products. The concentration used here (O.5mM) was based on earlier observations (26) and 
experience from other groups (J. Gietema, Invitrogen, personal communication), and so we 
did not further test other concentrations. To minimise the error rate during PCR 
amplification of the synthesised cDNA the heat stable Pfll polymerase contaiIling 
proofreading activity (29) was used because of its (16x) higher fidelity (31). Unfortunately, 
we were not able to successfully perform PCR directly on cDNA using only Pill. 
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Figure 2. Analysis of RT~PCR products generated by the standard method (2A) and by 
tbe modified primer extensiol/ method {2U} on Rhesus monkey serum. 
I-kb DNA Ladder (Boehringer) (lane I). Agarose (I %) gel electrophoresis of amplification products generated 
by primer pairs: 10077-9051 (lane 2), 10077-8048 (Jane 3), 10077-7278 (lane 4), 10077-6541 (Jane 5). 
10077-6060 (lane 6), 10077-5106 (lane 7), In each lane 20 J11 of a RT-PCR (100 1-'1) reaction is loaded, 
except for the lanes 6 and 7 in figure 2b where 75 ~ was loaded. 
However, peR perfOlmed using TaqIPfu mixtures or just Taq alone was successful 
under similar conditions. This suggests that Pfu needs a higher template concentration or 
has a much slower progression rate, both compared to Taq. Utilising Taq/PJu mixtures 
rather than Taq alone has been reported to allow the production of larger fragments with less 
PCR mistakes (7). Various Taq/PJII ratios were tested with the primer Nos. 10077 and 
5108 on pBK28 (24), generating 5-kb amplimers (data not shown). The ratio of Taq/PJII 
(1 un U) gave the highest yield in full-length product and was used in amplifications on 
SIV"socDNA templates. 
The final PCR protocol for the amplification of full-length cDNA consisted of two steps. 
The first PCR (10 cycles), using TaqlPJII mixtures, served only to generate sufficient 
template for the second PCR. The second PCR (35 cycles), using PJII only, was perfonned 
on 10 III of the first PCR amplification. The number of cycles we used in the first PCR was 
detenllined by a RT-PCR performed on virus RNA from serum with Taq/PJII. Thereafter, 
10 ~l samples were taken following 5,10,15,20 and 30 cycles. These aliquots served as 
templates for the second amplification (35 cycles), in which only PJII polymerase was used. 
Ten cycles in the first amplification were enough to yield detectable products after re-
amplification. The exonuclease activity of enzymes with 3'--> 5' exonuclease-mediated 
proofreading has also been reported to degrade primers for DNA synthesis, thus resulting in 
diminished primer specificity or no PCR product at all (36), As primers with 3'-tenninal 
phosphorothiolate linkages are resistant to this exonuclease activity (31), we consequently 
used phosphorothiolated primers in all amplifications. 
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Hot statt in PCRs is a commonly used method which increases low-copy-number 
specific atnplification but at the expense of side reactions due to mispriming. In hot start 
peR, reagent addition to the reaction tube is designed so that all reactants do not mix until 
reaching a temperature high enough to suppress primer annealing to non-target sequences 
(80-90"C). In all experiments described here we used the ArupliWaxTh' PCR Gem-mediated 
hot statt technique (3). PCR reactions perfonned under these conditions showed 
considerably less background and much higher yields of full-length products compared to 
amplifications without hots tarts. In addition, this method reduces cross-contamination 
which is considered to be a potential disadvantage of the hot start technique, requiring the 
ffiatlUal addition of the polymerase at 90°C. 
Results obtained with the modified RT-PCR method are depicted in figure 2B. Under 
optimised reaction conditions, no non-specific products were observed, and amplification 
products up to 5-kb wefe consistently seen (Figure 2B). The optimised RT-PCR method 
was tested three times and amplification products up to 5-kb was seen, but not smaller non-
specific products. Twenty clones of SIV containing the 3' genome half were obtained using 
this technique. Primer specificities and the presence of highly conserved restriction sites in 
the cloned fragments, demonstrated that the cloned 5-kb products were of SN origin 
(Figure IC). This was also confilmed by dot blot hybridisation of the amplified subgenomic 
fragments with viral RNA (Figure lD). Hybridisation as well as washes was carried out 
under such stringent conditions that positive signals due to PCR-primer (25-mer) homology 
alone were not likely to occur. 
Finally, to reduce the instability that occurs during the propagation of molecular clones of 
HN in bacteria (34), separate cloning of 5' and 3' halves of viral RNA genomes should be 
considered. By using this cloning technique it is possible to consider more routine isolation 
of full-length molecular clones (ca. lO-kb), which call be reconstituted either in vivo (37, 
42) or in vitro (14). After further optimisation, the modified RT-PCR method described 
here, may be of interest in the construction of molecular dones of lentiviruses directly from 
sera enabling the cloning and characterisation of biologically relevant virus populations. To 
avoid the accumulation of smaller products, which may occur because of the presence of 
two identical LTRs in retrovirus genomes, primers could be designed that specifically anneal 
to the 5' cap sequence and to the 3' poly (A) tail. These particular sequences are only 
present ill encapsidated RNA and not in proviral DNA. Last, this technique has the potential 
to be applied to the cloning and characterisation of other RNA viruses directly from bodily 
fluids. 
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4.2.1 ABSTRACT 
To enable biological characterisation of lentiviral varicUlts which emerge during infection 
and development of AIDS, we developed a method to construct molecular clones from 
circulating simian immunodeficiency vims (SIV) particles present in as little as 20 III of 
serum from infected rhesus monkeys. This technique uses a long distance RT -peR method 
optimised for the amplification of partly overlapping 5-kb SlY (half genome) amplimers. 
Ligation of the genome halves resulted in the constmction of full-length clones which, after 
transfcction, were able to replicate well in rhesus peripheral blood mononuclear cells 
(PBMC) and in various human T-cell lines inducing syncytia. In addition to the study of 
molecular cloned virus quasispecies emerging in circulation as a result of immune escape, 
this method may also be applied to obtain entire genes or full-length molecular clones. These 
clones may be present in other relevant extra-cellular body fluids such as, urine, saliva, 
tears, lymph, and bronchial or cerebral spinal fluid. Genes amplified in this way can be 
quickly inserted in new recombinant expression vectors and may then be applied in DNA 
vaccination approaches. 
4.2.2 INTRODUCTION 
Human immunodeficiency vims (lllV), discovered in the eighties as the etiological agent 
causing AIDS (I), still continues to spread worldwide (17, 27). A vaccine for HIV is now 
an urgent public health priority. The first and most extensively studied HIV -1 vaccine 
candidates were based on the recombinant envelope glycoproteins (rgp 120 and rgp 160 
(16, 20) of HIV-II~I' HIY-I sF_2 and HlY-I,,", These vaccine experiments resulted in poor 
protection of chimpanzees immunised with envelope-based immunogens after intravenous 
challenges with heterologous viruses (4-6, 14, 15, 30). Some papers have already dealt 
with immunological and virological analysis of persons which became HIV -1 infected while 
participating in recombinant gp 120 subunit vaccines trials (3, 10) as currently conducted in 
the United States (16, 20). Genetic characterisation of immune escape mutants was in 
general restricted to attempts to identify eventual patterns in the envelope protein variability. 
that could be considered indicative of vaccine-induced selective pressure among the infected 
vaccine recipients (10). 
lnunune escape of HIV, following challenge with heterologous virus strains after 
immunisation with regulatOlY proteins, may therefore best be studied by characterising the 
biological properties (co-receptor use, cell tropism, replication rate), of the molecular clones 
which are most abundant in circulation. As a consequence of the fact that most regulatOlY 
proteins act in trans, escape variants may contain mutations in both the regulatOlY gene itself 
as well as in the protein-binding site. The combined effect of these mutations may result in 
the production of a biologically modified vims that is able to escape host immunity. Detailed 
analysis of the biological features of such individual molecularly cloned escape variants may 
be more informative than analysing relevant but limited numbers of sequences obtained from 
the entire pool of circulating quasispecies. For these purposes the study of molecular clones 
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derived from the predominant circulating extracellular viral population in selUm or other 
body fluids is of particular interest. 
Clinical trials of fust generation HIV -1 vaccine candidates are in progress. As the 
number of trials increases information to guide the design and improvement of future 
generations of HIV -1 vaccines will be needed. Molecular clones will be invaluable for 
gaining insight in several aspects of viral immune escape. Our goal ,vas to investigate if a 
method could be developed for the routine constlUction of replication-competent lentivlral 
clones from circulating virus particles. We report on the optimised RT-PCR method that 
enabled us to generate full-length SIV clones from small numbers of viral RNA templates 
using serum from SlY-infected macaques as stalting material. 
4.2.3 MATERIALS AND METHODS 
4.2.3.1 Viral, RNA isolation and eDNA synthesis 
SIV 8980 was derived from SIV B570 (2, 25) by five subsequent ill vivo passages in Indian 
rhesus macaques (Holterman et aI., submitted). Serum from animal 8980 was used as 
starting material for constl11ction of molecular clones of SIV. Serum of animal 8980 
contained 6xIOs SlY-RNA copies per ml at the time of death. In this method selUlll aliquots 
equal to 3.105 copies were used to synthesise cDNA, the 5-kb amplimers were produced 
and cloned from lOOO-fold diluted eDNA samples (=300 SIV-RNA copies). A restriction 
map of the SIV 8980 genome was generated to facilitate cloning. Overlapping fragments 
ranging from 130 bp to 2571 bp, spanning the entire genome, were synthesised using a 
standard RT-PCR technique. eDNA synthesis was performed on viral RNA extracted by the 
guanidium thiocyanate-phenol-chlorophorm extraction method (7). First strand eDNA 
molecules were produced using SuperScript™rr Rnase H reverse transcriptase and 
perfOlmed according to the instmctions of the manufacturer (Gibco-BRL). PCR 
amplification was carried out on 5 r-tl of cDNA after addition of 10 pmol of both sense- and 
anti-sense primers and a mixture of 0.5 unit of both Taq-((28, 31) Perkin-Elmer, Gouda, 
The Netherlands) and Pfil (23); Stratagene, La Jolla, CA, USA) DNA polymerases. The 
PCR reaction mixtures (50 J1l) were overlaid with mineral oil and incubated as follows: 35 
cycles of denaturation for 60 seconds at 94°C, annealing for 45 seconds at 58°C and 
elongation for 0.5, I or 2 minutes depending on the length of the fragment. All 
amplifications were performed in a Perkin-Elmer DNA Thermal Cycler 480. Amplification 
products were then subjected to restriction endonuclease digestions and analysed on 1.5 % 
agarose gels. Based on this restriction analysis a cloning strategy for both genome halves 
was developed. The exact positions of all PCR primers (RDI I RD 18), relative to the 
SIVsmmFVf>.smhl genome (Los Alamos accession number: X14307) (18) were as follows: RDI 
(nt 1Ol38 to 10161) and RD2 (nt 9025 to 9049); RD3 (antisense primer) complementary to 
RD2 and RD4 (nt 8022 to 8048); RD5 (antisense primer) complementmy to RD4 mId RD6 
(nt 7253 to 7277); RD7 (antisense primer) complementary to RD6 and RD8 (nt 6550 to 
6575); RD9 (antisense primer) complementary to RD8 and RDIO (nt 5187 to 5211); RDII 
(anti-sense primer) complementaJ}' to RDIO and RDI2 (nt 5082 to 5106); RDl3 (antisense 
8t 
primer) complementaIy to RDl2 and RDl4 (nt 2536 to 2559); RDl5 (antisense primer) 
complementary to RDl4 and RDl6 (nt 1042 to 1065); RDl7 (antisense primer) 
compiementaIY to RDl6 and RDl8 (nt 75 to 102). Antisense primers were used to 
synthesise first strand eDNA's. 
4.2.3.2 Long range RT-PCR and cloning of amplified SIV genome 
fragments 
cDNA molecules containing either the 5' (LTR. gag, pol) or the 3' (pol, eliI', LTR ) SN 
genome halves (5-kb) were generated using all optimised RT-PCR method (19). Two 
cDNA synthesis primers (SP-l. SP-2) and seven aIl1plification (phosphorothioated) primers 
(L3-1, P3-1, P3-2, P5-1, P5-2, L5-1 and L5-2) were used in nested PCR reactions for 
producing long amplimers. Control experiments \vere performed without reverse 
transcriptase. To reduce the amount of nucleotide misincorporatiolls during peR a limited 
number of cycles were used for both genome halves (JMJ5/gag/pol and pol/ellv/U3fR) in 
the first round (15 cycles) and 35 cycles in the nested amplification. To fmiher increase 
fidelity the use of an optimised reaction buffer for eDNA synthesis was used. The mutation 
frequency of MML V -RT was decreased substantially (33%) by lowering the dNTP and the 
MgC12 concentration. To minimise the chance of creating artefacts due to template 
interactions during RT-PCR on SClUlll, we generated all5~kb products from low numbers of 
RNA- and DNA templates. Reverse transcriptase reactions were therefore canied out on 
diluted RNA templates. The eDNA's synthesised were used as templates in separate first 
round peR amplifications. The second round of PCR was perfOlmed on a 1:10 diluted 
reaction mixture generated in each of the first round PCRs. Samples from the second 
amplifications were analysed by gel electrophoresis. The highest dilution, which still yielded 
detectable amounts of 5-kb products on agarose gels was used for cloning and restriction 
analysis. The sequences and exact positions of all primers, relative to the SIV~mH4 genome 
(Los Alamos database), are shown in figure 1. Synthesis of LTRs was performed on DNA 
from peripheral blood mononuclear cells (PBMC) of rhesus monkey no. 8980 and used as 
template for PCR to generate complete 5' aIld 3' LTR sequences. The 5' LTR was amplified 
with primer pair: DLl-5 and DL2-5. The 3' LTR was generated using primer pair: DLJ-3 
and DL4-3 (Figure I). Both LTRs were synthesised by PCR at: 35 cycles of I minutes 
denaturation at 94°C, 30 seconds of annealing at 58°C and elongation periods of 1 minutes at 
n"C by using (2 U) Pfll DNA-polymerase and with phosphorothioated PCR primers. 
4.2.3.3 Plasmids 
To allow cloning of the peR products multiple cloning sites of commercially available 
plasm ids were modified by adapter insertions. pScript AB 12 was derived from pBluescript 
KS' after insertion of both adapters (AB and 12). Adapter AB was formed after annealing of 
oligomers A: 5'-GGCCAAGTCGGCCGCGGCCGCC-3' and B: 5'-TCGAGGCGGCCG-
CGGCCGACTTGGCCGGTAC-3'. Adapter AB contained NotI and SfiI restriction sites 
and could be ligated into the KplII / X/101 site. Adapter 12 originated after annealing of the 
oligomers: I: 5'-GAGCTCTGATCAGGGCCGCATAGCT-3' and 2: 5'-ATGCGGCCG-
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CGGCCGACITGGCCTGATCAGAGTICTGCA-3' contained SstI, Be/I, SfiI, NotI sites 
and could be cloned into 11 PstI I SstI site (deleting the SstI site). pScript CD56 was derived 
from pBlueseript KS' atier insertion of the two adapters ( CD and 56). Adapter CD was 
formed atier annealing of the oligomers: C: 5' -CGGCCAAGTCGGCCGCA-
TGCGATATCGATCCTGCA-3' and D: 5'-GGATCGATATCGCATGCGGCCGACTIG-
GCCGAGCT -3'. Adapter CD contained MboI, EeoR5, SphI, SfiI, restriction sites and 
could be inserted into a PstI / SstI site (inactivating the SstI site), Adapter 56 was formed 
after annealing of the oligomers: 5: 5' -GTGATCAACTAGTATGCATGATCGTACGCGG-
CCGCGGTAC-3' and 6: S'-CCGCGGCCGCGTACGATCATGCATACTAGTIGATCA-
CTGCA-3'. Adapter S6 contained KPIlI, NotI, NsiI, Spe!, Bef! restriction sites and was 
inserted into the KpllI I Pstl site (deleting the Kp"I site). All cloned (RT)-PCR fragments 
were transfected into MAXeftlciency STBL21M competent cells (Life Technologies, 
Roosendaal, The Netherlands) and cultured at room temperature for 8 hours. 
4.2.3.4 Transfection of C8166 cells, infection of rhesus PBMC. 
Two approaches were followed to reconstitute a full-length molecular clone from the two 
separate genome halves. Strategy A) the ill vitro ligation approach. The recombinant 
plasmids containing the 5' or 3' SIV genome halves were linearised by Bell digestion, 
precipitated and \vashed twice with 70% ethanol. Mixtures of 10 llg from each of the linear 
plasmids were ligated (5 units T4ligase) in 80 III at 18°C overnight. Ligation products were 
precipitated, washed and dissolved in 100 ~I RPM! (Gibeo, Roosendaal, The Netherlands). 
Human T-cell line C8166 cells (SxlO') were resuspended in 150 ~I of RPM! supplemented 
with 10% fetal calf serum (FCS) and mixed with 100 ~I of the ligated DNA. Ligation 
mixtures, of different 5' and 3' genome combinations, were eiectroporated (230 Volts and 
960 ~F) in a 4 mm gap cuvette. After the pulse (Biorad Gene Pulser), the cells were diluted 
in 8 ml RPM! (10% FCS) and divided over 4 wells of a 24-wells plate (Greiner 
Labortechnik, The Netherlands) and cultured for fourteen days in RPMI supplemented with 
10% FCS. 
Strategy B) the ill vivo ligation approach made use of the ability of eukariotic cells to join 
(non)-homologous sequences ill vivo (33). Five million cells were mixed with 10 llg of 
both circular plasmids (pS.SIVS'-3 and pS.SN3'-59) in 250ul RPM! supplemented with 
10% FCS in a 4 mm electroporation cuvette. After eiectroporation the cells were transferred 
to culture disks with the same medium composition. One-day post transfection medium was 
changed and cells were cultured for two more weeks with medium changes every two days. 
Southern blotting was used to detennine if proper recombination had occurred. Seven days 
after transfection, chromosomal DNA was isolated from transfected C8166 cells and 
digested to completion with Xbal. Digested DNA was transferred to a nylon membrane and 
probed with the 129 bp PCR-fragment generated by primer pair RDII and RDI2 (probe 
1112). The blot was washed at a stringency of 0.1 SSPE at 80° C for two hours. The 
recombinant plasmid (IS ~g) containing the full-length SN genome (pS.SIVF3,,), which 
was constructed later, was transfected using the electroporation conditions as described 
above. 
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DLI·5 ..... - .......... DL2·5 
I 
~- - - - - - - - - _ - - - - - - - - - - - ..... SP·I pJ·I ..... ________________ ...... L3·1 
P3·2 .. II L3·2 
I 
~- - - - - - - - - - - - - __ - - - - ~ SP·2 
L5·I ..... _________________ •• _ P5·1 
LS·2 .. I III P5·2 
nt:3117 _ nt: 6329 
/"'-RD12~ ~RDll 
Primer Sequence (5'-3') 
Amplification of the 3' SIV genome half 
SP1 GAGTGGCTCCACGCTTGCTTGCTTAAAGACCTCTTCMTAMGCTGCCM.TAGAAGTAAGC 
L3-1 GCAGCTTTA'ITGAAGAGGTCITTAAGC 
L3-2 CAGAGrGGCTCCACGC1'!GCrTGC1:T 
P3-l GGAGrAGTGGAAGCAATGAACCATC 
P3-2 GAAGGGGAGGMTAGGGATATGACTCC 
Amplification of the 5' SIV genome half 
SP2 GATGGGGCACATAACAAGCCATCTGTAGGi'Cr,rAGTGT'ATATTTCAGGTGTTTGA'GAGGC 
P5-1 CCTTTCCACAATAGCTCACCGGGTCC 
P5-2 GTCTCTGCCTTCTCTGTMTAGACCCG 
L5-1 GGAGAGGCTGGCAGATTGATGCCC 
L5-2 CCAGCACTAGCAGGTAGAGCCTGGG 
OLl-5 
OL2-5 
OL3-3 
OL4-3 
R012 
ROll 
Amplification of the 5' LTR 
CAGATTGGCMAA'ITACACATCAGG 
CTGCCTTCACTCAGCCGTACl'CAG 
Amplification of the 3' LTR 
ATAGCCl'AccrACAATATGGGTGGCG 
CCGAGATGACCAGGCGGCGACTAG 
Amplification of the probe 
GAGGMTAGGGGATATGACl'CCAGC 
TCTCTGCCTTCTCTGTMTAGACCC 
Xba Fragment (3212 bp) 
Probe 1112 (129 bp) 
Genoo:e position (nt) 
10120-10058 
10139-10112 
10077-10051 
4960-4985 
5076-5103 
5460-5397 
5250-5224 
5210-5183 
526-550 
562-5137 
75-100 
8131-857 
9026-9051 
10199-10175 
5082-5106 
5187-5211 
Figure 1. Schematic representation of the complete SIV genome with the locations of all (nested) primcr 
pairs used for: DNA-peR (DLI-SI DL2-S and DL3-3/DL4-3), eDNA synthesis (SP-l and SP-2) and RT-
peR (LS-I I PS-2, LS-21 PS-2, P3-1 I L3-1 and P3-21 L3-2). Names and sequenecsof all peR primers arc 
shown below. The nucleotide (nt) positions correspond to the SIV'mH4 genome (aec.no.Xl4307). TIle XbaI 
restriction fr~ment and the probe that were used to analyse the ill vivo recombination cvcnt of pS.SIVS' ~3 
and pS.SIV3' -S9 after eleetroporationofT-cclls are indicatedby the solid bars. 
In all tluee transfectionexperimentscultures were maintained for two weeks and used to 
prepare rhesus stocks. Five million Rhesus PBMC were isolated and infected with 100 
TCID 50 of the SIV 859 virus stock for four hours. Cell cultured were washed three times 
with RPMI supplemented with 10% FCS to remove the free unbound virus and cultured for 
fourteen days. 
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4.2.3.5 Immunocytological analysis of virus (p27) antigen prodnction 
Primary rhesus PBMC cultures were observed regularly for cytopathic effect (CPE). 
Infection with SIVl'359 was confinued by immunocytochemistry for the expression of 
SIV gag antigen. Single-cell preparations for immunocytochemistry were prepared on 
acetone cleaned glass slides, which had been air dried for 30 minutes. Cells were fixed in 
acetone/methanol (1:1) and in ethanol (70%) for 15 and 30 minutes, respectively. Slides 
were washed in 0.05 M Tris-HCI pH7.6. 0.1 M NaCI for 5 minutes and incubated with 20 
~I (1:25 dilution) of anti-gag monoclonal antibody (26). Cells were washed for 5 minutes 
and incubated with goat anti-Mouse IgG antibody for 30 minutes at room temperature. To 
amplify the signal the cells were washed and incubated with mouse-anti-alkaline 
phosphatase (APAAP-complex) (Boehringer). Cells were washed for 5 minutes and 
incubated with 20 "I substrate solution: (10:1:1) 0.1 M Tris-HCI pH 9.5, NBT (nitro-blue 
tetrazolium), BCIP (5-bromo-4-chloro-3-indolylphosphate), 5 mM levamisole for 30 
minutes at room temperature. Cells were washed for 5 minutes in tap water, one drop of 
(50%) glycerol/PBS was added per slide, and the cells was covered with a cover slip. TIle 
preparations were microscopically examined at a 40x magnification and CPE was 
quantified. In cell culture supematants virus was quantified by measuring p27 
concentrations (SN 1'27 antigen capture ELISA, Coulter Corp., Hialeah, FL). 
4.2.4 RESULTS AND DISCUSSION 
4.2.4.1 peR amplification and cloning of LTR and (5' and 3') genome SIV 
fragments 
The replication cycle of retroviruses consist of a integrated DNA (provirus) stage and a 
RNA (extracellular) stage. The two LTR's flanking the proviral genome each contain the 
complete U3RU5 motif while in the extracellular fonn only incomplete forms (RU3 and 
RU5); motifs which are present in the 5 'and 3' LTR respectively. Since only complete LTR 
sequences are able to aid in proviral integration DNA fragments from proviral 5' and 3' LTR 
regions, they were linked to the 5' and 3' genome halves respectively. Serum and 
lymphocytes were separated from the same blood sample collected from rhesus monkey no. 
8980 as the sources for extracellular viral RNA and proviral DNA, respectively. For 
subcloning purposes a restriction map of tltis particular SlY genome was made by 
synthesising overlapping RT -peR fragments. which covered the entire genome and ranged 
from 129 bp to 2571 bp. In addition two new recombinant plasmids pScript ABI2 and 
pScript CD56 were also constmcted. Utilisation of the SstI and PstI restriction sites just 
outside the 5' and 3' LTR aided in the exchange of the incomplete (virion) LTR's for 
complete (proviral) ones. The positions of all primers used in the synthesis of cDNA, the 
amplification of LTR's and of viral genomic sequences are shown in figure 1. The cDNA 
synthesis stm1ed at synthesis-primer SP-l located in the R region of the 3' LTR and SP-2 
which was located in the 3' part of the pol gene (synthesis represented by the dashed lines in 
figure 1. Complete 5' and 3' LTRs were generated with a single round ofPCR amplification 
of proviral DNA using primer pairs DLl-5 / DL2-5 and DL3-3 / DL4-3 respectively. 
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Figure 2. Cloning strategy of full-length SIV molecular clones, Both 5' and 3' LTR's were amplified from 
provirus DNA which was present in SIV&9W infected rhesus PBMC ·s. The 5' SIV genome half and 3' SIV 
genome half were generatedfrom serum using a modified RT-PCR method, All amplimers were doned and 
sub·eIonedin orderto fuse the 5' LTR ill front of the gag/pol-region and the 3' LTR behind the regulatory 
genes I ENV- region. After Iinearisation and ligation of the genome halves at the uniquely present BeI 
restriction site the entire SIV genome was reconstituted. 
Double stranded 3' cDNA moieculescontainingpolleJll'/U3/R sequences were generated 
by a nested peR amplification. The same anti-sense primer L3-1, was used with sense 
primer P3-1 in the first amplification and with sense primer P3-2 in the second peR. Both 
sense primers were located 90 bp apart. The 5' genome fragment was synthesised by a 
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nested PCR using primer pair LS-l / PS-l in the fIrst round and LS-2 / P5-2 in the second 
amplification round, generating amplimers of approximately 5-kb (Figure 1), Sequences 
derived from the U3-R region present in RNA were similar to the COlTcsponding region 
present in proviral DNA. The SIVpbj 1.14 clone was used as a characterised template for 
quality control of fIdelity of the PCR conditions. A S-kb amplimer of these e10nes was 
checked. Secondly, to control the fIdelity of the RT-PCR reaction fIve of our own 8980 
clones were partly sequenced and compared. To check for possible errors during 
amplification, one cloned S'SIV-genome half with defined sequence was amplified and 
sequenced. One (silent) mutation was detected between the original insert (5000 bp) and the 
amplified product. We calculated that the CITor rate of these amplifications was around the 
0.02% and comparable to previous results obtained with thermostable enzymes (12, 24). All 
four amplimers ( 5'-LTR and 3'-LTR, and R/US/gag/pol and pol/el1v/U3/R fragments) 
were separately cloned as blunt-ended fragments into the S'jI restriction site of PCR Script 
KS' ( yielding the plasmids pS-LS and pS-L3 and pS-RUGP and pS-PEUR) (Figure 2). 
The 5' and 3' LTR's were then subeloned respectively as a Hilldill / SstI and Hilldill / 
XbaI fragments into pScript AB12. Gag/pol (4.3-kb) and pol/elll' (3.8-kb) fragments were 
then retrieved from pS-RUGP and pS-PEUR as Sst! / Be/I and XbaI / Bell fragments and 
fused downstream to the cloned S' and 3' LTR (yielding the plasmids pS.SIV5' and 
pS.SIV3') (Figure 2). 
4.2.4.2 III vivo and ill vitro reconstitution of funclional full.length clones 
Three e10nes containing the 5' genome half (USRU3/gagqJOI) and three e10nes containing 
the 3'genome half (pol/el1v!USRU3) were linearised at the Bell site and ligated in vitro 
(Figure 1). Combinations of ligated genome halves were functionally tested for replication 
competence by transfecting full-length genomes in human C8166 T-cells. Vims production 
was assayed by screening for syncytia formation, the presence of p27 antigen in the 
supernatants and by immunohistochemistry. A total of nine ligation mixtures (three 5' 
halves combined with three 3' halves) were tested ill vitro. Cytopathic effect (CPE) caused 
by viral replication could be observed for all cells transfected with the combination of 
pS.SIVS' -3 and pS.SIV3' -S9. 
Rhesus PBMC were used for preparation of virus stocks. Characteristic CPE· with 
typical syncytium formation was observed 14 days post infection. All stocks were screened 
for vilUs production and a TCIDso was detemlined on (CS166) T-cells. Plasmids containing 
the functional 5' and 3' genome halves were analysed by gel electrophoresis and sequenced 
completely (Figure 3). 
In contrast, the nature of rearrangements that occur during ill vivo ligation is complicated 
and quite inefficient. Southern blot analysis was needed to convincingly show that the 
observed CPE and p27 production was produced by the (ill vivo) recombined full-length 
SlV genome rather than from one of the separate plasmids as a result of some unknown 
integration artefact. The positive signal on the southern blot had a similar relative nligration 
mobility as a marker fragment of about 3200 bp. A XbaI fragment of 3212 bp that 
hybddises to probe 1112 was in agreement with a conect SIV genome recombination. 
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Figure 3. A. Restriction pattern of the doned 5' SIV genome half (pS.SIV5'~3). DNA was digested with: 
Not- t (lane A), Not-BamHI (lane B), Not~EcoRI (lane C), Not-Hind III (lane D), Not-Pst (lane E), Not-Sst 
(lane F), Not-Xba (lane G) and Not-Xho (lane H), n. Restriction pattern of the cloned 3' SlY genome half 
(pS.SIV3'-59). DNA was digested with: Not~1 (lane A), Not-Pst (lane B), Not-Xba (lane C), Not-Pst-Xba 
(lane D), Not-Nco (lane E), Not-Nsi (lane F), Not-BamBI (Jane G), Not-BamHl-Pst (lane H), Not-BamHl-
Xba (lane I) and Not-BamH I-Xba~Pst (lane J). C. Restriction pattern of the cloned full-length SlY genome 
(pS.SIV-F359). DNA was digested with: Not-Sfi (lane A), Not-EeoRI-Sfi (lane B), Not-Neo-Sfi (lane C), 
Not-BamHI-Sfi (lane D), Not-Hind I1I-Sfi (lane E). Not-Pst-Sfi (lane F), Not-Xba-Sfi (lane G), Not-Sst-Sfi 
(lane H) and Not-EeoRY-Sf! (lane J), D. Southern blot analysis of (XbaI) digested chromosomal DNA of: 
non-transfected C8166 T-eells (lane A) and eo-transfeeted (p.5W5-3 and p,SIV3-59) C8166 T-eellline. The 
oligo-labelled PCR- fragment generated by primers RDll and RDI2 was used as probe. Molecular weight 
marker is indicated on the left of eaeh (A, B, C. and D). 
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The nine combinations of S' and 3' genome halves were evaluated three times in vitro 
ligation and transfection experiments. 111e combination of pS-SIV 5'-3 and pS-SIV3'-59 
yielded in all three cases infectious virus. Using the in ill vivo ligation technique infectious 
virus production were yielded in two cases. 
Virus production by ill vivo ligation of the genome halves required a longer time span to 
produce the same virus titre than the in vitro method (20 days versus 14 days respectively). 
No further study has been conducted to elucidate the failure of the other combinations to 
produce infectious viruses. However, we did prepare detailed restriction maps in order to 
detennine if (large) deletions or insertions might have been the reason for the observed 
results. We know that this is a rather insensitive method but since no differences were 
observed on polyacrylamide gels of different percentages we (carefully) believe tilat point 
mutation(s) may be considered as the cause of the biological inactivity of the other clones. 
4.2.4.3 Construction of a biological active molecular clone 
Subsequently, a plasmid containing the entire SN genome was generated. The 5' 
genome half was excised from pS.SIV5' -3 as a Bell / Sfi fragment and cloned into Bell / Sfi 
digested pScript CD56 yielding pScript CD56-5). 11,e 3' genome half was excised from 
pS.SIV3'-59 as a Bell / NotI fragment and cloned into pScript CD56-5, yielding pS.SIV-
F359. Recombinant clones were analysed by agarose gel electrophoresis and sequenced 
completely (Figure 3). Following electroporation pS.SIV-F359 induced CPE in the C8166 
T-cell line (Figure 4A). Virus stocks were prepared and titrated in rhesus PBMC (Figure 
4B). 
A 
• 
• 
B 
FJgure 4. Cytopathic effect of the SIVF359 on human T-cell line (C8166) (A); and on rh-PBMC (B) 
immunocyto!ogically stained for p27 antigen production. Cells were stained 12 days after infection with 
SIVF359 (stock propagated on rhesus PBMC). Photomicrographs 660 x magnification. 
89 
In summary, we describe an optimised long distance RT-PCR method used to derive 
molecular clones from circulating viral RNA in serum. Restriction fragment analysis and 
sequence analysis of both the genome halves and the full-length clone proofed the absence 
of (small) deletions, inserts or point mutations. The cumulative PCR elTor rate of less than 
0.02 percent indicated that by using the (highest) reliable pfu (13, 23) in combination with 
highly controlled reaction conditions functional clones could be generated from small 
amounts of SlY particles. The result of the transfection experiment that was obtained by 
using the ill vivo ligation potency of eucaryotic cells further extended the application of this 
technique to those cases in which no unique restriction site (such as BclI) was available. TIle 
expression of SlY (p27 antigen) in transfected human T-cell lines and the increase in p27 
concentration after inoculation of rhesus PBMC, with small volumes of (CS166) 
supernatant, revealed the replication competence as well as the infectious nature of this 
molecularly cloned virus. More detailed studies in a panel of rhesus macaques are being 
conducted with the SIV FJ59 molecular clone in order to characterise and compare the 
pathogenic potential of tlus clone with those previously described from proviral DNA. 
Using infectious molecular clones of HIV or SIV obtained from serum or plasma viral 
RNA has been considered more representative in AIDS pathogenicity (29), studies and have 
some imp0l1ant advantages over clones derived from provims DNA. Firstly, the RNA-
derived clones are more representative of the replicating virus pool than the proviral 
equivalents (8, 9). Secondly, the HN- or SIY-proviruses, present as DNA in infected 
lymphocytes contain high levels of replication defective proviruses containing deleted or 
otherwise mutated sequences (32). Finally, using circulating viral RNA as template for 
molecular clones (29) also circumvents the need to culture infected cells in vitro and hence 
diminishing the adaptations, observed in both individual viral genomes and in the quasi-
species composition of the viral isolate (22). Notably pathogenic molecular clones of HIV 
have been generated by PCR from proviral DNA (II), we report here the first to be derived 
from extracellular viral RNA. The main importance of using clones directly obtained from 
circulation is that they represent the most abundant virus variant population present ill vivo 
at a certain time in disease. These clones may become even more valuable now. Kimata et at 
has convincingly shown that pat1icular viral variants emerge and become dominant during 
the development of AIDS (21). These vims variants resulted from escape of the immune 
response within the host. In this manuscript we presented one full-length clone of SlY that 
was biological active displaying similar clinical signs as the parental strain. Sequence 
analyses of the V 1 region of SIV B59 (the molecular clone) and SIV B670 (the parental strain) 
revealed that despite ill vivo passage of SIV D670' the predominant viral genotype becomes 
characterised by the sequences encoded by the SIV F359 molecular clone. 
This observation proved that the efficiency of the method is sufficient to obtain these 
relevant SIV variants and that these may be valuable for gaining insight into viral escape and 
to further our understanding of AIDS pathogenesis. This strategy will allow the study of 
lentiviral variants in many different body fluids including CSP, lymph as well as peritoneal 
and thoracic transudates. 
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5,1 ABSTRACT 
End-stage SlY isolates arc suggested to be the most fit of the evolved virulent variants 
that precipitate the progression to AIDS. In vivo selection of a highly virulent SIV isolate 
was obtained by serial end-stage passage in rhesus monkeys (Macaca mlllalta), To dctcnnine 
if there were common characteristics of end-stage variants which emerge from accelerated 
cases of AIDS, a molecular clone was derived directly from the last serum sample collected 
prior to acute onset of AIDS in a rhesus monkey. Sequence analysis confllmed that this 
clone (F359) was a dominant variant selected by serial end-stage in vivo passage and was 
related to but distinct from other molecular clones of the SIV~,jSIV JIla..: group. It caused 
marked cytopathic effect (CPE) and replicated to very high levels in activated but not resting 
peripheral blood lymphocytes. Tllis clone also infected, but did not replicate in rhesus 
monocyte derived macrophages (MDM). Interestingly, although at low doses this end-stage 
variant did not use any of the known co-receptors except CCR5, it was able to infect and 
replicate in human PBMC homozygous for the 1I32 deletion of CCR5, suggesting the use of 
a novel co-receptor. Mature rhesus macaques infected with SlV F359 developed high virus 
loads, loss of CD4+ T -lymphocytes, anemia, weight loss and opportunistic infections 
characteristic of AIDS. It represents the fIrst pathogenic molecular clone of SIV derived 
from viral RNA in serum and provides evidence that not only the genetic but also the 
biological characteristics acquired by highly fit late-stage disease variants are distinct from 
one another. 
5,2 INTRODUCTION 
Simian immunodeficiency virus (SIV) of sooty mangabcys causes AIDS in macaques 
providing an important arumal model for Human lnununodeficiency Virus (HIV)-induced 
AIDS in humans (12, 18,20,29,38). Molecular clones of HlY and SlY have been valuable 
for addressing specific questions in AIDS pathogenesis (27, 41, 49), vaccine development 
(5,8,9, 12,28,50,52) and in the evaluation of antiviral drugs (2, 55). To date molecular 
clones of SIV have been derived from proviral DNA rather than viral RNA and most 
proviral clones have been obtained from cultured cells and frequently from infected human 
ceHlines (13, 22,29,33,41,46,48). It has been demonstrated that by ill vitro propagation 
cetiain viral variants are selected (19, 57). In particular, growth of virus in human celilines 
results in major changes in the SIV genome such as deletions leading to tn1l1cation of the 
transmembrane envelope protein (6, 23, 31, 32). This has resulted in impOliant biological 
differences between the derived clones and the original pathogenic virus population in the 
host. In addition, proviral DNA frequently contains a high propOliion of defective 
provimses (34, 39,40,43, 58). 
Recently it has been demonstrated that late-stage SlY variants are the most fit having 
acquired multiple mutations encoded at several genetic loci facilitating inunune escape and 
increasing replication and cytopathic properties (30). These observations have been 
supported by a different line of experiments. A series of ill vivo passage studies were 
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performed in which blood samples taken at the time of AIDS development were 
subsequently used to infect naive rhesus macaques. End-stage blood samples were taken 
from the most rapidly progressing animal and passaged il1 vivo. This in vivo passage of 
end-stage variants resulted in a progressively accelerated disease course with each 
successive passage until the fourth passage, by which time AIDS had developed in as little 
time as 2 weeks (26). Taken together the results of these two independent lines of 
investigation suggested that the passage of primate lentiviruses late in disease could result in 
the transmission of highly vindent variants capable of causing rapid progression to AIDS. 
Furthermore, data suggested that highly fit end or late-stage "fitness" variants had common 
biological properties (30). 
The provirus population in mononuclear cells ill vivo is generally considered to be a 
sanctuary of biological variants which have accumulated in such intracellular reservoirs as a 
consequence of previous host immune pressures and/or defective viral replication (58). In 
contrast we reasoned that extracellular virions represent a virus population which may be 
considered as dominant as they replicate to high titer, becoming most fit and predominant in 
the host at a pru1icular point in disease development. SIV and my clones that are derived 
directly from extracellular virus populations in biological fluids such as semm have not been 
characterised or evaluated for vimlence in vivo. A key feature of lentivims pathogenesis is a 
persistent high level cell-free viremia. Since the predominance of certain extracellular 
lentivimses after serocol1version is most likely the result of escape from inunune 
surveillance or escape from drug therapy during treatment, such viral variants are of 
particular biological interest. Recently we developed a strategy to generate pathogenic clones 
directly from extracellular virions present in the circulation, in semm or plasma (24, 25). 
Using this strategy we derived a full-length infectious moleculai' clone of SIV 8980' an end-
stage isolate from a macaque which had progressed rapidly to AIDS following serial end-
stage passage of SLY B670 ill vivo (26). Sequence analysis revealed a unique relationship 
placing tIus virus between the two groups of SIVsm and SIV mao: primate Ientiviruses. During 
in vivo passage the variability of YI decreased as vi11l1ence increased. The F359 molecular 
clone represented the most dominant variant that had emerged during end-stage passage. 
This variant was highly cytopathic and replicated to high titers ill vivo. It was predonunantly 
T-cell-tropic infecting but not replicating in macrophages. Of all the known co-receptors 
SLY 1-'359 was selective for CCR5, but could still replicate in human PBMC homozygous for 
the to.32 deletion, suggesting the additional use of a novel co-receptor. 
5.3 MATERIALS AND METHODS 
5.3.1 Molecular clone derived from serum 
SlY 89S0 was derived from SlY B670 by four subsequent ill vivo passages in Indian rhesus 
macaques. Monkey 8980 rapidly progressed to AIDS following the fourth ill vivo passage 
(26). Senull from this animal was, without culture, directly used to derive the F359 
molecular clone of SIV (24). Since the synthesis of full-length (IO-kb) SIV eDNA 
molecules from small amounts of RNA templates proved to be very difficult, a modified RT-
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peR technique was developed to separately generate S' and 3' halves of the SIV genome 
(25). By ligating these t\vo 5-kb fragments we were able to reconstihlte the F359 infectious 
molecular clone directly from serum as \ve have previously described (24). 
5.3.2 Characteristics ill "ilro. 
Primary rhesus PBMC cultures were maintained with mcdium change every two days 
and were observed regularly for CPE. Infection was confirmed by immunocytochemistry 
for the expression of SIV gag antigen. Single-cell preparations for immunocytochemistry 
were pI'epared on acetone c1eancd glass slides, which had been air dried for 30 minutes. 
Cells were fixed in acetone/methanol (1:1) and in ethanol (70%) for 15 and 30 minutes, 
respectively. Slides were washed in 0.05 M Tris-HCl pH7.6, 0.1 M NaCI for 5 minutes and 
incubated with 20 ftl (1:25 dilution) of anti-gag monoclonal antibody (47). Cells were 
washed for 5 minutes and incubated with goat anti-Mouse IgG antibody for 30 minutes at 
room temperature. To amplify the signallhe cells are then washed and incubated with mouse 
anti-alkaline phosphatase (APAAP-complex, Boehringer). Cells were washed for 5 minutes 
and were incubated with 20 ftl substrate solution: (10:1:1) 0.1 M Tris-HCl pH 9.5, NBT 
(nitro-blue tetrazolium), BCIP (5-bromo-4-chloro-3-indolylphosphate), 5 mM levamisole 
for 30 minutes at room temperature. Cells were washed for 5 minutes in tap water, one drop 
of (50%) glycerol/PBS was added per slide, and the cells was covered with a cover slip. 
The preparations were examined at a 40x magnification and CPE was quantified. In cell 
culture supernatants virus was quantified by measuring p27 concentrations (SIV p27 antigen 
capture ELISA, Coulter Corp., Hialeah, Fl.). 
5.3.3 In vivo infection 
Adult rhesus macaques (Macaca mulatta) used in this study were housed at the animal 
facility of the Biomedical Primate Research Centre (BPRC), Rijswijk, The Netherlands. 
Animals were negative for SlY, STLV and Simian D type retroviruses. Two outbred Indian 
rhesus macaques were inoculated intravenously with 50 TCIDso of the SIVsmF359 stock 
grown on rhesus PBMe. EDT A-treated blood samples were collected every two weeks post 
infection for quantitative virus isolations (QVI) from PBMC and for determination of SIV 
p27 antigen in plasma. Rhesus monkeys that developed clinical evidence of AIDS were 
euthanised and full pathological analysis was performed to confinn the diagnosis. For 
histological examination, tissues were fOl1nalin~fixed and paraplast-embedded. Four-
micron-thick sections were stained with hematoxylin and eosin (H&E). For the detection of 
microsporidia, a gram staining was applied on gall bladder sections. 
For QVI, PBMC were prepared from EDT A-treated blood by lymphocyte separation 
medium (LSM) density gradient centrifugation. Cells at the interface were collected and 
washed twice with RPMI. T\vo-fold dilutions ofPBMC (starting with lxl06 cells) were co-
cultured with 2.5 x 10' cells of the human T-cell line C8166 in a 24-wells plate (Greiner 
Labortechnik, The Netherlands) in duplicate. Cell culture mediuIll (RPM! with 10% FCS) 
was pillily changed twice a week. The cell cultures were screened regularly for the presence 
ofCPE. 
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The phenotype of rhesus PBMC was assessed by two-colour FACS analysis. 
Briefly, heparinised blood (100 ~I) was incubated with 10 ~I of monoclonal antibody mix at 
room temperature. After incubation, 2.5 ml lysing solution (Becton Dickinson, Etten-Leur, 
The Netherlands) was addcd followed by an incubation at room temperature for 10 minutes, 
then centrifugation for 10 minutes at 200g. Four ml PBS with 2% formaldehyde were added 
and the tubes were centrifuged for 10 minutes at 200g. The supernatant was aspirated and 
the cells were resuspended in 5 ml PBS with 2% formaldehyde and stored overnight at 4°C. 
Flow cytometry was performed on a FACScan using the CellQuest software (Becton 
Dickinson, The Netherlands) and 5,000 events analysed. To assess CD4 T-cell levels in 
peripheral blood thc following mAbs were used; anti-CD3 monoclonal (FNI8, BPRC-
Rijswijk) antibody covalently coupled to fluorescent isothiocyanate-phycoerythrin; and anti-
CD4 (SK3, Becton Dickinson) monoclonal antibody covalently linked to phycoelythrin 
conjugate. 
5.3,4 Cen tropism and co-receptor studies 
To assess susceptibility to infection of resting and activated lymphocytes, blood was 
taken from hcalthy rhesus monkeys, which were negative for SlY, STLV and type D 
retroviruses. PBMC were isolated by lymphocyte separation medium density gradient 
centrifugation and \verc washed twice with RPMI. Activated lymphocytes were prepared by 
ConA mitogen stimulation (5 ~g/ml, 48 hours) and interleukin-2 (IL-2) (50 units/mI, 
starting after virus adsorption and throughout the experiment). Resting lymphocytes were 
cultured in RPM! (+ 10% FCS) without PHA and !L-2. Resting and stimulated lymphocytes 
were distinguished by double labeHing by anti-CD3 antibody, specific for T-cells and anti-
MIB-I antibody specific for the ceilular proliferation marker Ki-67 (3, 14, 37). Resting and 
stimulated cell cultures (5x106) were simultaneously infected with 100 TCIDso of 
SIV tn.1.;-239fYEnd (a molecular clone capable of proliferating in resting cells) (14) or of the 
SIV 859 clone at 37°C for 18 hours. Unbound virus particles were removed by washing the 
cell peilcts five times with 5 ml of RPMI (+ 10% FCS) and the cells were cultured for 
twelve days in RPM! (+ 10% FCS) either with or without !L-2 for stimulated or resting 
PBMe respectively. Supernatants were monitored for the production of virus p27 by 
antigen capture ELISA. The absence of Ki-67 staining was used to confmn that resting 
lymphocyte cultures remained in a quiescent state. 
To detennine if SIV FJ59 was able to infect rhesus MOM cultures, LSM isolated PBMC 
were seeded at a concentration of 5xl06 cells per ml in 24 well plates in RPNll with 10% 
FCS. Adherence was allowed for 5 days. Prior to infection non-adherent cells were 
separated from adherent cells by rigorous washing with culture medium. Adherent cells 
were checked for purity (> 98%) and for being macrophages by demonstrating the presence 
of the cell surface marker COGS and by microscopic examination of their characteristic 
morphology. After infection with SIV mad16 (macrophage-tropic molecular clone of SIV as 
positive control) (44) or SIV!mE'59' unbound vims was removed by washing the cells twice. 
Macrophage cultures were maintained for 14 days in RP.MI 1640 medium supplemented 
with 20% FCS, penicillin and streptomycin with medium change once per week. At day 14 
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samples were analysed for intracellular gag expression and the presence of SIV p27 gag 
antigen in supernatants. 
SlY p27 gag expression in l\IDM cultures was studied by double staining 
immunocytochemistry. Briefly, cells were incubated with a mixture of the mouse anti-gag 
mAb 2E4 (IgG2a, kindly provided by Dr. M. Niedrig (47)) and mouse-anti-CD68 mAb 
KP 1 (IgG I, DAKO, Glostrup, Denmark), which was used to co-stain macrophages. 
Consequently, slides were incubated with alkaline phosphatase conjugated goat anti-Mouse 
IgG2a subclass specific antibody (Southern Biotechnology Inc., Birmingham, UK) and 
horseradish peroxidase conjugated goat anti-Mouse IgG 1 subclass specific antibody 
(Southern Biotechnology). All incubation steps were perfOlIDcd at 20°C for 30 minutes. 
Endogenous peroxidases were blocked with 0.1% NaN] plus 0.3% H20 2 in PBS after the 
incubation with the first antibody. Alkaline phosphatase activity was detected with naphthol-
AS-MX phosphate (Sigma chemical Co., st. Louis, MO), and Fast Blue BB (Sigma) in 0.1 
M Tris-Hel, pH 8.5 (20 minutes in dark) yielding a blue colour. Horseradish peroxidase 
activity was detected using IIp, (0.03%) and 3-amino-9-ethylcarbazole (ABC, Sigma) 
yielding a red colour. 
The co-receptor usage of the molecularly cloned vims was detennined by three different 
assays. The first assay involved the use of HOS/CD4+ cell lines expressing either the 
macaque or the human CCR5 and was based on illmmllostaining of SIV infected cells. The 
IIOSICD4' ceIl lines were infected with SIV,mF'59 by adding Ix!O' TCID,ofml vims to the 
adherent cells in 3 ml of medium. After 72 hours, cells were analysed for syncytia 
formation, washed once in serum free medium, fixed in methanol I acetone (50 I 50) for 2 
minutes at -20°C and washed twice in PBS supplemented with 1% FCS. Anti-gag mouse 
monoclonal antibody (0.6 mIl well) was added, incubated for one hour at room temperature 
and washed three times in PBS supplemented with 1% FCS. Goat anti-Mouse B-gal 
conjugated polyclonal antibodies (0.6 mIl well) were added, incubated for one hour at room 
temperature and washed three times in senlln free PBS. X-Gal substrate (0.6 mIl well) was 
added and the preparation was incubated in a sealed box for 30 minutes at 37°C. For 
quantification the stained cells were washed three times in PBS. 
The second assay used the astroglia cell line US7 stably expressing human CD4 and 
either one of the chemokine receptors CCR2b, CCR3, CCR5 or CXCR4. These cells were 
seeded in 24 welI plates at 2 x 104 ceHs per well in 1 ml of medium. Infection was 
perfo1TIled ovemight at 3TC with ten-fold serial dilutions of virus (l ml final volume) 
beginning with a 1:8 dilution of the SIVsmF359 stock. After infection, the cultures were 
washed three times with DMEtVl and cultured for 13 days. Medium was changed twice a 
week. Cultures were examined microscopically for cytopathic effect and supernatants, 
collected at several time points after infection, were tested for p27 concentration. 
In the third assay several CD4 transfoffiled human osteosarcoma HOS cell lines were 
used, expressing the chemokine receptors CCRl, CCR2b, CCR3, CCR4, CCR5, CXCR4, 
BOB/GPRI5, Bonzo/STRL33, CXCRI (V28), CCR8, APJ, GPRI and US28 (the reagents 
were obtained through the AIDS Research and Reference Reagent Program, Division of 
AIDS, NIAD, NIH from Dr. Vineet, N. KewaiRamani and Dr. D. R. Littman). The CD4 
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transfonned (under neomycin selection) HOS parental cells containing HIV-2 LTR driving 
green-fluorescence protein (GFP) introduced via co-transfection with the CMV promotor 
driving a hygromycin-resistant constmct, were maintained in Dulbecco's modified Eagle 
Medium (DMEM; Gibeo) supplemented with 10% FCS under selection of neomycin (G418 
0,5 rng/ml; Gibco) and hygromycin (100 f-lg/ml). Co-receptor genes were introduced via 
retroviral infection with the pBABE-puro vector (lO, 36) under the selection of puromycin 
(1 ~glml; Calbiochem, La Jolla, CAl. For cell-free infection experiments HOS-CD4 cells 
expressing the different co-receptors were seeded in 2 x lO4 cells per well (2 ml) in 12 well 
plates and cultured in DMEM \vith 10% FCS. The next day, infection with the virus stocks 
(500f1l!well) was performed in the presence of polybrene (20 ~glml) during overnight at 
37°C. After infection the cultures were washed and cultured for another day. Forty-eight 
hours after infection cells were analysed for OFP fluorescence with FACS. 
5.3.5 DNA sequencing and phylogenetic analyses 
Double stranded plasmid DNA containing the lO-kb SIV smFJ59 insert was used as a 
template for sequencing. DNA sequencing reactions \vere carried out using dye-primer 
chemistry and were executed on a LiCor automated DNA sequencer. The entire insert was 
sequenced from both directions. Nucleotide sequences were aligned using Clustal\V version 
1.7 (53). Alignments were examined and adjusted as necessary using the ODE (Genetic 
Data Environment) program (51). Regions of sequences that could not be unambiguously 
aligned were removed from subsequent analyses. Neighbour-joining phylogenetic analyses 
were conducted using the DNADIST and NEIGHBOR programs from version 3.5e of the 
PHYLIP package (16). Maximum likelihood (ML) analyses of ellv sequences from selected 
SIYs were performed using the PAUP' program (version4.0.0d60, Swofford) as follows: 
initial NIL estimates for the env tree were produced using a 2 SUbstitution-type model (HKY 
model) without rate variation among sites. The topology of tltis tree was used as a starting 
topology for subsequent analyses. The shape parameter (alpha) for the gamma distribution 
describing rate variation among sites was estimated using the maximum likelihood method to 
be 0.22966. Titis value W;JS used for the estimation of the parameters for the 6 substitution-
type model (general time reversible model). The values estimated (a=2.499, b=10.46, 
c~1.278, d~1.746, e~9.962, f~1) were then in turn used to refine estimates. Final estimates 
for the parameters were a~2.499, b~IO.44, e~1.278, d~1.745, e=9.95, f=l, 
alpha~0.23156. 
5.4 RESULTS 
5.4.1 Cen tropism ill I'itro 
To determine the replicative properties and cell tropism of SIVF359 a series of ill vitro 
assays were performed to compare the propel1ies of this molecular clone, with the well-
established characteristics of two other well-defined SIV III.lC molecular clones. Mitogen 
stimulated PBMC cultures were used to assess virus replication in rhesus lymphocytes. All 
vimses tested (SIV F359' SIV m~<:2J9IYEnd' SIV m.l~239) grew well in stimulated rhesus lymphocyte 
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cultures as measured by p27 concentrations in the supernatants (Figure 1A). These data 
indicate that all viruses including SIV F3S9 were able to infect and replicate in stimulated 
rhesus lymphocytes. Subsequently we determined the ability of SIV FJ59 to replicate in 
resting rhesus lymphocytes, a capability that has been reported for SIVsmmPBj (17) and 
SIV ma..:2.WIYEnd (14). Virus production was only observed in resting cell cultures infected with 
SIV Imc239IYFJld at day six post-infection producing 1.6 ng/ml of p27 in the supernatant, which 
increased to 12 ng/ml p271 ml by day twelve post-infection (Figure IB). 
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Figure 1. Production of SIV p27 antigen (nglml) in stimulated (A), resting (non-stimulated) rhesus 
lymphocyte cultures (B) and MD~'I cultures (C). Cultures were infected with equivalent amounts of either 
SIVF359 ( 0 ), SIY""d3WYErd ( • ), SIV rm239 ( li ), or SIV rna.:316 ( .&. ). 
Infection of monocyte derived macrophage (MDM) cultures with SlY f3S9 or SlY mad16 
yielded detectable virus production only upon infection with SlY mad16 with p27 
concentrations in cell supernatants increasing from 0.8 to 7.8 ng p27/ml, from day six to 
day twelve respectively. During the entire experimental period virus production in 
supernatants could not be detected in cultures infected with SlY BS9 (Figure IC). The 
absence of SIV FJ59 in the supernatants of MDM cultures was concluded to be due to the 
inability to either, I) infect, or 2) replicate efficiently in this cell type. MDM cultures were 
double stained immunocytochemically for the presence of both the macrophage marker 
CD68 and the viral antigen p27. Analysis of stained cells indicated that SIVFlS9, although not 
able to produce detectable amounts of p27 in supernatant, did infect macrophages and 
resulted in the expression of gag protein (Figure 2A). In contrast SIV m3cJJ6 not only infected 
:MDM (Figure 2B) but also replicated well producing substantial p27 concentrations in 
macrophage cultures (Figure Ie). In summary, these results were reminiscent of previous 
studies of late-stage variants in humans and macaques (30) indicating that the molecular 
clone SIV FJ59 was similar to cytopathic (syncytium inducing), rapidly replicating and 
predominantly T-cell-tropic variants but retained the ability to infect monocyte/macrophages. 
5.4.2 III l'il'o infection 
To investigate if the molecular clone SIVFJ59 was infectious and pathogenic ill vivo, two 
rhesus macaques (L52 and WT) were intravenously infected with 100 TCID50 of SIV F359 
propagated in rhesus PBMC. CD4' T-Iymphocytes were monitored by FACS analysis and 
fluctuations in vims loads were measured by Quantitative Virus Isolation (QVI) and are 
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depicted in Figure 3. For animal L52, these parameters were determined at two-week 
Intervals. The same measurements were performed for \Vf at weekly intervals during the 
first month, subsequently Ht two week and at monthly intervals. Animal L52 developed a 
virus load of 1024 vims producing cells/106 PBMC two weeks after infection. Decreased 
values (524 vims producing cellsll06 PBMC) were detected 4 and 6 weeks after infection 
and dropped further to 128 vims producing cellsllO' PBMC at weeks 8, 10 and 14 post-
infection A second peak of viremiH, which reached 514 virus producing cells/106 PBMC, 
was observed 15 and 17 weeks after infection. At weeks 19 and 21 virus loads decreased 
again to 256 and 48 infected cells per 106 PBMC, respectively. A third peak, which was 
higher than the previous ones, was observed at the end of the experimental period, from 
week 23 till week 37: virus loads as high as 2024 infected cells per 10' PBMC at week 32 
were detected (Figure 3A). The presence of this peak coincided with the development of 
severe anemia, diarrhea and the start of extensive weight loss. L52 was euthanised after 37 
weeks of infection. 
A 
Figure 2. Photomicrographs of infected MDM cultures infected with SIV",,,3[6 (A) and SIVFlS9 (B); 
infection is demonstrated by CD68+/p27' double staining. Photomicrographs 660x magnification. 
lOt 
The first positive virus isolation from monkey \VT was observed already one-week post 
infection (p.i): 512 virus producing cells per 106 PBMC were measured. This value 
increased to 1024 virus producing cells/106 PBMC at ,veek two and three post-infection but 
dropped over time to 64 virus producing celis/106 PBMC as detemlined at week 8 after 
infection. Relatively low virus loads, fluctuating between 256, 64, 128 and 16 vilUs 
producing cells/106 PBMC, were found 10, 12, 14, 16 and 19 weeks post-infection. An 
increase in virus loads from 700 to 4048 virus-producing cells/l06 PBMC was then detected 
from week 23 to week 41, respectively. During the last 22 weeks (till week 68) virus loads 
stayed at a constant level of 1012 virus producing cells/lO' PBMC (Figure 3B). WT was 
euthanised after 68 weeks. 
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Figure 3. Virus load (A,B) and changcs in CD4+ lymphocyte populations (C,D) of rhcsus monkeys WT 
(A,C) and L52 (B,D) after infection with molecularly cloned SlY mg. Progressive decline of CD4+ T-
lymphocytes in infected rhesus monkeys (WT, L52) as compared to control monkeys (8637, 8711) 
represented by (/).) and (0) respectively. 
Histopathology revealed moderate cathalThalic enteritis, severe lymphoid hyperplasia in 
spleen and lymph nodes with moderate atrophy of splenic follicles. CD4 cell numbers of 
inoculated animals were compared to two uninfected rhesus monkeys of the same sex, age 
and body weight. The two infected animals showed a decrease in CD4+ T-cell lymphocytes 
during the course of the experiment (25% for L52 (Figure 3C) and 21 % for WT (Figure 
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3D). CD4+ T -lymphocytes cultured from these animals were positive- by immunocyto-
chemical staining for p27 antigen expression (data not shown). The uninfectcd animals had 
stable CD4 cell counts as expected. 
In both animals histopathological findings were consistent with the diagnosis of AIDS. 
Cryptosporidial enteritis without remission as seen in WT is observed in advanced 
immunodeficiency (42) and is one of the criteria for the diagnosis of AIDS in man. In LS2, a 
cholecystitis due to a microsporidial infection was identified. The etiologic organism has 
only recently been detected in SIV -infected rhesus monkeys and was classified as 
Enlerocyfozoo!l bieflellsi-like microsporidial protozoan. EnterocylozooJ1 bieneusi is a 
common opportunistic pathogen of AIDS patients causing significant morbidity. 
5.4.3 Co-receptor usage 
To further con-elate the observations of cell tropism, the co-receptor use of SlY F359 was 
characterised. Infection experiments with SlY F359 virus were performed Oil HOS/CD4+ cell 
lines expressing either the macaque or human CCRS co-receptor. Both cell lines were highly 
susceptible to infection with SIV B59' and almost 90% of the cells fonned syncytia, which 
stained positive for SlY p27 antigen. To investigate the ability of SIV F359 to use additional 
co-receptors, the extent of its replication in GHOST cells and U87MO-CD4 expressing 
CCRI. CCR2b, CCR3, CCR4, CCR5, CXCR4, BOB/GPRI5, BonzofSTRL33, CX3CrI 
(V28), CCR8, APJ, GPRI and US28 co-receptors (II, 21) was assayed in parallel with the 
well characterised SIV,mdw and SIV madl6 molecular clones. All three viruses were found to 
use CCR5 for infection (Table I), as was detennined by FACS analysis while SIVFJ59 
proved to be unable to use any other co-receptor than CCR5 at standard doses. This 
observation taken together with the capability of SlY Em to infect T -cells and macrophages 
corroborates previous findings that the CCR5 receptor is used by both M-tropic and T -tropic 
HIV-I (7, 15). Interestingly, both SIV ='" and SIV ="" used multiple co-receptors 
including BOB/OPRIS and Bonzo/STPR in contrast to SIV F359. Furthermore, the 
macrophage-tropic molecular clone SlY mac316 used as a fourth co-receptor CCR3 (Table 1). 
Finally. to determine if the SIV FJ59 clone was truly restricted to only CCR5 co-receptor use, 
we cultured SIV F359 on human PBMe homozygous for the 32 deletion that renders these 
cells resistant to viruses, which only use the ACCRS co-receptor. Interestingly, although 
SIV F359 was unable to use any of the other known co-receptors it could replicate on these 
cells, while other CCRS restricted isolates could not. At much higher doses there was 
evidence that SIV FJ59 could also infect cells bearing BOB, but it was unlikely that these were 
physiological concentrations of virus. These data suggested that the SlY FJ59 clone may 
additionally utilise a novel, previously undescribed co-receptor for entry. 
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Table 1. Comparison of co-receptor use and cell tropism of the well-defined T-cell-tropic 
and M-tropic SIV = strains compared to SlV F359. Infection of SIV mlc239' SlV m~c316 and 
SIV FJ59 in HOSICD4', GHOST cells and U87 cell lines stably expressing the human co-
receptors listed (partial list) in this table. 
Co-recelltor use: 
CCRI 
CCR2B 
CCR3 
CCR4 
CXCR4 
CCR5 
BOBiGPRl5 
Bonzo/STPR 
Properties: 
M-tropism/infection 
i\-l-tropism/productive 
mac239 
+ 
+ 
+ 
Virus clone 
mac316 smF359 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
5.4.4 Is SIVY359 representative of the predominant variant following ill pil'o passage? 
TIle first hypervariable region (VI) represents the most variable region of the SlV 
genome and therefore it provides a sensitive indicator of the genotypic variation present 
within a quasi-species of an infected animal. Trichel et al identified twelve different 
genotypes in the SIV B670 inoculum based on sequence analyses of the VI region (54). TIle 
V 1 regions derived from the viral variants emerging during the ill vivo passage (26) were 
detennined (56) and compared with the V I sequences of the viral variants that were present 
in the original SlV B670 inoculum (54). Homologies were quantified by using software that 
calculated the actual "alignment fit" as the fraction of the optimal fit. SlV D670-CL12 emerged 
as the predominant variant from the original SIV R670 infection and represented the highest 
genome stability during the passage experiment (Figure 4). Clones obtained during the 
subsequent passages represented viral variants that were more closely related to SlV B670-
CLl2 than to any other B670 clone (Figure 4). Tllis indicated that SlY B67o-CLl2 possessed 
the optimal fitness for replication in both B670 and the animals it was transmitted to. 
Indeed, based on our observations of high persistent virus loads in the most rapidly 
progressing animals (26) certain variants Illay have acquired mutations making them 
relatively resistant to neutralisation (30). VI sequences derived from passage samples were 
compared to the SIV H670-CLI2, which had shown the highest homology with evolving 
variants during the passage study. Specifically, during the subsequent passages the number 
of different VI clones decreased from four (out of four) to two (out of four) (Figure 4). 
These findings demonstrated that during in vivo passage there was a selection for the most 
fit variants (30). TIle molecular clone SIV F359 represented the dominant variant and had 
retained the identical VI sequences observed in P4.1, P4.2 and P4.3 envelope clones 
(Figure 5). 
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Figure 4. Comparison of VI sequences of envelope clones that emerged during the in l'h'o passages (PI to 
P4) to obtain SIVS9SO from which the molecular clone SIVF3S9 was derived, and the VI sequences of the viral 
variants (eLl to CLl2) which were present in the original SlY B670 inoculum (54, 56). 
S.4.S Phylogenetic analysis of SIV.,59 
Phylogenetic analysis of env sequences using the neighbour-joining and GTR maximum 
likelihood method (16) confIrmed that SIV F359 clustered together with SIV,m clones such as 
SIVsm9 and SIVsmmPBj.jAI and was not closely related with SIV rna.: clones such as SIV mac25P 
SIV mJc239 and SIV mJdAI!' As could be expected from the origin of SIV B59' this clone was 
most closely related to but distinct from SIV B670 (envelope sequence only available) (Figure 
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6A). SIV B670 had been isolated from a rhesus macaque infected with material containing SIV 
from a sooty mangabey housed at the Tulane Primate Centre (45). These two vimses branch 
separately from other characterised SIVsm viruses, which had also been derived from sooty 
mangabeys but originating from the Yerkes primate colony (17). Interestingly, these vimses 
fanned a unique cluster of strains \vhich branched separately from those macaque adapted 
isolates derived from the New England (mac251, mac239) and Califomia (mac1Al!) 
Regional Primate Centres (35). Neighbour-joining phylogenetic analysis performed on the 
entire sequence showed similar relationships within the SIV cluster (Figure 6B). The 
predicted amino acid sequences of SlY F359 proteins were more similar to those of SIVSmH-I 
(87%) and SIV,mmPBjHl (88%) than to those of the SIV~ cluster (83%) (Table 2), TIle 
greatest similarity with other SIVs was present in the gag (average 92%), pol (average 93%) 
and vpx (average 92%) genes, whereas the greatest divergence was seen in nef (average 
similarity 75%) and tat (average similarity 72%) genes (Table 2), 
Table 2. Predicted amino acid similarity of SIV F359 compared to other SIV molecular clones. 
F359 % Similarity 
protein 8670 SmH4 s1l11l1PBj4.41 ll1ac239 llIac1All SIVmac Stm Moe mean 
Gag 96 95 90 91 92 88 93 92 
Pol 97 95 92 91 92 91 93 93 
Vi! 93 89 84 84 85 78 84 85 
l'px 94 92 94 94 93 88 88 92 
Vpr 8t 96 87 84 86 88 89 87 
Tat 75 80 65 80 75 69 62 72 
Rev 78 81 77 76 75 80 78 
EI/)' 95 88 86 83 80 78 83 83 84 
Ne! 81 75 78 74 66 77 75 75 
mean 87 88 83 84 82 83 83 
5.4.6 Virulence of the SIV FJ59 molecular clone 
To detennine if the SlY FJ59 molecular clone had retained the same pathogenic potential as 
the parental SlY 8980 isolate, an additional eight animals were infected with the same dose of 
the SlY FJ59 virus stock. As illustrated in figure 7, animals infected with the SIV 859 stock 
had very similar survival curves as compared with the SlY 8980 stock from which it was 
derived, and was much more pathogenic than the original pre-passage SlY B670 isolate. TIle 
molecular clone was slightly less pathogenic. as could be seen by the slight shift of the 
survival curve to the right. This however could be a consequence of the genetically 
homogeneous nature of the SlY FJ59 inoculum as compared to the more heterogeneous 
SIV 8980 inoculum, which represented a highly vim lent quasi species. Indeed, a 
heterogeneous quasispecies is more likely to escape from the inmmne responses of an 
outbred host. 
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Figure 5. Amino acid sequence alignments of the VI envelope region of the predominate clone 12 (CL12) 
in the pre-passage SIV 116iO inoculum. This sequence persisted through the passage as the diversity of the 
inoculum decline (figure 4). TIle CLI2 VI sequences are compared with the sequences of clones derived from 
the 4 different passages (PI to P4). Clone P4.3 represents the same VI sequence found in the molecular 
clone, F359, and which was originally found in CLl2 within the quasispecies found in the pre-passage 
SIV B670 inoculum. 
5.5 DISCUSSION 
\Ve have utilised a novel cloning strategy to derive an infectious pathogenic molecular 
clone of a primate lentivims without cell culture passage directly from seflnn. This molecular 
clone from selUm (SIVF359) has unique properties. It is highly cytopathic in vitro and causes 
marked syncytia in lymphoid tissues in vivo. It readily infects activated but not resting 
rhesus lymphocytes. Infection of MOM cultures was demonstrated, however, in contrast to 
SIV ITllc3t6 no VilUS production in the supernatmlt was detectable. Co-receptor use of this 
clone was restricted to only CCR5 in contrast to that of other well-characterised SIV mac2J9 (T-
cell-tropic) and SIVm~~316 (macrophage-tropic) molecular clones studied for comparison. 
Suprisingly, although this virus did not use any of the know 13 primate lentivirus co-
receptors it could replicate on human cells defective for CCR5. 
The use of molecular clones derived from extracellular virions may provide additional 
insight into the evolution of the lentiviral pathogen. For instance, tlus cloning strategy may 
aid the analysis of the specific biological properties of viral variants in plasma or serum, 
which have escaped host immune responses at a specific point in time. Similarly, the study 
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of virus populations, which arise and become predominant in various extracellular 
compartments is feasible using this methodology. Studying the evolution of viruses using 
this strategy has a number of important advantages over conventional techniques that 
involve cloning provimses from infected lymphocytes. 
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Figure 6. Phylogenetic trees based on the SIV $.G1859 sequence as compared with (A), envelope sequences 
from the parental SlY 8670' and as compared to less related SIY""'Hi' SIV"" and SIV,tm sequences. Tree was 
constructed using a GTR maximum likelihood analysis. Based on full-length sequences (B) phylogenetic 
analysis comparing the SNsmF.l59 molecular clone to other SlY, HIV-l and HIV-2 clones. Phylogenetic trees 
were constructed by the neighbour-joining method using the PHYLIP program (version 3.5c). 
The SlY FJ59 molecular clone was derived from a rhesus macaque, which had developed, 
AIDS following the fourth ill vivo passage of virus derived from SlY B670' The ViIUS isolate 
SIV B670 originated from one of the first reports of simian AIDS in macaques, since has been 
used in a wide variety of studies (1,4. 45). Phylogenetic analyses using available ellv genes 
or the entire SIV genomes revealed that SIV B670 and SlYSmFJ59 branch off between two 
separate clusters of SIV!m clones, represented by SIV,mm9 and SIVsmmPBj4Ai> derived from the 
Yerkes Primate Colony, and SIV mac clones, such as SlY ={"251 and SlY mac2J9' derived from the 
New England Primate Colony (figure 6), As could be expected from the origin of SlY F359' 
this clone was related to but distinct from SIV B610' Originally SIV B670 had been isolated from 
a rhesus macaque (B670) infected with material containing SIV originally derived from a 
sooty mangabey from the Tui<me Primate Centre (45). Using the entire sequence for 
phylogenetic analysis SlY FJ59 was found to branch separately between other characterised 
SlY isolates derived from sooty mangabeys or macaques (figure 6). The characteristics of 
the envelope evolution of SIV B670 during serial passage to animal 8980 from which SlY FJ59 
was derived have recently been described (56). 
In summary, we have utilised a new dolling strategy to generate infectious molecular 
clones of lentiviIUses from extracellular viral RNA in body fluids. TillS has facilitated the 
isolation of a unique pathogenic molecular clone designated SlY FJ59' Characterisation of 
SIV FJ59 ill vivo and ill vitro revealed that it was highly pathogenic causing marked syncytial 
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giant cell fonnation if! situ in lymph nodes and CPE in rhesus CD4+ T -cells in vitro. It was 
found to have limited and novel co-receptor usage (CCR5 and a yet undefined co-receptor) 
and could infect but not replicate in rhesus MDM. Neve11heless, it proved to be able to cause 
a rigorous infection and AIDS in rhesus macaques. It was genetically distinct from other 
molecular clones, mapping between two clusters of previously characterised clones (the sm 
and mac molecular clones respectively). The SIVB59 molecular clone may provide further 
insight into the pathogenesis of AIDS in the macaque model, and in pru1icular to address 
specific questions snch as the evolution of co-receptor use, cell tropism and disease 
progression. 
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6.1 ABSTRACT 
The net gene has been demonstrated to be an important viral factor in the pathogenesis of 
lentivirus induced AIDS in primates. Several studies have revealed that in rhesus macaques 
infected with SIV TIl.l>: molecular clones with attenuating point mutations in nej. the virus 
quickly reverts to wild-type resulting in progression to disease. Furthermore, the repair of 
defective ne! genes is often correlated with an increased ability to fe-isolate virus. It remains 
unknown, however, if the mutated virus variants persist in the host and to what degree they 
may influence disease progression. A particularly interesting lief mutation resulted in a TAA 
stopcodon at amino acid position 107 in a novel molecular clone of SIVs9S0 designated 
F359. To determine the kinetics of reversion of nef and if reversion was associated with an 
increase in viral RNA in plasma, ten rhesus monkeys (5 juvenile and 5 mature) were 
simultaneously infected with the same dose of the molecular clone SIV F359' Individual nef 
clones isolated from plasma of the various monkeys were used to analyse the correlation of 
lief reversion with virus load and disease progression. Half of the animals developed high 
virus loads and progressed rapidly to AIDS-like disease. The remaining five were either 
intennediate or non-progressors. An important correlation between the predominance and 
persistence of this specific !lef variant in plasma and the subsequent course of disease was 
found. 
6.2 INTRODUCTION 
Unlike the genes gag, pol, env, tat and rev the accessory gene llefis dispensable for HIV 
and SlY replication ill vitro (2, 8, 11, 15, 25). Functional nef, however, is an impol1ant 
virulence factor ill vivo and thus facilitates the development of the full pathogenic potential 
ofHIV-1 (3, 14) and SIV,mlm" (I 2). 
Nef down-modulates the cell surface expression of the CD4 glycoprotein which is the 
receptor for both SIV,m/=, (I, 7) and HIV-I (9, 17, 23). Experiments with cells over-
expressing CD4 receptors indicated that an excess of CD4 receptor on the T-cell surface 
impairs virus release. Therefore, the observation that Nef has an enhancing effect 011 the rate 
of viral spread and infectivity may in part be explained by the specific down-regulation of 
the CD4 receptor. Several studies yielded evidence that Nef down-regulates also .MIlC class 
I genes. III vivo this may facilitate an increase in virus load by allowing infected cells to 
escape from CTL directed lysis and to persist while continuously producing virus. 
The nefgene in both the HIV and SlY genome is located at the 3' end of the env gene. It 
extends into the U3 region of the 3' long temunal repeat (LTR) and encodes a 27- to 34-
kDa myristoylated protein that is produced early after virus infection (13, 20). Myristoyation 
influences the intracellular localisation of Nef during the vims life cycle. 
Nef of SIV,,1=, and HIV -I binds to cellular kinases, tyrosine kinases (HCK and LCK) 
as well as serine/threonine kinases (16, 22). Since these enzymes are known to be involved 
in signal transduction and cell activation pathways, this strongly suggests that the various 
effects of Nef may in part be brought about by modulation of cellular regulatory processes. 
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The elucidation of the mechanisms of action by which Nef exerts its functions is 
complicated by the fact that the activities of different lie! alleles vary considerably (17, IS). 
In fact, Nef proteins of various viral isolates differ significantly in their biological propel1ies 
(10) and different domains of Nef mediate different functions. Several variants of Nef can 
exist in a viral quasi species in a host at a particular point in time. In this study we wanted to 
obtain support for the hypothesis that the predominant variant, which is expressed by the 
most actively replicating vims in circulation, may have the most significant biological effect 
in the host and will determine the clinical outcome. 
To address this question ten rhesus monkeys were infected with a novel molecular clone 
encoding a Nef protein being truncated due to a premature stop codon located after the 
PKVP motif. The time point of appearance and proportion of lief-open revertants of the 
attenuated fief variants in circulation (plasma) were found to be decisive factors for the 
subsequent disease course. 
6.3 MATERIALS AND METHODS 
6.3.1 Animals 
A total of ten rhesus monkeys were used, one group consisting of five young (1.5 years 
of age) and a second group consisting of five mature animals (age> 4 years). All animals 
were from an outbred stock of Indian origin and were captive~bred at the Biomedical 
Primate Research Centre (BPRC). All animals were negative for STLV~l, Herpes B, CMV 
and Type D retrovil11ses. Animals were euthanized upon evidence of AIDS~like disease. 
6.3.2 Infection and monitoring of macaques 
Approximately 5xl06 CS166 T-cells were transfected with 10 ~g of plasmid DNA 
containing the full~length molecular clone SIVsmF359 by electroporation. After the pulse, cells 
were resuspended in RP!vlI supplemented with 10% FCS andwere incubated at 37 C. TIle 
supernatants of wells containing syncytia were harvested on day 12. The 50% tissue culture 
infectious dose (TCID,,) of stored aliquots (-SO 0c) was determined on CS166 cells. The 
two groups of llilimals were inoculated intravenously with 100 TCID50 of SlY F359' From 
each inoculated macaque blood samples were obtained weekly through the first 8 weeks 
after inoculation and monthly thereafter. The health status of the macaques was carefully 
monitored for the duration of the experimental period by measuring hematology and clinical 
chemishy parameters, and by analysing their CD4+ T lymphocyte levels by FACS as 
previously described (19). In order to monitor viral loads in PBMC, virus isolations were 
perfonned by co-culturing primary PBMC from each time point with C8166 indicator cells. 
Viral RNA levels in plasma were quantitatively measured by a RT-PCR assay (24). Each 
macaque was carefully monitored for clinical evidence of disease progression. The clinical 
diagnosis of simian AIDS was confIrmed by autopsy for each monkey. 
115 
6,3,3 RT-PCR and sequencing of mutated regions of lief 
Heparinized-hlood samples were collected and viral RNA present in plasma was isolated 
using the Qiagen viral RNA isolation kit (Qiagen GmbH, Gelmany). First strand eDNA 
molecules were synthesised using primer lief-I: 5'-CTAAGATTCTATGTCTTCTATC-
ACT-3'. peR amplifications were carded out on 2 JlI of the eDNA reaction as template in 
100 ~I PCR reaction mixtures containing 10 mM Tris-HCL (pH 8.3), 50 mM KCI, 1.5 111M 
MgCI" 200 ~ of each nucleoside triphosphate, 100 nM (each) oligo-primers lIef-l and 
l1ef-2: 5' -CTGGTTCCAAGAAGCAG TCCAAG-3', and a mixture of 0,7 units of both the 
AmpliTaq and Pfll polymerases (DE Applied Biosystems and Stratagene, The Netherlands). 
Reaction mixtures were overlaid with 100 J1l of mineral oil and subjected to 35 cycles of 
amplifications (95'C for I minute, 55'C for I minute and n'c for I minute) followed by 
72°C extensions for IO minutes (first round). Five microliters from each reaction mixhuc 
were transferred to new reaction tubes containing peR reaction mixhlfcs plus 100 nM of 
primers l1ef-4: 5'-GTGGAGAGACTTATGGGAGAC-3' and lIef-5: 5'-CTATAAAATATC-
CCTTCCAGTCC-3'. The mixture was then reamplified for another 35 cycles under the 
same conditions. Nef ampliiners were isolated from agarose gels and cloned into S11 pre-
digested pScript SK+ (Stratagene, The Netherlands). Recombinant clones were propagated 
in the E.coli DH5 strain. Sequencing of the cloned insert was perfonned with pUCIM13 
forward and reverse sequencing primers which bind on either site of the cloned inserts. 
Analysis was done on an ABI PRISM 310 Genetic Analyzer (DE Applied Biosystems, TI,e 
Netherlands). 
6.3.4 Determination of virus load 
Quantitative RNA PCR was used to estimate the virus load in plasma as described 
recently (24). In brief, RNA was extracted from 200 ~l EDTA plasma using guanidine 
isothiocyanate-mediated lysis, followed by propanol-2 precipitation. A known amount of 
internal standard RNA (IS-RNA) was added before the RNA extraction and was co-purified 
to monitor the efficiency of the purification. The RNA was reverse transcribed and amplified 
in a single reaction using rTtIz DNA polymerase and biotinylated primers. The IS-RNA was 
co-amplified to monitor the amplification efficiency. The amplified fragmentK were 
denatured and hybridized to an il11mobilised capture probe in a microwell plate. They were 
detected by an avidin-enzyme conjugate-mediated colorimetric reaction. The amplified 
internal standard was hybridized to a different capture probe in separate microwells. TIle 
lower detection limit of this RT -PCR method was 40 RNA equivalents per ml plasma. 
6.3.5 Quantitative virus isolation 
PBMC were isolated from EDTA blood samples by lymphocyte separation medium 
(LSM) density gradient centrifugation. Cells at the interface were collected and washed 
twice with RPM!. Two-fold dilutions of PBMC (starting with Ix106 cells) were co-cultured 
with 2.5x 10' cells of the human T4 lymphocyte cell line C8166 in a 24-well plate in 
duplicate. Cell culture medium (RPMI with 10% FCS) was changed twice per week. TIle 
cells were scored weekly for the presence of cytopatic effects and the concentration of SIV 
p27 antigen was determined after 14 days of culture. 
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Figure 1. Comparison of amino add sequences of the entire Nef protein from the molecular clones 
SIVF35~' SIV,mm P~JI~ and SIV",_,,, 2W' A dot indicates amino acid identity; a dash indicates a gap in the 
sequence. TIle arrows indicate the presence of premature stop codons (,,) in lIefof SIVm9 and SIV nu.: 2.W. 
6.4 RESULTS 
One of the infectious molecular clones derived from SlY 89S0. designated SIV FJ59 encodes 
a tmncated Nefprotein due to a premature stop codon (TAA at codon 107) in the lief gene 
(Figure I). A pilot experiment with two adult rhesus monkeys had demonstrated a rapid 
reversion of the stop codon to a leucine encoding one (ITA) and had revealed the 
pathogenic potential of reverted SIV FJ59 in rhesus monkeys. To determine, if the reversion 
of the nef mutation influenced vims load and if this was intluenced by the age of the host, 
we infected a total of ten Indian rhesus monkeys with the SIV B59 molecular clone carrying 
the same lie/mutation. Five young (age'; 1.5 years) (95012. 95021. 95032. 95038 and 
95047) and five adnlt (age> 4 years) rheslls monkeys (l4B. 408. 58A. 88A and 97A) were 
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each infected with 100 TCIDso of the SlV F3S9 nefstop mutant. After infection the number of 
virus producing cells in circulation, plasma RNA viral load, CD4+ T-cell levels and the 
frequency of reversion of the nef stop codon were determined. These findings were 
compared with the clinical and pathological outcome for each animal. 
Infection resulted in AIDS-like disease of four (95047, 95012, 95021 and 95038) out of 
five juvenile monkeys and two (88A and 14B) out of five adult monkeys (Figure 2). Tllis 
difference was, however, not significant according to Fisher's exact analytical test. Those 
five of the ten animals which developed a rapid disease course are subsequently referred to 
as rapid progressors (RP). A sixth mlimal, 95038, developed disease relatively slowly and 
was euthanized at week 64 because of signs of disease, and was designated as an 
intemlediate progressor (IP). The four remaining animals, namely one (95032) out of the 
five young monkeys and three (40B, 58A and 97A) out of the five adult monkeys, did not 
show any clinical or pathological evidence of disease development when euthanized at the 
end of the experimental period (68 weeks). These four monkeys were designated as long-
term survivors (L TS). 
10' A 
.95012 
095021 
<> 95038 
10' ,. 95047 
A 148 
• BBA 
" 0 t' 10° 
0 , , , , 
~ 0 20 40 60 80 ~ 
E 
'" ~ 0 B 0 10' ~ 
• 95032 
0408 
<> 5eA 
,. 97A 
weeks post infection 
Figure 2. TIle kinetics of CD4+ T-cclls in the peripheral blood of SIVF359-infcctcd rhesus monkeys. A) 
rapid progressors, and B) slow or non-progressors. 
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Clinical evidence of disease progression was confrrmed by the measurement of the CD4+ 
T-cell levels in peripheral blood. In the group of rapid progressors there was in general a 
marked loss of CD4' T lymphocytes (Figure 2A) as compared to the LTS (Figure 2B). The 
two monkeys 95012 and 14B which were euthanized due to clinical signs of AIDS-like 
disease at weeks 29 and 33 post-infection, respectively, had a progressive decline in CD4+ 
T-cells (Figure 2A), while in the velY first two monkeys which developed disease (95047, 
88A) percentages of CD4' T-lymphocytes, were not significantly reduced. The CD4' T 
lymphocyte levels in the LTS / non-progressors were relatively stable 68 weeks of the 
study. Only one of the LTS, animal40B, showed a downward trend (Figure 2B). 
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FiguI'e 3. Plasma viral loads in A) rapid progressors and B) slow or non-progressors in weeks post-
infection_ Virus loads are expressed as RNA Equivalents per ml of plasma. 
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Cell-free viral loads estimated by SIV RNA present in plasma were determined at all 
available time points. All animals were positive in the quantitative SIV RT-PCR one week 
post-infection. All rapid progressors established stable high virus loads in the range of 
2xlO'to 8xlO' RNA Eq/ml. (Figure 3A). At week 12 RNA concentrations of 1.5xlO', 
7xlO', 8.2xIO', 3.3xlO', 2.5xlO' and 5.5xlO' Eq/ml were observed for 95012, 95047, 
88A , 95021 , 95038 and 14B respectively. At the time of euthanasia in animals 95047 
(week IS), 88A (week 19),95021 (week 25), 95012 (week 29), 14B (week 33) and 95038 
(week 64) viral loads of 6x10" 2.5xIO', 7xlO', 2xlO" 2.5x10' and 1.5xlO' RNA 
copies/ml plasma respectively were measured (Figure 3A). 
The group of long-term survivors showed two types of responses. One group consisting 
of 95032 and 97 A (Figure 3B) showed relatively low levels of viral RNA loads of 1.2x lO' 
and l.4x 105 Ri'1A copies /1111 plasma at week two, respectively. At weeks six and eleven 
levels dropped from 2.8x10' to 2xlO' for 95032 and from 2.3x10' to 5.3x10' for 97A. 
Later on in the experimental period the number of viral RNA copies decreased to below 
detection limit at weeks 52, 62 and 68 post infection for 95032. In the same period RNA 
levels for 97 A declined from 76 to 65 and to undetectable levels ($ 40 RNA copies/ml 
plasma) (Figure 3B). The other two animals, 40B and 58A, showed considerably higher 
initial values of Ix106 and 8,Sx105 at week two compared to the first group, From week 
two till week 68 for both animals RNA values declined to 1.4xlO' for 40B and to 3.2x lO3 
for 58A (Figure 38). 
Thus, all the rapid progressors showed viral loads that were higher than the pathogenic 
threshold (lO' copiesl ml plasma) at time of euthanasia (Figure 3A). This in contrast to the 
group of long-term survivors that showed values equal or beneath this threshold (Figure 
3B). Levels of cell-associated viremia as measured by QVI essentially paralleled those of 
plasma viremia (Figure 4A and B). 
Next, we examined the frequency of reversion of the stopcodon in /lef in the rapid 
progressors (95047, 88A, 95012, 95021, 14B and 95038) and the longterm non-
progressors (95032, 97A, 58A and 40B) (Figure 5). We detemlined the relevant lie! 
sequence containing the stopcodon of the SIV FJ59 inoculum and of virus isolated from all 
monkeys at week 2, week 6, week 15 and at time of euthanasia. From each animal and for 
every time point ten RT-PCR fragments of nefwere cloned and sequenced. All virus from 
infected animals contained a premature stop codon in the /lef gene at week 0, as did the 
inoculum. Our sequencing re.suIts demonstrate that reversion of the mutation had occUlTed 
as early as two weeks post-infection. In the group of the rapid progrcssors animals 9S047, 
88A and 9S0 12 which developed disease first virus clones showed the fastest reversion 
(Figure SA). In these cases, 10, 8 and 7 out of 10 10 lief clones, respectively, harboured a 
leucine instead of a stop codon as early as two weeks pi. and the proportion of reve11ants 
accumulated to 100% at week 15. Monkeys 95021 and 14B which were euthanized at 
weeks 29 and, respectively, showed initially a lower proportion of lief revertants, but week 
IS all stopcodons had reverted. In the intemlCdiate progressors, animal 9S038, 4 out of 10 
nef clones were identified as revertants until week IS (Figure SA). At euthanasia (week 64) 
the number of revertant clones had increased to 80%. The long-term non-progressors 
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showed a much lower proportion and a delayed occurrence of revertant viruses. These 
became first detectable only at week six (Figure 5B), At the time of euthanasia (week 68) all 
long-teml survivors had a proportion of viruses in plasma that still contained the nej stop 
codon mutation equal or huger than 50%. 
6.5 DISCUSSION 
Four distinct regions in lIeJ (I) RxxL (aa: 17-20), (2) YxxL (aa: 28-31), (3) YxxS (aa: 
39-42) and (4) PxxP (aa: 104-107) have been described, based on scquence homology, 
conferring binding to specific cellular kinases. The importance of these regions became clear 
from studies in the SIVnu,; model in which the amino acids RQ (region I, Figure 1) of 
SlV m~c239' were substituted for YE residues. These changes conferred the ability of the 
mutant to both activate and replicate in resting T-cells, a feature uniquely described for the 
acutely pathogenic SIV'nllllPBJ isolate (5). 
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One of the initial studies \vhich brought to light the rclev<Ulce of the lie! gene in viral 
virulence was the study of SIV rmm9 with a premature stop codon at position 92 
(SIV mad39.~top) (4, 21). Infection of macaques with this attenuated Ile!mulalant resulted in an 
attenuated disease course which was characterised by the difficulty to re-isolate vims from 
infected animals (12). This Ncf truncation resulted in lower numbers of infected PBMC per 
ml of plasma and a longer disease-free period (25), As a consequence sequences required 
for interaction of Nef with serine kinase are not present in this protein, a feature which was 
associated with the inability of the vims to replicate in macrophages (6). 
Recently, we have characterised a novel molecular clone (F359), which is 
phylogenetically sep,mlte from SIV!Il1ClJ9 and SIV,mPIlJ (Hoitelman et aI., submitted). This 
clone has several unique features regarding lief. It has a RERL motif in contrast to the 
RQRL or YERL motifs found in SIV Illic2J9 and SIV phj respectively at region one (Figure 1). 
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The YGRL motif (region Iwo) of SIV 859 is identical to those of SIV mac239.slop and SIVpbj ' 
Region three (YxxS) differs just at one amino acid from the corresponding region in 
SIV mac239.~top also present in SIV FJ59 (Figure 1). An impOl1ant difference to SIV mac2J9-SIOp was 
the presence of a stop codon in clone F359, which was located just downstream of the 
PKVP motif. The SlY F.159 Nef contains the PKVP motif whereas SIV!Illc2.\9,slop lacks this 
motif. SIV F359 can infect macrophages, but like SIV mac2.\9-ltop' it lacks the ability to replicate 
in these cells to detectable levels (Hoitennan et ai, submitted). Experiments perfOlmed by 
Flaherty e/ al. (16) showed that vimses expressing this SIV mac239.>!op tmncated Nef protein 
replicated inefficiently in primary macrophages. Based on these observations it was 
hypothesized that the conserved PKVP motif or other sequences downstream of this region 
contain critical elements necessary for yielding a productive infection in macrophages ill 
vivo (6). However, SIV ('359 which does contain the PKVP motif but showed similar 
biological characteristics in macrophages as SlY mac2J9.stop (efficient infection but no viral 
replication). Our new data suggest that sequences downstream the PKVP motif rather than 
this motif itself are involved in processes neceesary for viral replication inmacrophages. 
In tIus study we also investigated if infection of rhesus macaques with this unique mutant 
nef resulted in similar kinetics of infection and rapid reversion of the stop codon to wild-
type !lef as previously reported with the SIV mac239.stop clone (12). Infection of five mature and 
five juvenile macaques with SIV F359 resulted in two different patterns of infection 
irrespective of age. One group developed lugh steady state virus loads and proceeded to 
AIDS-like disease. Analysis of nef clones plasma of each of the ten animals revealed an 
impor1ant correlation between survival and the persistence of the stop codon mutation in 
virus circulating in the animals. Those animals wluch did not revert to the F359 net wild-
type viruses and wluch had persistently elevated levels of mutant nefviruses in plasma were 
long-term survivors. Conversely, rapid progression to AIDS correlated with a quick 
emergence of wild-type lIefvimses. Notably, the proportion of revertants over time strongly 
correlated with RNA virus load and disease progression. Not only do these results support 
previous observations about the quick reversion of a tmncated to a full-length Hef it also 
reveal the timing and predominance of Ilefvariants in infection and their influence on disease 
progression. Finally, these data strongly suggest that the predominant variants in circulation 
(plasma) may ultimately detennine the course of the disease. 
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7.1 ABSTRACT 
We describe an efficient method of DNA inoculation to establish SIV infection in rhesus 
monkeys as a tool for studying the pathogenesis of AIDS. Four different strategies of 
administration of DNA of the F359 molecular clone of SIV were evaluated in four individual 
rhesus macaques. These included two different gene gun inoculations directly to exposed 
lymph nodes. and two different fonllulations of SIV-DNA-lipid complexes (lipofectin and 
DMRIE-C) inoculated directly into the lymph nodes. Gene gun inoculation or DMRIE-C-
mediated delivery of DNA did not result in infection of animals. However, injection of 
lipofectin-DNA complexes resulted in the establislunent of persistent SIV infection in rhesus 
monkeys. This strategy was much more efficient than the intramuscular injection of large 
volumes of naked proviral DNA previously reported. Lipofectin-rnediated delivery will 
enable the in vivo characterisation of molecular clones of variant viruses in nonhuman 
primates at local sites such as lymph nodes and mucosal surfaces. This teclmique will help 
avoid the changes in the gcnetic and biological properties of primate lentivimses, which 
occur during ill vitro propagation of inocula. Most importantly it will facilitate the direct in 
vivo study of primate lentiviruses variants and help to elucidate their specific role in the 
pathogenesis of diseases such as AIDS. 
7.2 INTRODUCTION 
The induction of an AIDS-like disease in rhesus macaques by infection of sooty 
mangabeys (SIVsm) with simian immunodeficiency vitus has provided a valuable non-
human primate model for AIDS research (4, 7). The infidelity of retroviral reverse 
transcriptase causes a high mutation frequency (16, 19), resulting in a large number of 
closely-related but biologically different viral variants (quasispecies) within the host (ll. 
20). In order to study the contribution to diseao;;e of pru1icular viral variants, infectious 
molecular clones are utilised (10). In general, transfection of susceptible cell lines with 
molecular clones ill vitro is used to produce viral inocula. Unfortunately. if! vitro replication 
frequently results in undesirable alterations of the genetic and the biological properties of the 
virus (8, 12, 13). Direct inoculation of an infectious molecular clone ill vivo would avoid in 
vitm artefacts and wiII allow the direct study of viral variants at the molecular level in vivo. 
Intramuscular inoculation of large amounts of naked DNA has been routinely used to 
immunise mice with specific antigens and successfully used to induce FIV infection in 
domestic cats (14). SIV infection has been reported in a rhesus macaque but intramuscular 
inoculation and infection has not proved to be reproducable in this species (15). The direct 
delivery of viral NA to the target tissue has been a more successful approach in the case of 
hepatitis viruses. For instance liver-specific infections with genome-length RNA of hepatitis 
A and C viruses have been reported (5, 15). 
For the purposes of immunisation with specific antigens delivery of DNA ;,Z vivo has 
been qescribed using gene gun-mediated delivery (2, 3) by membrane fusion of cationic 
Iiposomes-DNA-complexes (1, 17), as well as using direct injection of naked DNA (6, 18). 
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The gene gun strategy utilises DNA-coated gold particles that are delivered by high velocity 
impact with the target tissue and has the advantage that relatively small amounts of DNA are 
required. These strategies have not been evaluated for their ability to deliver full-length viral 
genomcs to target tissues ill vivo, 
Here we report a study in which we directly target the lymph nodes of four rheslls 
monkeys with DNA of the SIV F.159 molecular clone (9) using different methods of DNA 
delivery. 
7.3 RESULTS AND DISCUSSION 
In order to select for optimal DNA-lipid mixtures for the delivery of molecularly-cloned 
SlY to cells we performed ;11 vitro transfections of the human T -lymphobJastoid cell line 
C8166 using four different cationic lipid compounds (Iipofectin, DMRIE-C, lipofectamine, 
and cellfectin) (Life Technologies, Breda, The Netherlands). After transfection, samples of 
cell culture supernatant were taken at regular intervals and analysed for SlY production 
using a Coulter SIV p27 antigen capture ELISA (Coulter Corp., Hialeah, FI., USA). These 
pilot experiments revealed the superiority of the fIrst two formulations, lipofectin and 
DMRIE-C, to induce SIV infection ill vitro. 
One approach to establish ill vivo SlY infection consisted of gene gun administration 
directly to lymph node tissue of two rhesus monkeys. The second method used direct 
injection of the two different liposome-DNA formulations in lymph nodes of two other 
rhesus macaques. All animals were inoculated at four sites (two axillary and two inguinal 
lymph nodes). For the gene guu administration a small surgical incision was made to expose 
the axillary and inguinal lymph nodes. Plasmid DNA containing the fun-length SIV F359 was 
bound to 2.6 ulll-diameter gold particles (Sigma-Aldrich Chemie, The Netherlands) to a 
concentration of 2 Ilg of DNAlmg of gold. Gene gun cartridges were prepared to a final 
payload of 1.0 ~g of DNA bound to 0.5 mg of gold and administered directly to the lymph 
node tissues at 200 psi pressure. For the preparation of the Jipofectin-DNA-complex and the 
DMRIE-C-DNA-complex, 5 ~g of SIV",,-DNA was diluted into 100 fd Opti-MEM I 
Reduced Serum Medium (Life technologies, Breda, The Netherlands). The liposome 
solution was prepared by dilution of 25 III of lipofectin reagent or DMRIE-C reagent into 
l00,..IOpti-MEM medium. Both the DNA and liposome solutions were incubated at room 
temperahlre for 45 minutes before they were gently mixed and incubated at room 
temperature for another 20 minutes. Four lipofectin DNA-complex mixhlres (200 J.lI each) 
and four DMRIE-C-DNA-complex mixtures (200 J1I) were then inoculated directly into each 
of the four lymph nodes in separate animals. 
Infection of macaques was monitored at regular time points. Evidence of infection was 
determined by the presence of SIV in serum qualitatively (RT -PCR) as well as quantitatively 
(QC-RT-PCR). For the RT-PCR assay, first strand cDNA molecules were synthesised 
using primer lIel-1 (CTAAGATTCTATGTCTTCTATCACI'), PCR amplifications were 
can'ied out on 2 ~I of the eDNA reaction using 100 nM (of each) primer lIel-1 and lIe!-2 
(CTGGTTCCAAGAAGCAGTCCAAG), and a mixture of 0.7 units of both the AmpliTaq 
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and Pfll polymerases (Perkin-Elmer Biosystems, The Netherlands and Stratagene Europe, 
The Netherlands). Reaction mixtures were overlaid with 100 pI of mineral oil and subjected 
to 35 amplification cycles (95'C for 1 minute, 5SQC for 1 minute and 72°C for 1 minute) 
followed by a 72°C extension step for 10 minutes. Five microliters from the first reaction 
mixture were transfelTed to new reaction tubes containing a nested PCR reaction mixture 
containing 100 1ll\1 of primer l1el-4: (GTGGAGAGACITATGGGAGAC) and l1ef-5 
(CTATAAAATATCCCITCCAGTCC) and amplified for another 35 cycles uuder the same 
conditions. Nef amplimers were analysed on agarose gels (Figure 1). The Q-RT-PCR 
method was performed as previously described (21). 
PCR analysis revealed that neither the gene gun technique nor the SIVF359-DNA-DMRIE-
C-complexes were successful in facilitating SlY F359 infection of rhesus monkeys. Each of 
these animals remained negative by both RT-PCR and QRT-PCR. However, the inoculation 
of lipofectin-DNA-cornplexes directly into peripheral lymph nodes did result in systemic 
SlY infection which was detected four weeks post-infection (Figure 1) and remained 
persistent for the duration of the experimental period of four months (16 weeks). 
We demonstrate the feasibility of establishing persistent SIV infection by direct injection 
of DNA-lipofectin-complexes to the lymph nodes of rhesus monkeys. This method of 
experimental SIV infection reveals the potential of the direct administration of DNA to 
different well-characterised tissues. This strategy provides a versatile tool for studying the 
pathogenesis of AIDS in selected target tissues with specific molecular clones representing 
distinct biological variants of Ientivimses. 
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Figure 1. Evidcncc of viral infection in rhesus macaque 8903 following inoculation with SIVF3W-DNA-
lipofcctin complexes as detem1ined by Q-RT-PCR (20. DNA-complexes (10 J-Ig) were administered by 
injection into two axillary and inguinal lymph nodes. Serum samples were analysed at regular time points 
for SIV infection using Q-RT-PCR. TIle insct shows an agarosc gel demonstrating the presence of lief 
amplimcrs generated by RT-PCR. Lane I: negative control, lane 2: positive control, lane 3 to 8: amplimers 
derived from plasma samples obtained at 4. 6. 8. 10. 12, and 14 weeks post-infection. 
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GENERAL DISCUSSION 
An understanding of the pathogenesis of mv infection will undoubtedly provide 
valuable information for the development of effective vaccines for the prevention of AIDS. 
Studies in humans are limited in practice since when HIV infection is eventually diagnosed 
valuable infolll1ation is already lost. For instance, little or nothing is known with regard to 
the source, the viral characteristics of the inoculum, the route of infection, the exact time 
point of infection and the biological and molecular events which took place early in infection 
and which define the later disease course. There is enormous variation in survival time in 
people with HIV infection whose clinical course is defined as rapid, intelmediate or Jong-
term progression (14). This spectmm of disease progression is due to a complex interaction 
of viral and host factors (4, 15). To define these complex factors, prospective studies are 
needed in model systems to fill in the gaps of knowledge that otherwise cannot be obtained 
from retrospective human studies. The SIV model of AIDS macaques has proven to be 
particularly valuable for the study of the interactions between host and virus (13). 
Little is known about viral virulence and its effect on rapid progression to AIDS. The 
research that was conducted using SIVSmpbj is in fact the only example of an acute disease 
syndrome (8), but which unfortunately represents an atypical rapid disease not characteristic 
of AIDS (11). It causes an acute haemonhagic enteritis in infected pigtailed macaques and is 
considerably less pathogenic in rhesus monkeys which, if they survive the acute syndrome, 
a year later develop AIDS. For these reasons, SIVsmpbj is considered to be an atypical 
lentivirus and thus not an appropriate model to study rapid progression to AIDS (1/). 
It has been known for some time that an infectious viral inoculum consists of a 
quasispecies that evolves as the disease progresses. The limited evolution of a HIV-l 
quasispecies observed during rapid progression to AIDS, is in contrast to that in long-tetm 
survivors, and reflects ineffective host-mediated immune pressures on replicating viral 
variants (7). When we began these studies several years ago our working hypothesis was 
that the most vimlcnt viral variants would be found in rapid progressors and that they would 
be predominrutt at the end of the disease. Indeed whcn we transmitted blood from rapid 
progressors the diseasc course in age and sex matched rhesus macaques was found to 
accelerate (Holterman et al., 1999; Chapter 2). This observation was in agreement with later 
studies in the SIV model which demonstrated that the viral vru'iants which emerge in late 
stage (AIDS) were neutralisation resistant in the host and also in subsequent hosts following 
in vivo passage (18). These end-stage varirults were found to have optimal fitnesses for 
replication in these hosts and influenced the clinical outcome of the viral infection. 
Subsequently, we isolated this vimlent SIV isolate (designated SIVs98o)' This new SIV 
isolate caused an AIDS-like disease which was similar to the disease characteristics of the 
original SIVB670 strain, but disease developed more rapidly in SIVs9S0 (a minimum 
progression time to AIDS of 0.5 months versus 7 months or more). The significant change 
in pathogenic potential was convincingly shown by Kaplan-Meier plots comparing the 
parental (pre-passage) SIV B670) isolate ,vith the post-passaged SIV S9S0 isolate. 
In HIV -1 infection, the plasma level of viral RNA has proven to be the parameter with 
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the highest predictive value with regard to disease progression (22, 28). Recent studies in 
rhesus monkeys revealed that a pathogenic threshold of vims load could be deftned which 
correlated with the vilUlence potential of a particular SIV isolate or SHIV chimeric to cause 
AIDS (34). Indeed viruses, which are more pathogenic, have increased concentrations of 
vinIS in plasma. One concern of our ;'1 vivo passage study was that we had inadveltently 
transmitted higher doses of virus by choosing end stage blood samples from rapid 
progressors even though in that experiment (Chapter 2) a consistent number of PBMC (2 x 
106) were passaged. It was therefore critical for our intelpretation to l1lIe out that the 
accelerated disease observed with each transmission was not due to a dose effect. This 
question was addressed in Chapter 3 in which rhesus monkeys were inoculated with doses 
of SlY ranging from 100 to less than 1 ID50 • The study clearly revealed that there was a 
correlation with dose and infection but no correlation between the dose of the viral inoculum 
and viral loads ill vivo. Furthermore, the results of that study demonstrated that differences 
in viral dose were not responsible for the accelerated disease progression observed during 
the SIV passage. 
Several publications have suggested the possible role of other possible pathogens as co~ 
factors in the pathogenesis of AIDS (5, 27, 29, 37). This possibility had also to be 
excluded. Two approaches were taken. The first approach was a retrospective screening of 
the viral inoculum and samples from infected animals in the ill vivo passage study. Although 
no new seroconversions for potential pathogens were observed during the study we could 
not fully exclude the presence of some unknown agent or pathogenic variant in the inocula 
that might have some pathogenic effect which would influence our interpretation of the in 
vivo passage experiment. 
In order to conclusively exclude the effects of any possible infectious co-factor we 
developed a strategy to derive a representative pathogenic molecular clone of SIV 8980. We 
reasoned that if a virus derived only from the genetic infonnation encoded by SIV sequences 
in the passage monkeys could reproduce the disease observed this would help mle out other 
infectious co-factors. This clone should represent the dominant viral variant and should 
induce the same disease characteristics in approximately the same time frame as the uncloned 
virus (SlV 8980). Meeting these criteria dictated a novel approach different from previous 
strategies used for constlUcting earlier molecular clones of SIV or HIV-l (Chapter 4). 
The previous molecular clones of SlY were established using relatively insensitive 
molecular biological techniques such as the screening of genomic libraries. Since the 
number of infected cells ill vivo were too low for these insensitive techniques, the in vitro 
propagation of the virus on human T-cell lines was needed to increase the number of virus 
infected cells (32). The artificial culture conditions and the forced replication of a monkey 
virus to adapt to human cell lines unknowingly caused genetic alterations in the SIV genome 
(16). III vitro culture caused the preferential replication of some vints variants over others 
resulting in quasiespecies that differed from the original ill vivo material (23). Furthermore, 
viral sequences often proved unstable resulting deletions or atypical mutations in viral clones 
(6,38). One may wonder in what respect these molecuhu clones represented the biological 
viral isolates they originatcd from. The application of the highly sensitive peR technique 
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made it possible to use SlY infected PBMC as starting template and thus to circumvent the 
ill vitro culture problems. The fIrst heat stable DNA polymerases used in peR lacked 
proofreading activity and were thus inaccurate (mutation rates of 10-4 and 10-5 per nucleotide 
per round of replication). These first enzymes also had limited synthetic capacity and could 
generate amplimers of a maximum of 5-kb with many mutational CITorS. 
The next generation of DNA polymerases had proofreading activity and thus lower 
mutation rates. When \ve started the constmction of the molecular clone only small aliquots 
of proofreading enzymes were available on request from suppliers. Later it was discovered 
that mixing two DNA polymerases had a synergistic effect on both the synthesising capacity 
as well as on the fidility of thc PCR (2). The clone which we wished to constmct had to be 
the dominant variant (the one which was most abundant in extracel1ular circulation). As a 
consequence and for our purpose the viral RNA present in plasma had to be used as RT-
peR template. It is known that SIV-DNA present as provims in surviving blood 
mononuclear cells contains accumulated mutations of past viral variants. These gcnomes 
persist in host cell DNA but are replication defective. Hence, we were concemed that using 
proviral DNA as templates that we would frequently clone unwanted mutants or minor viral 
variants. We reasoned that many mutations would be self-limiting with reduced replication 
efficiency or so called fitness. In Chapter 4.2 an optimised RT-PCR strategy was developed 
which resulted in a molecular clone (F359) containing all the coding sequences derived from 
RNA obtained from rhesus monkey 8980 (P4) in the passage study described in Chapter 2. 
This development allowed us to characterise the disease potential as well as the biological 
and molecular characteristics of this pruiicular clone. Recently, studies have shown that the 
variants, which replicate most rapidly, precipitate the development of AIDS. Based on 
similar reasoning we assumed that the biological characteristics of the dominant virus variant 
would be representative of the virulent variant influencing the acute disease course. 
Comparison of the biological characteristics of the clone with the original SlY 8980 isolate 
should demonstrate that we cloned the dominant vimlent variant. For instance, co-receptor 
usage (25, 30), and the ability to replicate in resting versus activated CD4+ T-cells (9) and 
macrophages (33, 39) are characteristics considered to influence pathogenicity. In this 
regard, no differences were observed between the cloned vil11s and the virus isolate in that 
both recognised only the CCR5 co-receptor and neither replicated in resting PBMC nor 
macrophages. The subsequent ill vivo passages of SlV B670 resulting in SlY 8980 were 
carefully monitored. The original SlV B670 inoculum was also used in studies performed by 
Tricher et a!. (35) and Amadce et a!. (I). They had detennined the number of different 
genotypes in the SlV B670 inoculum based on the first hypervariable region (VI) sequence 
divergence (3, 24). Twelve different genotypes could be recognised in this isolate (B670-
CI.l to CI.l2). The envelope sequence of B670 CI.l2 was one of the sequence variants 
present in the original SlV B670 stock. During our passage experiment the sequence variant 
Cl.12 had acquired an optimal fitness represented by its prevalence in the early SlY B670 
isolate and in its maintenance during the passages. Indeed the SlV 859 molecular clone had 
the highest (96%) homology with B670-C1.l2 and therefore is representative of the 
dominant virus variant of SlY B670' 
t34 
The in vivo experiments in rhesus macaques demonstrated similar clinical and 
pathological characteristics of SIV F359 compared to SIV 8980. Several SIVSmlmac clones have 
been reported to cause different patterns of disease including attenuated vimlence compared 
to the virus isolates from which they were derived. With specific regard to the first SIV 
molecular clones which were derived, a viral adaptation and attenuation often occurred as a 
result of ill vitro propagation. This attenuation phenomenon may also be due to a failure to 
clone the dominant vims variant, possibly as a consequence of using proviral DNA as 
biological template or due to the llse of biological material that contained still a «balanced" 
composition of early (M~tropic, slow~replicating, NSI-type) and late variants (T~tropic, SI~ 
type and fast replicating). It may also reflect a certain synergistic effect of a quasiespecies 
that do not exist in case of a single molecularly cloned virus. A study demonstrating a 
regulatory effect on HIV replication mediated by defective proviruses has provided evidence 
in that direction. Convincing data has stru1ed to accumulate which explains the progression 
to AIDS in terms of the biological propel1ies of vitus variants which emerge during the 
course of infection. However, results from other studies suggest a more complex cascade of 
events in which variants in combination with other factors are involved in AIDS 
pathogenesis. 
Studies of HlV -I infected individuals revealed that vimses which appear to be 
cytopathogenic in vitro m-e found in about half of the individuals progressing to AIDS, but 
not in long-term asymptomatic individuals (31). The fact that syncytium-inducing variants 
are not found in all individuals progressing to AIDS raises the concern that they arise only 
following the failure of the immune system rather than being a cause of the failure. 
Furthermore, the relentless massive turnover of vilUs that occurs in HIV -1 infected 
individuals (17, 26) emphasises the fact that minor changes in the growth properties of the 
VilUS could have a major impact on the delicate balance between vilUS and the available 
target cell reservoir. 
The diversity of the vilUs population present within an infected individual can be 
enormous. However, direct analysis of viral quasispecies in HlV-l infected individuals 
reveals a correlation between outgrowth of a relatively unifonn vims population in quickly 
progressing individuals and more rapid and greater diversification of the virus population in 
slowly progressing or nonprogressing individuals (20, 21,40). The data of Edmonson et 
a1. demonstrated that the formation of a diversified lentivllus population, while one of the 
more insidious propel1ies thought to be crucial to escape from the immune system and 
fulminate persistence in the host, is not a prerequisite for the development of AIDS (10). 
III vivo passage has been conducted in various occasions and resulted III vilUs isolates 
with properties distinct from those of the parental strain. For example, the acutely 
pathogenic SIVsmPDJl4 isolate was derived following a single ill vivo passage of the 
minimally pathogenic SIBsmH9, (12) and molecular clones of that isolate have been shown to 
recapitulate the rapidly fatal phenotype (8). Interestingly tlils highly pathogenic property 
causing acute haemOlThagic enteritis appears to be in pru1 conferred by a pat1icular "YE" 
motif in the Ilef gene. Transfer of this motif to another molecular clone (SIV mac289 .. conferred 
the ability of that molecular clone to replicate in resting CD4" T-cells and the ability to cause 
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acute haemorrhagic enteritis. Interestingly, the SIV 859 had a number of similar and different 
nefmotifs which may explain its particular pathogenic characteristics. For instance, instead 
of a YE motif it has a RE motif which may be responsible in part for its potential to cause 
rapid progression to AIDS. The occurrence of a mutation causing a premature stop codon in 
lief allowed us to design a study of the effect of this lief genotype upon reversion to a fully 
translated F359 lief variant. 
The fate of the premature stop-codon that is present in SIV F359 nef was studied ill vivo in 
rhesus monkeys. Infected animals (rapid progressors) which showed high vims loads and 
died of AIDS had the highest rate of stop-codon revertants (between 50 and 100%) within 
weeks of infection. In contrast, the non-progressors had very low viral loads, stayed 
healthy during the experimental period, had lower rates of reversion to the wild type net, 
and the mutant lief genotypes remained dominant. The survival curves of the ten rhesus 
macaques infected with SlVB59 and SIV8980 showed a "biphasic" pattern. Kaplan-Meier 
survival plots revealed that the rapid progressors (lief revertants) coinciding with the curve 
of the parental SIV 8980 infected group represents the contribution of the (non-revertants) 
nOll-progressors (Chapter 6, Figure 5). From both the nature of disease and the time of 
disease progression of SIV FJ59 compared to SIV 8980 infected animals, we conclude that 
SIV F359 once the nef gene is repaired, represents the virus characteristics of the dominant 
variant present in SIV 8980' \Ve showed that reversion to a functional llef protein can occur 
quickly ill vivo (within two weeks), but occurred only in some animals a finding which is in 
contrast to other SIV lief studies. 
Mutations arise in SlY molecular clones due to ill vitro cultures. Indeed I<to culture is to 
perturb" (36). By deriving the F359 molecular clone directly from serum, we had achieved 
the most representative molecular clone possible. Unfortunately, routine use and analyses 
require that virus stocks must be propagated by transfection of the molecular clone ill vitro 
for short-term culture. Ideally, we wished to completely circumvent tlllS step to avoid any 
possible atypical mutations which could occur. Liska et al. repoI1ed that direct injection of 
molecular clone DNA intramuscularly could result in SlY mac infection of rhesus monkeys 
(19). This technique, however, proved to require tremendous doses of DNA and was not 
reproducible by other laboratories including our own. In Chapter 7, we describe a technique 
using DNA of the F359 molecular clone and lipofectin to induce SIV infection by directly 
delivering the virus to its target tissue, the lymph node. In this thesis we report on strategies 
to completely circumvent ill vitro culture artefacts by deriving a molecular clone from in vivo 
material and delivering infectious molecular clones directly back to the host for study. In 
addition to increase insight into the role of viral vimlence and rapid progression to AIDS, 
we also prqvide the tools for future studies to detennine the molecular detemlinants of viral 
virulence in the SIV model. 
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SUMMARY 
AIDS (Acquired Immuno Deficiency Syndrome) is caused by the Human 
Immunodeficiency Vims (HIV). Most of the knowledge of both the vims and the disease 
we obtained from research pClformed on biological samples of infected individuals. 
However, a lot of scientific questions remain which crumot be studied in humans. For these 
studies relevant animal models are used. The SIV -rhesus macaque model has been used for 
studies described in this thesis. In general studies to the role of specific viral virulence as 
major factors in the rapid progression to AIDS has been described. Viral factors responsible 
for a delayed or very slow disease progression is known and are relatively well understood. 
Little is known, however, about viral vllulence factors that may accelerate the disease 
causing a relatively acute AIDS syndrome. In chapter 1 an overview of the development and 
applications of the Simian Immunodeficiency Virus (SIV) macaque animal model for AIDS 
research in humans is presented. Rhesus macaques, when infected with SIV derived from 
sooty mangabeys, develop a disease which closely resembles AIDS in humans. HN and 
SIV inocula contain many related but genotypically and phenotypically different viral 
variants (quasispecies). To address certain specific questions in AIDS research it is 
necessary to develop well-defined and representative molecular clones from specific viral 
variants. Current infectious molecular clones of SIV vary from highly pathogenic to non-
pathogenic. They differ in the nature as well as the rate in which they induce the 
development of AIDS in vivo. In addition, differences with regard to replication, cell 
tropism, cytopathic effect and co-receptor recognition exists between specific molecular 
clones. The importance of these biological differences can be addressed in the macaque 
model of AIDS. The information gained has the potential to he applied to the development of 
new therapeutic andlor vaccinc strategies. In chapter 2 a study is described in which we ask 
ourselves the question if viral virulence is a factor in cases of rapid progression to AIDS. An 
animal model for rapid disease progression was established by serial end stage passage of 
SIV B670 in rhesus macaques. Virus from the fust animal to develop AIDS was transferred to 
recipients ill vivo five subsequent passages. This reduced the survival of the subsequent 
recipients from a minimum progression time of 7 months to 2 weeks, from passage 1 to 
passage 4, respectively. The possibility remained that these observations were not due to 
increased vimlence but alternatively were due to increased dose of SIV in the subsequent 
inocula or were caused by the (co-)passage of other pathogens present in the inocula. TIle 
study we describe in chapter 3 addresses the question whether virus vimlence or viral dose 
influenced the rate of disease progression. Two experiments were perfolTIled (chapter 3.1 
and 3.2). The fIrst study involved the follow-up of rhesus macaques infected with different 
doses (ranging from more than 100 to less than I IDlO ) of the cell free SIV"80 stock. The 
study revealed that there was no cOLTelation between dose and the rate of disease 
progression. In the second experiment monkeys infected with an ill vitro passaged 
attenuated SIV strain (SIV BK28) were superinfected with another, more virulent strain 
(SIV 8980) to determine if the second pathogenic infection resulted in a more rapid disease 
course. The rate of disease remained constant and representative of the initial inoculum. 
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From these experiments we concluded that the rate of progression to AIDS was independent 
of the viral dose and was predominantly influenced by the viral characteristics of the initial 
infection. Having addressed the flrst question raised in chapter 2, in chapter 4 we describe a 
study in which we focussed on developing a method to obtain molecular clones, which 
represented the most abundant vims variant. The work of Kimato et al. (1999) demonstrated 
that SIV variants which emerge at the end of disease contribute most to the clinical outcome 
of SIV infection. We reasoned that the most dominant SIV variant in circulation could best 
be cloned from RNA from virions in plasma rather than accumulated proviral DNA, 
surviving from previous viral populations. Deriving molecular clones from end stage serum 
or plasma samples required an RT~PCR method that first needed to be optimised in order to 
obtain SIV amplimers of sufficient length. Such RT-PCR optimisation experiments are 
described in chapter 4.1. The constmction of the full-length SIV molecular clone 
(designated SIVFJ5,) is described in chapter 4.2. Chapter 5 describes the ill vivo 
characterisation of this new clone (SlY F359)' Phylogenetic analyses demonstrated that 
SIV F359 was related to but distinct from other SIVsm and SIVmac clones. Most SIV 
recognise multiple co-receptors (CCR5, BOB, Bonzo). In contrast, the parental strain of 
SlY 8980 and the molecular clone SLY F359 were found to have the same restricted CCR5 co-
receptor usage. SIV FJ59 was able to infect and induce syncytia in the human C8166 T-cell 
line, as well as in rheslls- and human peripheral blood mononuclear cells (PBMC). This 
clone was unable to replicate to detectable levels in unstimulated rhesus PBMC or in 
monocyte-derived macrophages, although it could illfeet the latter cell type. Pilot 
experiments conducted in two rhesus macaques revealed that the SLY r359 molecular clone 
was infectious as well as pathogenic ill vivo. It was able to induce a similar (albeit slower) 
pattern of disease progression as observed with SIV 8980' the parental virus inoculum. In 
chapter 6 the study to the vimlence factor Ilefby examining the effect of a mutant premature 
Nef stopcodon in SlY H59 is described. Ten rhesus monkeys were infected with this !lei 
mutant of SlY f'359' The group that progressed to AIDS showed significantly higher vims 
loads and a higher prevalence of vimses which reverted to the wild type net In comparison, 
the group of non-progressors stayed healthy during the experimental period and contained 
much lower levels of the repaired lief stop codon. We concluded that the predominance of 
the attenuated SlY F359 llef varimlt facilitated the maintenance of low viral loads and an 
asymptomatic disease course. In chapter 7 we describe the refinements of the model in order 
to minim.ize the ill vitro manipulations (which generate atypical mutations) by direct 
inoculation of rhesus macaques with SlY 859 DNA rather than using a virus stock requiring 
ill vitro propagation. This approach proved that it was feasible to establish infection ill vivo 
by direct injection of DNA of just one single viral genotype, enabling direct and detailed 
studies of the contribution of separate genes to viral pathogenicity. 
These studies together now provide the basis for further studies to identify and 
characterise the molecular determinants of lentiviral vimlence responsible for accelerating the 
progression to AIDS. 
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SAMENVATTING 
De ziekte AIDS (Acquired Immuno Deficiency Syndrome) wordt veroorzaakt door het 
Humaan Immunodeticientie Virus (HIV), Veel kennis over het virus en de ziekte is 
verkregcn door de bestudering van biologisch materiaal van zowel geYnfecteerde als zieke 
individuen. Er blijvcn echter wctcnschappelijke vragen bestaan die Iliet bestudeerd kunnen 
worden door onderzoek van mensen. DaarorTI wordt tevens gebruik gemaakt van relevante 
diermodellen. De SlV -rhesus makaak is eell van de diermodellen die het mogeJijk maakt 
studies uit te voeren zoals beschreven in dit proefschrift. SIV (Simian Inununodeficientie 
Vims) is cen vims dat zich handhaaft in rhesus makaken en is vergelijkbaar met HIV. Virale 
factorcll die verantwoordelijk zijn VOOf een verlraagde ontwikkeling van AIDS worden in de 
Iiteratuur relatief goed beschreven. Er is echter veel minder bekend over VITale factoren die 
versllelde ziekteprogressie veroorzaken en welke resulteren in AIDS. Dit proefschrift 
beschrijft o.a. de rol die vimlel1tiefactorel1 spelen in de snelle pragressie naar AIDS. Een 
overzicht van de ontwikkeling en toepassing van het SIV-rhesus makaak model voar 
onderzoek naar AIDS in de mens is in hoofdstuk I beschreven. Wanneer rhesus makaken 
worden geInfecteerd met SIV atkomstig uit sooty mangabey apen (SIVsm) ontwikkelt zich 
een ziekte die sterke overeenkomsten vertoont met AIDS bij de mens. HIV en SIV isolaten 
bevatten verwante, maar genotypisch en fenotypisch verschillende virale varianten 
(quasispecies). Voor het beantwoorden van specifieke vragen op het gebicd van AIDS is het 
nodig om te beschikken over goed gekarakteriseerde en reprcsentatieve moleculaire klonen 
van specifieke virale varianten. Infectieuze moleculaire klonen van SIV kunnen sterk 
varieren in pathogeniciteit. Ze verschillen in de biologische aard en de snelheid waatmee ze 
de ontwikkeling van AIDS in vivo induceren. Het belang van deze verschillen kan in het 
SIV -rhesus makaakmodel bestudeerd worden. De zo verkregen infOlmatie kan worden 
toegepast bij de ontwikkeling van nieuwe therapieen en/of vaccinatiestrategieen. In 
hoofdstuk 2 is beschreven welke rol virulentie speelt in gevallen waarin een snelle 
progressie naat· AIDS plaatsvindt. Een diennodel voor deze snelle progressie is ontwikkeld 
door opeenvolgende passages van SIV B670 in rhesus makaken (SIV atkomstig van sooty 
mangabey 8670). Hiervoor zijn bloedcellen uit het eerste dier met AIDS gemjecteerd in cen 
tweede dier, waarna op dezelfde wijze nog drie passages volgden. Hierdoor daalde de 
minimum overlevingstijd van 7 maanden in het eerste dier tot 2 weken in dieren na de vierde 
passage. De mogelijkheid bestond dat deze verandering niet een gevolg was van cen 
tocname in vintlentie, maar van cen toenatne van de hoeveelheid SIV in de opeenvolgende 
inocula, of veroorzaakt werd dat deze door mede-passage van andere pathogenen in de 
inocula. De ral van vim len tie versus de hoeveelheid gei'njecteerd vims bij de progressie van 
AIDS is in hoofdstuk 3 beschreven. Twee studies werden uitgevoerd (hoofdstuk 3.1 en 
3.2). In de eerste studie werden rhesus makakcn gei'nfecteerd met verschillende 
hoeveelheden (van mindcr dan I tot meer dan 100 ID50) van de celvrije SIVs980 stock. Vit 
deze studie bleek dat er geen cOlTelatie bestaat tussen de hoeveelheid geInjecteerd vims en de 
snelheid van ziekteprogressie. In de tweede studie werden makaken, die geInfccteerd waren 
met een ill vitro gckweekte en verzwakte SIV stam (SIV llK1S)' opnieuw geInfecteerd met een 
andere, meer pathogene starn (SlV 8980) om te bepalen of deze tweede infectie resulteerde in 
een snellere ziekteprogressie. De snelheid van ziekteprogressie bleef constant en 
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representatief voor bet eerste inoculum. Hieruit blijkt dat de progressiesnelheid naar AIDS 
onafilmlkelijk is van de hoeveclheid gei'njecteerd virus en voomamelijk be'invloed wordt 
door de virale karakteristieken van de eerste infectie. In hoofdstuk 4 is een studie 
beschreven waarin eell methode werd opgezet om moleculaire klonen te verkrijgen die 
representatief zijn voor de meest-voorkomende virale variant. Kimata et a1. (1999) hebben 
aangetoond dat de dorninante SIV -variant in het eindstadillm van AIDS, vermltwoordelijk 
was voor het uiteindelijk ontstaan van het ziektebeeld. We gingen ervan uit dat deze SIV-
variant het beste verkregen kon worden 1.1it viraal RNA aanwezig in plasma of serum, in 
plaats van via proviraaJ DNA afkomstig van cellen in de circulatie. Voar het verkrijgen van 
maleculaire kloncn uit eindstadium plasma monsters moest een RT -peR mcthode 
geoptimaliseerd worden. Deze is beschrevcn in hoofdstuk 4.1. De constmctie van de 
volledigc SIV moleculaire kloon (SIV F35,l wordl beschreven in hoofdsluk 4.2. Hoofdsluk 5 
beschrijft de ill vivo karakterisering van deze nieuwe kloon (SlY FJ59)' Stamboomanalyse 
toonde aan dat SIV FJ59 gerelateerd is aan zowel SIVsm klonen als SIVmac klonen. 
Fylogenetisch gezien zal SIVFJS9 tussen deze twee vimsgroepcn in geplaatst moeten worden. 
Doorgaans gebruikt SlY meerderc co-receptoren, o.a. CCR5, BOB, Bonzo. Echter, het in 
dit proefschrift gebruikte SIV 8980 isolaat en de daarvan afgcleide moleculaire kloon SIV FJ59 
gcbruiklen aileen CCR5. SlY"" bleek in slaal om zoweI de humane T-cellijn CS166, als 
rhesus en humane pcrifere bloed monollucleaire cellen (PBMC) te kunnen infecteren, en 
bleek tevens in staat am syncytia te vomlen. Deze kloon vertoonde echter geen detecteerbare 
velmenigvuldiging in niet-gestimuleerde rhesus PBMC of in macrofagen, terwijl 
macrofagen weI door het virus ge'infecteerd werden. In een pilotexperiment in twee rhesus 
makaken bleek de SIV FJ59 moleculaire kloon zowel infectieus als pathogeell te zijn. De kloon 
veltoonde cen vergelijkbaar, maar trager patroon van ziekte-ontwikkeling met dat van 
SIVs980 ' In hoofdst1.1k 6 is het onderzoek beschreven naar cen mutatie die resulteerde in cen 
lief stopcodon in SIV FJ59' Deze mutatie werd gebruikt om de ral van ne! in de virulentie van 
SIV te bestuderen. Tien rhesus makaken werden met deze J1e! mutant van SIV FJS9 
gei'nfectcerd. De dieren die AIDS ontwikkelden, hadden een relatief hoge virusconcentratie 
en een hogere prevaientie naar het wildtype teruggemuteerd virus. De dieren zander 
ziekteprogressie hadden een veel lagere virusconcentratie en een aanzielllijk lager aantal 
virusdeeltjes met een hersteld ne! stopcodon. Hiemit hebben wij geconcludeerd dat de J1et 
mutatie verantwoordelijk is voor de lage virusconcentratie en de afwezigheid van 
ziekteverschijnselen na infectic. Vervolgens is in hoofdstuk 7 de studie beschreven waarin 
het diennodel zodanig aangepast werd dat het aantal handelingen in vitro zoveel mogelijk 
bepcrkt kon worden. Dit werd bereilct door de rhesus makaken rechtstreeks mct DNA van 
SIV F359 te infecteren en niet, zoals gebmikelijk, met een virus preparaat die veel tijdrovende 
manipulaties vereist. Het is gelukt am met het DNA van de moleculaire kloon van SIV cen 
infectie te veroorzaken. Dit betekent dat het in principe mogelijk is am nauwkeuciger de 
invloed van apat1e genen op het ziekteproces te onderzoeken. 
Tezamen leggen de studies van dit proefschrift de basis voor verdere studies voor de 
identificering en karakteriscring van de moleculaire determinanten die verantwoordelijk zijn 
voor de versnelde progressie naar AIDS. 
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Louise de Colligny" scholengemeenschap in Leiden. In 1983 werd begOll11Cn met de studie 
Biologic aan de Universiteit Leiden. De doctoraalfase was samengesteld uit het hoofdvak 
Moleculaire Biologie (Faculteiten Biologie en Scheikunde) en het bijvak Biochemie 
(Faculteit Scheikunde). Het doctoraalexamen werd behaald in 1989. Na vervulling van de 
(vervangende) dienstplicht bij TNO-Rijswijk werd in oktober 1991 begonnen met het 
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Research Centre (BPRC) te Rijswijk, en stond onder leiding van Dr. J.L. Heeney en Prof. 
dr. J.1. Haaijman. Sinds oktober 1999 is hij werkzaam binnen de afdeling Parasitologic van 
het BPRC in Rijswijk. 
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DANKWOORD 
Nou, hier voigt dan eindelijk de nageboorte van mijn proefschrift: "het dankwoord". Het 
zal de insiders ruet ontgaan zijn dat het hier om cen zware bevalling ging. Dankzij de hulp 
van vele collcga's is "the never ending story", zoals het op een gegeven moment al werd 
genoemd, uiteindelijk tach afgesloten. Ik wil jullie dan oak hartelijk bedanken voor die 
hulp. Verder wil ik aIle coHega's en stagiaires van de afdelingen Virologic en Parasitologie 
bedanken yoar de prima sfeer binnen gebouw 157. Het was voomamelijk deze sfeer 
waardoor ik toch (bijna) altijd "fluitend" naar m'll werk ging, oak al waren de fmstraties 
over mislukte experimenten mij 80ms tot het oogwit gestegen. De timing van de cynischc en 
zure grappen die door jullie gemaakt werden gaven blijk van cen prettig soort relativisme dat 
ik altijd zeer heb kunnen waardercn. Zander iemand tckort tc willen doen wil ik toch een 
aantal mensen met name bedankcn. 
Allereerst mijn promotor Prof. dr. Joost Haaijman, die in 1998 helaas overleden is. Ik 
heb het erg prettig gevonden dat hij altijd verlrouwen heef! gehad in de goede afloop, maar 
vaoral dat hij mij dat op de een of andere manier oak kon doen gel oven. Zelfs toen hij al 
ziek was en nog maar halve dagen werkte zette hij ons tach op de agenda en bleef hij 
enthousiast meedenken over toekomstige experimenten. Zijn interesse in mijn werk heb ik 
zeer gewaardeerd en ik vind het erg jammer dat hij geen getuige kan zijn van de afronding. 
Prof. dr. R. Benner en Prof. dr. M.e. Horzinek, wil ik graag bedanken voor het op zich 
nemen van de taak van promotor, na het overlijden van Joost. Hoewel de bijeenkornsten met 
jullie altijd heel soepel verliepen was het voor mij meteen duidelijk dat er nu spijkers met 
koppen geslagen werden. Teen op een zo'n bespreking een definitieve datum voor de 
promotie werd vastgelegd en het manuscript binnen zes weken klaar moest zijn, Hep het mij 
dun 'door den broeck' . Achteraf bleek dit de enige juiste aanpak te zijn en wiI ik jullie graag 
bedanken voor dit belangrijke "duwtje in de rug". 
Jonathan Heeney, Jon ik zalje zeggen dat ik het zeer gewaardeerd heb hoeveel tijdjij de 
afgelopen weken in mijn promotie hebt gestopt. Met het dieptepunt op 8 september toen wij 
tot diep in de nacht bezig waren om alles de volgende dag af te hebben. Jouw schaamteloze 
optimisme, dat mij al eens eerder was opgevallen, heeft rnij toen erg gemst gesteld. Tussen 
vastlopende computers en "verdwenen" documenten had jij het maar steeds over "even een 
COITecne doorvoerell", "Illl nog ietsjes in endnote opellen", "elfe primell" en dit en dat en 
zus en zo terwijl al die goddeloze klere computers allang waren vast gelopen. Het staat dan 
ook als een paal boven water dal dit boekje er niet was geweest zonder jouw inzet. Jon, ik 
wiI je graag bedanken voor aIle steun en hulp die je mij vanaf het allereerste begin gegeven 
hebt. 
Rob, Wim, Peter, Nel, Tam en Henk. Jullie wilde ik graag heel hmtelijk bedmlken voor 
de vele testen, expcrimcnten en bepalingen die jullie voor mij uitgevoerd hebben. Het 
mengsel van jullie typische, zure en bijtende humor heeft diepe sporell in m'n geheugen 
achtergelaten. Vooral het werk achter de sluis met Rob zal ik niet snel vergeten. Ik weet nog 
weI dat er op een gegeven moment gekeken moest worden of mijri gefmnnik met DNA 
eindelijk iets had opgeleverd. Daarorn rnoesten wij soms lang door de microscoop gluren op 
jacht naar bell en, bubbels, opgeblazen cellen of andere eigenaardigheden. Best spann end, 
omdat het bepalend was voor het vervolgonderzoek. Maar door jouw kenmerkende 
gezelligheid en enOlme ervaring was het althans voor mij toch een prima tijd. Over zure 
humor gesproken! Wim, jij hebt het vast uitgevonden. Heb je een week hard gewerkt, 
echter zonder resuitaten, zegt ic: "zo joh, wal heb je nOll bereikt deze week ? ... lliets 
?!!!, ... noll, vel711elligvuldig dat dall maar mel 52 ell dan met 30 ell dat is de bijdrage die jij 
nag aall de welenschap gaat leveren". Toch zijn het dit soort opmerkingen van jOll, Wim, 
die mij aJtijd weer vrolijk maken en de koffie pauzes cq werkbesprekingen meer dan de 
moeite waard maken. Peter, van onze na-borrelse avonturen heb ik altijd erg genoten, 
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ondanks het gcldverslindendc karakter ervan. Tach ben ik ergens oak wei bIij dat de kans 
op dat soort excessen tegenwoordig fllnk is afgenomen. Het vrijdagavond bezoek aan Locus 
moesten wij misschien toch maar weer eellS oppakken, vind je niet? Peet, bedankt voar al je 
hulp in het lab en met de computer in de afgelopen jaren. Ik ben blij dat je 'quantitative 
assay' zo goed werkt, het heeft ons twee keer het "Ieven gered". Nel, jij was nooit te 
beroerd am een 'scquencjc' tussendoar te doen. Bedankt! Torn, ik zal het niet gamv 
vergeten: "een veri oren dag, is een dag te Iaat". Henk, ettcrbak, bedankt voor je hulp en 
vooral je droge Orentse humor, het kon am'dig mindel'. 
Ernst en Brigitte wil ik graag bedanken voor de bereidheid om op het laatste nippertje 
nag even kritisch een manuscript door te lezen en dan tach nag de kans te zien am met 
opbouwende kritiek terug te komen. Brigitte, ik ben je erg dankbaar voar je nauwkeurige 
rnanier van lezen, herlczen cn eorrigeren, vooral aan het einde van de rit. Emst, jouw 
ongecomplieeerde reeht toe reeht aan opmerkingen en je oud Hollandse smartlappen zijn een 
lust voor het oar. De f1itsende manier van corrigeren en jouw grammaticale chirurgie hebben 
mij, zoals je weet, zeer geholpen. Gerrit, ik heb het erg op pdjs gesteld dat je mij op 8 
september net op het juiste moment kwam helpen met de laatstc loodjes. Verder hoop ik dat 
je nog langje hobby's (bokbieren whisky) met ons wilt delen. 
De duizenden computer problemen die ik wist te creeren hebben mij altijd versteld van 
mijzelf docn staan. Gelukkig waren er altijd handige gasten die dat wisten op te lossen. 
Saxwin was weI degene die het meeste puin geruimd heeft. Saxwin, bedankt dat je altijd 
snellangs kwam en 't Iliet tclefonisch probeerde op te lassen. 
Jeannette, enorrne kanjer!!! Heel erg bedankt voor het maken van dit boekje. Ik was 
altijd al onder de indruk van je efficicnte manier van werken en je professionele aanpak, 
maar hoe je deze killS geklaard hebt, is ronduit geweldig. Zelfs tijdens de Iaatste lange dagen 
vlak VOOI' de dlUkker was je goede humeur onverwoestbaar. Ik vind het januner dat ik nu in 
een andere karner zit, want ik kon altijd erg lachen met jou. 
Henk van Westbroek, sorry voar al die warrige laatste moment klussen die wij keer op 
keer weer van je vroegen. Ondanks ons gezeur heb ik je nooit kwaad gezien en kwam je 
altijd met de prachtigste plaaues grafieken, foto's en dia's tevoorschijn. Bedankt VOOI' je 
geduld en perfcctionisme. Mea, bedankt voor je bereidheid om in te springen tijdens je 
vakantie met het ontcijferen van de correcties die Jon uit Amerika naar ons toe faxte. Alle 
dicrverzorgers, vooral Ko de Vast, voor hun inzet en toewijding bij de verzorging van de 
apen en voor hun gezelligheid tijdens de barrels. 
am mijn ouders en zus op passende wijze te bedanken voor hun jarenlange steun, 
motiverende belangstelling en interesse in alles wat ik decd, zou cen tweede boekje nodig 
zijn. Daarom kort maar krachtig: Mama en Dorine, ik ben heel blij dat jllilie altijd voor mij 
klaar staan en dat ik met alles wat mij bezig houdt bij jullie terecht kan (al is het midden in de 
nacht). Helaas dat pa dit niet heeft kunnen meemaken maar hij hOOli er natuurlijk nog steeds 
bij, daarom is dit boekje voor hem. 
Dan natuurJijk Juu!. Jouw begrip Vaal' mijn rare werktijden en je bereidheid om je 
afspraken weer eens op het laatste moment te verzetten heb ik altijd erg gewaardeerd. Verder 
wiI ik je bedanken VOOI' je positieve instelling die je in de afgelopen jaren toch steeds weer 
hebt wetcn te behouden. Ik weet dat ik je incasseringsvermogen danig op de proef heb 
gesteld met alles wat ik heb uitgespookt. 
Lieve Bmije, moeht je later ooit nog eens besluiten om te promoveren, kljk dan eerst nog 
eens naar je vader en wie weet bedenk je je nag net op tijd, afgesproken ? Nu kap ik ennee, 
het is moDi geweest en trouwens 't heeft lang genoeg geduurd ............ . 
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